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Abstract 
The permanent cell cycle arrest known as cellular senescence is a major block to 
tumorigenesis. Currently the effects of latent senescence signaling on disease 
progression, response to therapy and outcome are poorly understood. 
Furthermore, the role of microRNAs in the regulation of senescence remains to 
be fully elucidated. For immortalisation to occur replicative senescence must be 
bypassed usually by activating a telomere maintenance mechanism (TMM). 
However, the expression differences between TMMs are also poorly understood. 
To address these questions a combination of gene expression and miRNA 
microarray profiling, virtual drug and siRNA kinase screening were utilised. 
These findings highlight the distinct roles of secretory and damage associated 
senescence pathways in disease progression and in response to therapy. 
Examination of the differentially expressed genes between TMMs also highlighted 
a differentially expressed gene expression network surrounding TERT, regulated 
by c-Myc and TCEAL7 in TMMs. These findings give further insight into the 
complex regulation network surrounding senescence signaling during 
tumorigenesis. 
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1 Introduction  
1.1 Cellular Senescence 
To become fully transformed, cancer cells must undergo a process of 
immortalization after which they are able to grow and divide unrestricted. 
Immortalization requires the bypass of the permanent cell cycle arrest induced 
by the activation of the senescence program. Upon induction of the senescence 
program, cells remain metabolically active but permanently exit the cell cycle, 
stalling at the G1/S checkpoint (di Fagagna et al. 2003). Senescent cells also 
become large and flattened in phenotype. Furthermore, senescent cells can be 
identified in vitro through the histological identification of -galactosidase 
expression (Dimri 2005). Another marker commonly used in senescence 
identification, are the formation of senescence associated heterochromatin foci 
(SAHF). SAHF are unique senescence induced chromatin foci that contain HMGA 
proteins and are mediated by the heterochromatin chaperone molecules ASF1a 
and HIRA. Furthermore, SAHF have been associated with the repression of 
proliferative markers such as the E2F genes and may therefore be directly 
involved in senescence induction rather than simply associative markers (Narita 
et al. 2003; Zhang et al. 2005; Narita et al. 2006). Characterisation of the exact 
mechanisms behind SAHF function and pathways regulating their function 
continues. Recently, the HIRA associated protein UBN1 was found to be 
sequestered to SAHF during senescence and was shown to be required for SAHF 
formation (Banumathy et al. 2009). Furthermore, overexpression of UBN1 was 
found to reduce cellular proliferation and increased -galactosidase staining, 
thus suggesting a direct role for UBN1 and SAHF in the induction of senescence. 
Senescence induction occurs in response to multiple stimuli however always 
results in the same phenotypic endpoint suggesting higher levels of molecular 
regulation coordinating a preprogrammed cellular response as visualized in 
Figure 1.1.   
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Figure 1.1 - The establishment of a complex cell phenotype, such as senescence, requires 
the interaction of many regulatory mechanisms leading to changes in individual pathways 
and processes.  
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1.1.1 Replicative Senescence 
Cellular senescence induced in response to critically short telomeres, known as 
replicative senescence, represents a key mechanism by which cells prevent 
unlimited cellular proliferation. Telomeres consist of 1000-2000 tandem DNA 
hexanucleotide repeats of the sequence, TTAGGG in humans. Telomeres exist at 
the ends of chromosomes to protect coding DNA from degradation through the 
end replication problem of the cell cycle (de Lange 2009). To achieve this 
telomeres form a DNA-protein complex, with 6 protein subunits TRF1, TRF2, 
POT1, TIN2, Rap1 and TPP1 proteins, known as the shelterin complex (de Lange, 
2005) . This complex protects chromosomes from end-to-end fusion events and 
recognition as DNA double strand breaks by introducing secondary structure to 
the chromosome end. However, with each successive round of cellular division 
short sections of the end of the telomeres are lost, circa 50bp per cell doubling, 
due to the DNA polymerase’s inability to copy the last section of a linear 
chromosome (Levy et al. 1992). Eventually telomeres become critically short, 
circa 4 kb, and induce a crisis stage, which in turn induces the cellular 
senescence program. On a molecular level, it is thought that it is the recognition 
of the critically short telomeres as DNA double strand breaks leading to the 
induction of a DNA damage response that induces senescence rather than the 
physical length of the telomeres themselves.  
The induction of the senescent phenotype is thought to occur through the 
complex interactions of multiple signaling cascades (see Figure 1.2). This 
signaling is thought to primarily occur through the tumour suppressor gene p53 
and secondarily through pRB. 
Although there is some disagreement in the field as to whether actual p53 
protein levels increase (Atadja et al. 1995; Kulju et al. 1995), p53 DNA binding 
activity has been shown to increase upon the induction of the replicative 
senescence in diploid fibroblasts. This indicates a primary response of p53 to the 
DNA damage signaling of telomere erosion (Atadja et al. 1995).The tumour 
suppressor protein p53 is a transcription factor, encoded by the gene TP53 in 
humans, commonly expressed at low levels in normal cells and tissues.  p53 is a 
well known mediator of DNA damage responses and the apoptotic pathways and 
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Figure 1.2 - An overview of some of the many genes implicated in senescence signaling. 
Also shown are the known functional relationships present in the MetaCore interactions 
database between them.  These interactions highlight the multiple feedback loops that exist 
within the senescence cascades as well as the central nature of p53 and pRB regulation. 
Red lines indicate negative interactions whereas green indicate positive. P = 
phosphorylation, TR = transcriptional regulation, IE = influence on expression, CM = 
covalent modification. 
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 mutations of p53 are found in up to 50%  of human tumours (Bitomsky et al. 
2009). Furthermore, p53 has been observed to play regulatory roles at the G1 
and G2/M cell cycle checkpoints (Agarwal et al. 1995) concurrent with its ability 
to induce the cell cycle arrest required for the senescent phenotype. As the 
ability to bypass accumulated DNA damage responses, apoptotic pathways and 
senescence signaling through the perturbation of a single molecule would be a 
highly efficient route to tumourigenesis; it is therefore unsurprising that 
mutation of p53 is commonly observed in cancer. One mechanism thought to 
influence the activity increase of p53 during replicative senescence is through 
the neutralisation of p53 inhibitor MDM2 (HDM2 in humans) by p14ARF, commonly 
known as ARF (Pomerantz et al. 1998). The release of p53 from HDM2 targeted 
degradation leads to increased p53 stabilisation and activity. Consistent with 
this concept HDM2 is frequently overexpressed in cancer where such tumours 
have little or no detectable p53 (Momand et al. 1998). In addition, further 
inferences to the central nature of p53 in the induction of the senescence 
program is gained from gain of function p53 mutations in mouse models. Mice 
with a p53 gain of function mutation in one allele show increased accumulation 
of senescent cells compared to wild type in response to radiation induced DNA 
damage (Hinkal et al. 2009). 
As a consequence of increased transcriptional activity of p53 in senescing cells, 
p53 downstream target p21 also shows increased transcription in senescent cells 
(Roninson 2002). The role of p21 itself in replicative senescence signaling is 
becoming increasingly investigated. Cyclin-dependent kinase inhibitor 1A, 
CDKN1a also known as p21, plays a central role in the transduction of DNA 
damage signals during the cell cycle. Through regulation of cyclin-CDK 
complexes and PCNA, p21 causes G1\S cell cycle arrest upon the activation of 
DNA damage signals (Cazzalini et al. 2010). The importance of p21 in mediating 
p53 signals to bring a successful halt to the cell cycle at the G1/S checkpoint is 
exemplified by the fact that p21 knockout mice show similar extended 
proliferative lifespan as those with deficient p53 (Deng et al. 1995). 
Interestingly, knockout of p21 does not lead to the same tumourigenic potential 
as the knockout of p53 suggesting that although a key mediator in the 
prevention of tumourigenesis, p53 may have further effector mechanisms 
through other downstream targets (Deng et al. 1995). However, increased p21 
expression is a well established hallmark of replicative senescence induction and 
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is therefore likely to be a primary mechanism by which p53 signaling induces a 
G1/S arrest in response to the DNA damage signals caused by critically short 
telomeres. 
However, the absence of functional p53 signaling alone is not sufficient for 
complete replicative senescence bypass, although p53 deficient cells do show an 
increased replicative potential compared to wild type p53 cells (Medcalf et al. 
1996; Dulic et al. 2000). p53 independent senescence induction is thought to 
occur through the actions of the pRB regulator p16INK4a. The nuclear 
phosphoprotein RB1, or pRB, was the first tumour suppressor gene to be 
identified. Progression of the cell cycle through the G1/S checkpoint requires 
inactivation of the pRB protein by phosphorylation. pRB regulates the cell cycle 
through transcriptional repression of the E2F family of transcription factors 
(Harbour et al. 2000). The stalling of the cell cycle of senescent cells may 
therefore be further amplified through deactivation of the proliferative E2F 
family of transcription factors as hypophosphorylation of pRB is commonly 
observed (Jarrard et al. 1999). Deactivation of pRB during the cell cycle is 
caused by phosphorylation by cyclin D-dependent kinases CDK4 and CDK6. During 
cellular senescence the CCDK4/CDK6 inhibitor cyclin dependent kinase 2A, or 
p16INK4a, shows increased expression (Jarrard et al. 1999) and it is through this 
mechanism that pRB reactivation is thought to occur during cellular senescence. 
Consistent with this the INK4a locus, which encodes both ARF and p16INK4a, is 
frequently deleted in human cancers (Kim et al. 2006). A recent study used a 
combination of a dominant negative allele of shelterin component TRF2 and 
siRNA to directly explore the role of p16INK4a in response to telomere damage 
(Jacobs et al. 2004). Upon transfection with a dominant negative allele of TRF2 
and p16INK4a siRNA, some but not complete alleviation of telomere damage 
induced damage growth arrest was observed. Although siRNA knockdown of p16 
alone was insufficient to alleviate telomere damage induced growth arrest, 
combination of p16 knockdown with knockdown of p53 lead to near complete 
bypass of senescence, consistent with previous observations in fibroblasts using 
SV40 T-antigen (Shay et al. 1991). In addition, perturbation of the pRB-p16INK4a 
signaling pathway through the expression of polycomb protein BMI1 has been 
observed to increase the replicative lifespan of human diploid fibroblasts 
(Itahana et al. 2003) is insufficient for complete senescence bypass. As p16INK4a 
and ARF are derived from the same locus, BMI1 may therefore be down-
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regulating the expression of both p16INK4a and ARF and further enhance the anti-
senescence signal by reinstating MDM2 inhibition of p53 in combination with pRB-
p16INK4a depletion. This suggests that although not the primary mechanism the 
pRB-p16INK4a senescence signaling pathway does have a potentially important 
secondary signaling regulatory role in the induction of the senescent phenotype. 
Consistent with p16INK4a signaling being a secondary signal, p16INK4a induction has 
been observed to be a particularly slow event when compared to that of p53 and 
p21 and has been suggested to be more involved in senescence maintenance 
than senescence induction per se (te Poele et al. 2002; Jacobs et al. 2005). 
Furthermore, the observation that p16INK4a is required for the establishment of 
the senescence associated heterochromatin foci is suggestive that its role in 
senescence induction may go further than a simple back-up mechanism to p53 
signaling (Narita et al. 2006). The induction of replicative senescence signaling 
appears therefore to be a complex highly regulated process, with multiple 
opportunities for perturbation to achieve the immortalization required for 
tumourigenesis. 
Additional pathways also have evidence of involvement in response to replicative 
senescence stimuli. The ATM/ATR kinase pathway is commonly activated in 
response to damaged telomeres (d'Adda di Fagagna et al. 2003). ATM and ATR 
are normally activated in response to DNA damage signals, and through 
inhibitory phosphorylation of cell cycle positive regulator Cdc25 via CHK2 and 
CHK1 respectively, ATM and ATR regulate cell cycle progression (Reinhardt et al. 
2009). Furthermore, ATM and ATR signaling leads to phosphorylation of H2AX 
( H2AX), which then flanks the DNA double strand breaks and attracts further 
DNA damage machinery to the DNA lesion. Observations of co-localisation of 
H2AX and p53 in senescent cells adds a further mechanism by which ATM and 
ATR may play an important role in the induction of replicative senescence, by 
directing the senescence machinery to the critically short telomeres (d'Adda di 
Fagagna et al. 2003).  
Further complexity to the cross-talk between senescence signaling cascades are 
found when considering reports of the cooperative nature of ARF and ATM/ATR 
signaling in response to oncogene expression (Pauklin et al. 2005). The complex 
and often overlapping signaling cascades utilized to induce the senescence 
phenotype may be reflective not only of the requirement to coordinate multiple 
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signaling pathways to halt to the cell cycle but also of potential fail-safe 
mechanisms should one aspect of the senescence machinery be perturbed. Such 
fail-safe mechanisms may make the successful transformation of damaged cells 
into neoplasms the rare event it currently is. 
1.1.2 Oncogene induced senescence 
Replicative senescence although the most studied mechanism for cellular 
senescence is not the only mechanism by which senescence forms a barrier to 
tumourigenesis. Senescence induction is also a common event in response to 
oncogene activation. Upon expression of the oncogene RAS, increased 
accumulation of p53, p16 and pRB proteins are observed (Serrano et al. 1997). 
Furthermore, cells undertake a large flat morphology, arrest at the G1/S 
checkpoint of cell cycle and stain positively for -galactosidase at pH 6. All of 
these factors give strong evidence that induction of RAS expression induces a 
senescence phenotype similar to that induced by telomere erosion in replicative 
senescence. The human RAS family of oncogenes includes HRAS, NRAS and KRAS 
all of which under normal circumstances provided proliferative signals following 
stimulation by growth factor receptors. RAS family activating mutations are 
common events in human neoplasms. A recent review of RAS mutation rates in 
different tumour types showed KRAS to be the most frequently activated RAS 
family member with activation found in up to 90% of pancreatic cancer 
(Downward 2003). In contrast to the signaling pathway observed in replicative 
senescence, bypass of oncogene-induced senescence caused by RAS 
overexpression is achievable by mutation of either p16 or p53 alone (Serrano et 
al. 1997). This may suggest that the strong proliferative signals given by the 
oncogene are enough to push the cell forward into the cell cycle and negate the 
need for bypass of both genes. Further elucidation to the mechanisms behind 
oncogene induced senescence through RAS overexpression is gained when 
examining the effects of downstream signaling molecule MEK. Examination of 
the effects of constitutive MEK overexpression highlighted differential effects on 
normal mortal fibroblasts and those lacking functional p53 or p16INK4a (Lin et al. 
1998). The study showed that in response to a gain-of-function mutant of the 
dual specificity kinase MEK1, normal fibroblasts were caused to senescence with 
the characteristic p53, p21 and p16 protein level increases and -galactosidase 
staining. Treatment of fibroblasts with a MEK specific inhibitor was sufficient to 
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bypass RAS induced senescence, suggesting that MEK signaling is a required 
pathway for oncogene induced senescence by RAS. Consistent with their previous 
study the group also observed that cells deficient in either p53 or p16 and ARF 
transfected with the same gain of function mutant in MEK caused senescence 
bypass.  Providing further evidence for a core role in oncogene induced 
senescence for MEK, the oncogene RAF was also observed to induce cellular 
senescence that is dependent on MEK function (Zhu et al. 1998). RAF also signals 
to the proliferative MAP kinases through MEK and therefore MEK dependent 
senescence appears to form a major barrier to tumour formation by both 
oncogenes. Furthermore, the senescence inducing potential of the Ras/Raf 
pathways are further exemplified by the ability of an oncogenic mutant variant 
of the downstream kinase BRAF, known as BRAFE600, to also induce oncogene 
induced senescence (Michaloglou et al. 2005). Gain-of-function in the RAS/RAF 
pathways are not the only mechanism available to tumour cells for senescence 
bypass. Loss of tumour suppressor genes regulating RAS or RAF would also be 
sufficient to increase their proliferative signaling. Interestingly however, loss of 
the tumour suppressive function of the gene NF1 has also been shown to induce 
oncogene induced senescence (Courtois-Cox et al. 2006) suggesting that 
activation of this pathway in any form, without the loss of p53 or p16 function, 
will induce the cellular senescence program. Evidence of RAS induced 
senescence in vivo is given by observations in various benign premalignancies 
such as adenomas (Collado et al. 2005) and melanocytic nevi (Michaloglou et al. 
2005).  
Oncogene activation represents only one of the two main mechanisms for 
neoplastic transformation. The suppression of tumour suppressor genes is also a 
common event in human cancer. Evidence is beginning to gather for a novel 
mechanism of senescence induction through the tumour suppressor gene PTEN 
that is independent of oncogene induced senescence. PTEN deletion/inactivating 
mutation is a common event in many human cancers, such as prostate cancer 
(Jiao et al. 2007).  The involvement of PTEN loss in the induction of cellular 
senescence was first highlighted by Chen and colleagues in 2008. The 
investigation of PTEN and p53 inactivation models in mice showed that PTEN 
inactivation with a wild-type p53 background induced non-lethal prostate 
cancers. Furthermore, loss of both p53 and PTEN induced an invasive prostate 
carcinoma. Examination of mouse embryonic fibroblasts with PTEN loss 
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highlighted the induction of p53 dependent cellular senescence. Furthermore, 
recent research by the group confirmed that the induction of PTEN-loss-induced 
cellular senescence was independent of DNA damage responses and its 
applicability in humans through its activity in a human xenograft model of 
prostate cancer (Alimonti et al. 2010). In addition, this study highlighted the 
requirement of mTOR function for the induction of PTEN-loss induced 
senescence through the abolishment of the phenotype through the inhibition of 
mTOR using Rapamycin. However, p53 stabilisation through the application of 
the MDM2 inhibitor Nutlin-3 was able to overcome mTOR inhibition and restore 
PTEN-loss induced senescence, further confirming the dependence of the 
phenotype on p53 activity. Whether PTEN loss causes or represses cellular 
senescence induction is currently under debate. The identification of CSIG adds 
confusion to this field. CSIG was identified as a gene whose expression is 
reduced upon the induction of replicative senescence and CSIG overexpression 
delayed the onset of replicative senescence (Ma et al. 2008). Characterisation of 
the function of CSIG showed that it inhibited translation of PTEN conflicting with 
the reports by Chen and colleagues of PTEN-loss induced senescence induction. 
Therefore, further investigations into the role of PTEN in cellular senescence is 
required before therapies targeting this signaling cascade can be utilized. 
However, not all oncogenic events trigger a senescence response. Recent 
evidence has shown that the chromosomal translocation responsible for the 
Ewing’s family of tumours, the EWS/FLI1 fusion, is an inhibitor of senescence. 
EWS/FLI1 knockdown appears to induce the activation of pRB and down 
regulation of pRB inhibited targets suggesting that EWS/FLI1 either directly or 
indirectly represses the activation of the senescence program through the 
inhibition of pRB (Matsunobu et al. 2006; Hu et al. 2008). Indeed, after 
knockdown Ewing’s cells exhibit the phenotypic characteristics of senescent 
cells including a large flat morphology and staining for -galactosidase. The 
effects of other known oncogenic chromosomal rearrangements on senescence 
induction pathways is currently unknown, future study in this direct may 
elucidate new mechanisms of senescence induction and bypass.  
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1.1.3 Stress induced senescence 
A further senescence inducing stimuli is that of non-cytotoxic cellular stress. The 
induction of oxidative stress through the exposure of multiple cell types to a 
hyperoxidative environment has been shown to induce the same cellular 
characteristics as replicative and oncogene induced senescence (Toussaint et al. 
2000). Furthermore, treatment of human diploid fibroblasts with an oxygen 
scavenger extends their replicative potential under oxidative stress. Examination 
of the mechanisms behind stress induced senescence by H2O2 treatment of 
human diploid fibroblasts highlighted the role TGF  (Frippiat et al. 2001). Cells 
that were exposed to sub-cytotoxic doses of H2O2 for 2 hours showed senescence 
induction, measure by -galactosidase staining, and was thought to be mediated 
through TGF . Consistent with this theory cells stimulated by increasing 
concentrations of TGF  showed a dose dependent induction of senescence and 
antibody mediated knockdown of TGF  activity significantly decreased the 
proportion of cells that underwent senescence induction in response to H2O2 
cellular stress. Furthermore, senescence induced by cellular stress caused by 
low level UVB exposure show increased levels of TGF  expression (Debacq-
Chainiaux et al. 2005).  The exact molecular mechanisms underlying stress 
induced senescence are currently not fully understood but appear to involve 
multiple regulatory cascades. For example stress induced senescence caused by 
treatment with ethanol or tert-butylhydroperoxide is protected against by 
overexpression of the anti-apoptotic molecule apolipoprotein J (Dumont et al. 
2002) and repeated UVB exposure induced an increase of apolipoprotein J 
expression (Debacq-Chainiaux et al. 2005). This suggests a potential negative 
feedback loop that could be used to promote cellular survival and prevent 
senescence induction in high stress environments. 
1.2 Senescence pathways 
Closer examination of the combined signaling cascades highlights the complex 
and highly regulated nature of senescence induction and the regulation of key 
molecules, such as p53 and pRB, by many different mechanisms (Figure 1.1 & 
1.2). The roles of individual molecules in the induction of cellular senescence is 
well studied.  However, in today’s era of high throughput genomics it is 
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becoming increasingly necessary to looking beyond individual genes in linear 
signaling cascades and consider the larger phenotypic implications of signaling 
pathways and networks. To date, little is clearly understood about the roles and 
impacts of these larger senescence pathways in human cancer. 
1.2.1 Damage associated senescence  
The induction of the senescence molecular signaling cascades appears to induce 
a damage-associated cellular response regardless stimulus. Upon receiving a 
cellular senescence stimulus cells induce signaling pathways classically 
associated with  DNA damage for example p53, p16INK4a, ARF, ATM and ATR 
regardless of whether DNA damage is actually involved, for example in the case 
of oncogene induced senescence. Furthermore, senescence associated 
heterochromatin foci are suggestive of the recruitment of DNA repair machinery 
to sites of DNA damage. Again, senescence associated heterochromatin foci are 
induced in response to oncogene overexpression where no actual DNA damage 
has occurred. It is therefore possible that the use of the DNA damage machinery 
is more reflective of the activation of a larger cellular damage pathway that is 
used to protect against potentially tumourigenic mutations and bypass of 
cellular replication limits. A recent model of an anti-viral origin for senescence 
has recently been proposed (Reddel 2010). The induction of this damage 
associated pathway stalls the cell cycle at the G1/S stage and may therefore 
help to prevent the successful replication of infecting viral DNA. The induction 
of cell death by apoptosis after infection by a virus may risk viral particle 
release into the neighbouring cellular microenvironment and risk infection of 
nearby cells. The stalling of the cell cycle through the damage associated 
senescence pathway would therefore protect against such events and allow 
sufficient opportunity for natural clearance of such cells by the immune system. 
1.2.2 Secretory senescence  
The clearance of virally infected senescent cells by the immune system would 
require a mechanism for attracting immune cells to the site of infection. Such 
opportunity is given by the secretory senescence pathway. The first hints of the 
importance of the secretory senescence pathway came from a key study into the 
mechanisms behind oncogene induced senescence (Kuilman et al. 2008).The 
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authors had observed the requirement for an IL6 regulated pro-inflammatory 
network for successful oncogene induced senescence induction. The direct 
observation of a secretory element to senescence signaling led to further 
investigations and eventually the identification of secretory signatures of 
senescence. One of the first of these signatures to be published was senescence 
associated secretory phenotype (SASP). SASP was identified as an independent 
signaling mechanism from experiments using antibody arrays to assess those 
factors secreted by cells undergoing senescence (Coppe et al. 2008). The study 
highlighted the increased secretion of IL6, IL8, IGFBP3 and GRO1 after DNA 
damage caused senescence induction. Furthermore, SASP induction was 
observed in a number of different cell types normal epithelial cells, epithelial 
tumours and normal fibroblasts as well as directly in vivo in tumour biopsies 
from prostate cancer patients after DNA damage inducing chemotherapy. This 
observation confirmed that the secretory senescence pathway was a novel 
unexplored aspect of cellular senescence and further similar signatures soon 
confirmed the importance of secretory senescence signaling, highlighting further 
elements of the pathway.  
Many senescence studies utilise mouse models to investigate the specific role of 
individual molecules in senescence signaling cascades and recent investigations 
of the secretory senescence pathway are no exception. However, a recent study 
of the secretory senescence pathway highlights the need for care when 
interpreting such results and the false assumption that human senescence 
signaling will be identical to that in the mouse. Investigations of the presence of 
SASP in mouse cells under standard culture conditions of ~20% oxygen showed 
that the fibroblasts showed no signs of SASP unlike they counterpart human 
fibroblasts (Coppe et al. 2010). Upon culture in lower oxygen levels more similar 
to those fund in vitro, ~3% oxygen or senescence induction by radiotherapy the 
mouse fibroblasts were found to trigger SASP. This may suggest that mouse cells 
have potentially different pathways for stress induced senescence via oxidative 
stress that differ from those found in humans, however given the correct 
environmental conditions these cells can still be utilized to model senescence 
pathways in humans. This study highlights the need for validation of senescence 
signaling cascades discovered through the use of mouse cells under standard 
culture oxygen levels (~20% oxygen) using a more physiological conditions and 
where possible using human cellular models directly. 
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Further expansion of the original SASP genes was provided shortly after by 
Peeper and Kuilman through detailed collation of experimental evidence in the 
literature for a secretory aspect to senescence, or the secretory-messaging 
secretome (SMS) (Kuilman et al. 2009).  The secretory senescence pathway now 
included over 13 molecules each with evidence for a role in senescence. IGFBP3 
had been previously identified as part of SASP but SMS also included further 
interferon growth factor bind proteins 5 and 7 as well as IGF1. Both IGFBP3 and 
IGFBP5 had been found to be associated with the induction of replicative 
senescence (Kim et al. 2007; Kim et al. 2007) during the study of human 
umbilical vein endothelial cells whereas IGFBP7 had been similarly shown to be 
mediate BRAFE600 oncogene induced senescence in human fibroblasts and 
melanocytes (Wajapeyee et al. 2008). The evidence for the involvement of IGF1 
was not as direct. IGF1 overexpression was found to extend the replicative 
lifespan of skeletal muscle cells through the activation of AKT signaling however 
senescence biomarkers themselves in response to IGF1 have yet to be directly 
tested (Chakravarthy et al. 2000). Further molecules of particular interest in SMS 
are WNT2, CXCR2, and PAI1. WNT2 has previously been implicated in the 
maintenance of cellular proliferation signals. Its potential involvement in 
senescence is implicated by its pRB and p53 independent repression during both 
oncogene (RAS) induced and replicative senescence leading to increased SAHF 
formation (Ye et al. 2007). CXCR2, also known as IL8Rb, is a receptor that 
transduces multiple cellular signals by molecules previously implicated in the 
secretory senescence pathway, such as GRO1 and IL8. CXCR2 has been shown to 
be upregulated during replicative and oncogene induced senescence (Acosta et 
al. 2008). Furthermore, the same study showed that shRNA mediated knockdown 
of CXCR2 alleviated replicative and oncogene induced senescence. As a 
downstream target of p53, the role of the serine protease inhibitor SERPINE1, 
SERPINE1 in humans, in senescence is unsurprising.  RNA interference of 
SERPINE1 in mouse embryonic fibroblasts and human diploid fibroblasts was, 
however, found to be sufficient for replicative senescence bypass (Kortlever et 
al. 2006). This implicates SERPINE1 as a potential key effector of p53 mediated 
senescence. 
Subsequent additions to the secretory senescence pathway provide links 
between the damage associated pathway and secretory senescence pathways. 
Study of telomere dysfunctional mesenchymal stem cells, revealed increased 
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expression of CRAMP, stathmin, EF1  and chitinase and were detectable in the 
blood/serum of aging mice and humans (Jiang et al. 2008). As the proteins were 
induced to be secreted by the damage associated senescence pathway they 
provide evidence for a functional link between the two pathways. Furthermore, 
their induction as a post damage event is also suggestive of a higher order to the 
signaling of the two pathways during senescence induction. Consistent with this 
concept, a recent study of human diploid fibroblasts with induced DNA damage 
through high dose radiation exposure highlighted increased IL6 secretion 
alongside the formation of SAHF in arrested cells (Rodier et al. 2009). 
Interestingly a low dose of radiation, such that it was only sufficient to induce 
temporary DNA damage signaling before returning to the cell cycle, did not 
cause increased IL6 secretion. This suggests that DNA damage signaling alone is 
not sufficient for secretory senescence activation instead the damage associated 
pathway and the senescent cell phenotype must instead first be established to 
trigger the induction of secretory senescence. Through the knockout of key 
effector molecules of the damage associated senescence pathway the group also 
showed the secretory senescence signaling was triggered through the ATM 
signaling cascade and did not require p53 during replicative or oncogene induced 
senescence. Interplay between the two known senescence pathways is therefore 
evident and current evidence suggests that the main function of the secretory 
senescence pathway is to signal the cells’ surrounding microenvironment of the 
induction of cellular senescence. 
Unfortunately, such signaling events may have a pro-tumourigenic effect on 
surround cells due to the increased blood flow from proangiogenic signals and 
proliferative signals intended to stimulate the immune system. Such antagonistic 
pleotrophy may have originally been intended to signal cellular distress to 
surrounding microenvironment due to ongoing tumourigenic events or cause 
senescence induction in neighbouring cells that may have also been infected 
with the virus. Regardless of whether senescence was derived from an anti-viral 
response, the attraction of the immune system through the release of pro-
inflammatory and chemotactic signals would also be of benefit to an anti-
tumourigenic mechanism and as such may have been retained as the senescence 
response evolved. Indeed increased local immune infiltration is associated with 
improved survival in cancer patients (Roxburgh et al. 2009) and activation of the 
secretory senescence pathway may be intended to evoke this response. 
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However, as with all biological systems, the exact levels of such signaling must 
be closely regulated. Over-activation of the secretory senescence pathway may 
also have a deleterious effect, reflected by the fact that patients showing an 
increased system-wide immune activation, as opposed to tumour localized 
immune response, show a poorer prognosis (Roxburgh et al. 2009). Due to the 
relative infancy of the investigations into the secretory senescence pathway, the 
exact details and implications upon clinical factors such as outcome of the 
secretory senescence pathway are still under investigation but may in the future 
present novel opportunities for adjuvant pro-senescent therapies.  
1.2.3 Autophagy and senescence 
The latest pathway to be implicated in senescence induction is that of 
autophagy. Current evidence of the exact mechanisms by which autophagy and 
senescence interact is underdeveloped but the few studies that do exist have 
quickly identified what may be a particularly important factor in senescence 
induction. Autophagy, or self-eating, is the genetically orchestrated process of 
digesting internal organs and proteins of a cell. As such, it represents a third cell 
fate upon the receipt of cellular stress signals distinct from that of apoptosis or 
senescence. More precisely autophagy consists of the formation of double 
membrane vacuoles, known as autophagosomes, containing the organ or proteins 
to be digested. The autophagosomes are then fused with lysosomes to provide 
the digesting enzymes. The most frequently utilized marker of autophagy is LC3, 
which when bound to the autophagosomes, known as LC3-II, can be identified 
using immunoblotting techniques (Young et al. 2009). Upon starvation conditions 
autophagy can be induced to recycle proteins into their amino acid constituents 
for use in protein synthesis. Furthermore, autophagy activation is frequently 
observed when a cell needs to change from one metabolic state to another and 
facilitates the fast turn over of proteins to facilitate this. As senescence involves 
a major switch from a proliferating cell state to an arrested cell state 
accompanied by large phenotypic changes it is logical that autophagy may 
facilitate the large protein turn over required for this. 
The most compelling evidence for a link between autophagy and senescence 
comes from a large and detailed recent study by Young and colleagues (Young et 
al. 2009). In this study, the authors utilized a combination of the 
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aforementioned immunoblotting techniques for LC3-II and protein degradation 
assays on human diploid fibroblasts induced to senescence by RAS or MEK 
overexpression to investigate whether autophagy became activated upon 
senescence induction. LC3-II concentration was found to increase upon both RAS 
and MEK activation implying that upon senescence induction autophagy became 
activated. Furthermore, LC3-II increases did not occur when the induction of 
senescence was blocked. The group then went on to model the kinetics of 
autophagy activation during senescence induction using an inducible RAS 
activation model. The authors observed that after RAS activation the cells 
underwent a brief spell of increased cellular proliferation followed by 
senescence induction 5-6 days after. It was during the 4-5 days between the 
proliferative burst and induction of senescence that autophagy activation 
reached its peak. This suggests that autophagy may mediate the conversion of 
the proliferative cellular state to the senescence phenotype, through increased 
protein turnover. Some contradictions in the involvement of autophagy do exist 
however. mTOR has previously been seen to be required to induce the PTEN-loss 
induced senescence pathway however mTOR has also been observed to be a 
negative regulator of autophagy (Mathew et al. 2007). As such, senescence 
induction should repress the autophagic process. Upon investigation of the 
phosphorylation activity of mTOR, Young and coworkers found that an initial 
spike in activity following RAS activation then decreased in correlation with the 
activation of the autophagic transition to senescence. This suggests that 
continuous mTOR signaling is not required for maintenance of the senescent 
phenotype, an initial burst of activity is sufficient to activate the signaling 
cascade and induce senescence completely. This is consistent with the negative 
feedback loop through NF1 inhibition of downstream RAS pathways previously 
observed to regulate oncogene induced senescence (Courtois-Cox et al. 2006) 
Furthermore, NF1 has been shown to directly repress mTOR (Johannessen et al. 
2005) and thereby may provide a further direct pro-autophagic signal upon 
activation of oncogene-induced senescence. Through microarray analysis, Young 
and colleagues went on to show that overexpression of the gene ULK3 was 
sufficient to induce both autophagy and senescence and may provide a key 
signaling molecule for the concurrent activation of both pathways. Although the 
only study to date that mechanistically links autophagy with senescence 
induction, Young and colleagues have made a convincing argument for 
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autophagy as an effector mechanism for the switch from proliferating to 
senescent phenotype. 
Although to date -galactosidase staining at pH6 has been the most consistent 
marker for senescence available the exact mechanism behind the association of 
-galactosidase expression and senescence still remains a mystery; autophagy 
may provide a reason behind the marker however. -galactosidase staining in 
senescent cells was recently attributed to the activities of the gene GLB1 (Lee 
et al. 2006). GLB1 encodes lysosomal -D-galactosidase, which is one of the 
enzymatic components of autophagosomes. Knockdown of GLB1 with shRNA has 
been shown to delay -galactosidase staining but not the induction of the 
senescent phenotype (Lee et al. 2006). Furthermore, knockdown of autophagy 
upregulated genes ATG5 and ATG7 has been observed to delay the onset of -
galactosidase activity in senescent cells (Young et al. 2009). If -galactosidase 
activity in senescent cells is truly representative of autophagy-mediated 
senescence then it makes some sense of an observation of lack of -
galactosidase activity in melanocytic nevi in vivo (Cotter et al. 2007). If -
galactosidase activity is a product of the autophagic transition phase of 
senescence and this phase is limited to the transition between proliferative and 
senescent phenotypes, then the lack of -galactosidase activity in melanocytic 
nevi may suggest that these cells have moved passed the transition phase and 
are fully in the senescent phase. Further investigations of the dynamics of 
autophagy and senescence in vivo are required however, before any firm 
conclusions as to the relationship between senescence associated -
galactosidase staining and autophagy can be made. It is, however, curious to 
think that the most recent addition to the senescence story is behind one of the 
most consistent markers for senescence detection. 
1.3 Physiological Senescence: Senescence in vivo 
With an increased understanding of the molecular mechanisms behind 
senescence gradually coming to light the physiological roles of senescence 
become increasingly important. Senescence in vivo has so far been seen to play 
important roles in three major processes; tumour suppression, aging and wound 
healing. 
Kyle Lafferty-Whyte, 2010  Chapter 1,19 
1.3.1 Senescence and Aging 
As senescence is a mechanism of controlling the level of cellular proliferation 
and, in the case of replicative senescence, halting cell division after a set 
number of cell cycles it makes logical sense that it should have some links with 
the larger process of aging.  Indeed an increase of cells showing senescent 
markers in aging tissues and age related diseases such as atherosclerosis, skin 
ulcers, osteoarthritis and liver cirrhosis has been observed (Herbig et al. 2006, 
Sedelnikova et al. 2004, Campisi 2005; Price et al. 2002; Wiemann et al. 2002).   
The premature aging syndrome dyskeratosis congenita (DKC) adds further weight 
to the role of senescence in the process of organismal aging. DKC is an 
autosomal dominant disorder caused by mutations in the genes diskerin, TERT or 
TERC and results in a failure to maintain telomeres in stem cells and the germ 
line (Kirwan and Dokal 2009).  DKC results in bone marrow stem cell failure as 
stem cells telomeres are no longer maintened by telomerase and therefore 
eventually induce replicative senescence. Furthermore, patients with DKC often 
present with premature aging-like symptoms such as premature hair 
loss/graying, deafness, osteoporosis and liver disease (de la Fuente and Dokal 
2007).  
Although observation of the senescence markers in aging tissues and organisms 
presents a strong case for the role of senescence in the aging process further 
function studies are required to directly link the two processes. Mechanistic 
studies in the BubR1 insufficiency mouse models of premature aging and have 
shown that p16 inactivation attenuates both cellular senescence and premature 
aging while ARF inactivation exacerbates both phenotypes (Baker et al. 2008). 
However, as discussed in the discussion of the secretory senescence pathways 
(see 1.2.2) the use of mice to model complex phenotypes in humans must be 
done with caution as results are not always directly comparable. In the case of 
of p16’s role in the aging process there is some evidence that this link may not 
be limited only to mouse models however.Recently p16 has also been suggested 
as a human molecular marker of ageing due to its increased expression in human 
tissues and particularly peripheral blood lymphocytes (Liu et al. 2009).  
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The premature aging of patients with DKC; reduction of tissue function and the 
induction of age related diseases may be a further example of where 
senescence, whilst providing a barrier to potentially harmful diseases such as 
cancer (see 1.3.3) may also cause harm in the longer term.   
1.3.2 Senescence and Wound Healing 
A recent addition to the repertoire of senescence in vivo is its role in the repair 
of tissue damage known as wound healing. Upon receipt of an injury tissues 
undergo a program of tissue repair and remodeling that involves the activation 
of fibrosis to heal the wound and maintain tissue stability (Friedman et al. 
2008). Recent evidence highlighted the prescence of senescent hepatic stellate 
cells, the cells initially responsible for the production of the fibrotic 
extracellular matrix, in the liver in response to injury induced by carbon 
tetrachloride (Krizhanovsky et al. 2008). These senescent hepatic, like other 
sencescent cells, secrete matrix metalloproteases as part of the secretory 
senescence pathway and therefore serve to limit the level of fibrosis created 
during the process of wound healing in the liver. More recently the link between 
senescence and wound healing was further strengthened by a study by Jun and 
Lau. In this study the matricellular protein CCN1 was found to induce senescence 
in fibroblasts through the activation of p53 and pRB pathways (Jun and Lau 
2010). These senescent fibroblasts were found to accumulate in cutaneous 
wounds and CCN1 knockout mice were found to have extra fibrosis in cutaneous 
wounds, corrected by the application of CCN1 protein solutions directly to the 
wound. The evidence for the role of senescence as a crucial component of the 
normal healing process is therefore growing and with further mechanistic studies 
will continue to aid our understanding of the different physiological roles of 
senescent cells. 
1.3.3 Senescence as a block to tumour progression. 
Immortalisation, the ability to proliferate exponentially, is a prerequisite of the 
transformation of a normal cell into a cancer cell. As senescence has the ability 
to permanently remove the cell from the cell cycle it forms a major barrier to 
neoplasia and tumour progression. In fact senescence induction appears to 
perfectly placed to respond to early tumorogenic events and prevent the 
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establishment of the tumour through its activation in response to oncogene 
activation and inhibition of tumour suppressors. Furthermore, the removal of the 
cells from the cell cycle would also prevent the accumulation of further 
neoplastic mutations that may overcome other tumour suppressive signaling 
cascades with continued rounds of cell division. 
Detection of cells with the chacteristics of senescence have been detected in 
vivo in a number of different tissue types. Through the investigation of 
senescence markers, β-galactosidase staining and p16 expression, in an inducible 
KRas mutant mouse model Collado et al highlighted the prescence of senescent 
cells in adenomas of the lung and in premalignant pancreatic lesions (pancreatic 
intraductal neoplasias (Collado et al. 2005). These senescent cells were seen at 
much lower levels in adenocarcinomas and pancreatic ductal adenocarcinomas 
implying that the senescent cells may indeed be early cancer cells prevented 
from entering full immortality by the senescence program. Similarly, senescent 
cells have also been observed in benign dermal neurofibromas and melanocytic 
nevi (Coutois-Cox et al. 2006, Braig et al. 2005. Michaloglou et al. 2005).  
As the majority of melanomas rely on activating mutations in BRAF, which has 
been seen to trigger the senescence reponse, it makes logical sense that 
senescence should be activated in the early pre-cancerous cells and establish 
benign nevi instead. In fact recent clinical trials into the inhibition of BRAF 
expression in melanoma have been highlighy successful (Bollag et al. 2010). 
Unfortunately, many of these studies focus on the oncogenes addiction of these 
tumours and do not examine senescence markers so it is not always possible to 
say whether this is through the reversion of cancerous melanoma cells to a 
scenecent state.  However, mouse model studies in liver carcinomas and 
sarcomas, showed that restablishment of key senescence genes, such as p53, 
successfully causes tumour regression (Xue et al. 2007; Ventura et al. 2007). 
Furthermore, senescence has been observed to be induced in response to 
chemotherapeutic agents in vivo (te Poele et al. 2002) and as such senescence 
therefore presents a strong role as a tumour suppressive mechanism in vivo as 
well as in vitro. 
A further mechanism by which senescence presents a block to tumourogenesis is 
through the potential of the secretory senescence pathway to induce a local 
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immune response and immune clearance of premalignant cells that have entered 
senescence. As discussed previously (see 1.2.2) the secretory senescence 
pathway results in the secretion of many proinflammatory and immune 
activatory proteins and as such may be able to attract the immune system to 
cells that are undergoing pre-malignant transformations. In support of this 
concept work in mouse liver carcinomas showed that reactivation of p53 induced 
cellular senescence and clearance by the innate immune system (Xue et al. 
2007). The tumour clearance was seen to be mediated by the NK cells of the 
immune system which was ablated by the application of NK blocking antibodies 
or gadolinium chloride. Therefore although the secretory senescence pathway 
may be pleotrophic in its ability to suppress tumorigenesis there is strong 
evidence that if utilised correctly it may be an important tool in the induction of 
tumour regression. 
Senescence therefore presents a major block to tumour establishment and 
progression however as cancer does still exist it is obviously not a fool proof 
mechanism. In fact even in well established models such as melanocytic nevi it is 
know that a small number of nevi established for decades still progress to 
cancerous melanomas (Michaloglou et al. 2005). Therefore although senescence 
exists as a tumour suppressive mechanism in vivo, cancer cells also have 
adapted a number of senescence bypass mechanisms.   
1.4 Senescence bypass by telomere maintenance 
The induction of replicative senescence through telomere attrition forms a 
major barrier to tumour progression. Regardless of a cell’s ability to tolerate 
oncogene overexpression or cellular stress, the gradual telomere shortening 
caused by repeated cell cycling still requires bypass. In order to become fully 
tumourigenic cells commonly bypass senescence through the induction of a 
telomere maintenance mechanism.  
1.4.1 Telomere maintenance by telomerase 
The enzyme telomerase is a ribonucleoprotein with reverse transcriptase activity 
capable of lengthening telomeres and is utilised by the majority of cancer cells 
to overcome crisis and avoid senescence (Ju et al. 2006). The only normal cell 
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types observed to naturally express active telomerase are germ cells (Kim et al. 
1994), stem cell populations, such as haematopoetic stem cells (Vaziri et al. 
1994; Counter et al. 1995; Yui et al. 1998) and leukocytes (Counter et al. 1995). 
Recent evidence from mutations in the hTERT gene suggest that lack of 
telomerase activity in stem cells may lead to their premature loss (Hills et al. 
2009). Furthermore, mutations in the components of the telomerase enzyme 
have also been observed in cancers such as acute myeloid leukemia (Calado et 
al. 2009) and may highlight the potential importance of other mechanisms of 
telomere maintenance in these tumour types.  
Telomerase consists of two components, the catalytic component encoded by 
the hTERT gene and the RNA template component encoded by the hTR gene. 
Expression of both subunits is required for in vivo telomerase activity (Weinrich 
et al. 1997) and consistent with this, hTERT and hTR, are specifically up 
regulated in cancer compared to normal tissues and cell lines (Parkinson et al. 
1997). Dyskerin, encoded by DKC1, has also recently been shown to be 
associated with telomerase and is thought to stabilize the RNA/enzyme complex 
(Cohen et al. 2007).  Further evidence for the potential requirement for dyskerin 
for telomerase activity is provided by the reduced telomerase activity resulting 
from mutated dyskerin (Mitchell et al. 1999). In addition to this the autosomal 
dominant disease dyskeratosis congenita is attributed to reduced telomerase 
activity and, to date, mutations in only DKC1, hTR and hTERT have been seen to 
cause the phenotype (Mitchell et al. 1999; Vulliamy et al. 2001; Armanios et al. 
2005). Previous studies have highlighted the ability of the components of 
telomerase to dimerise (Wenz et al. 2001) and examination of the molecular 
weights of hTERT, hTR and dyskerin of purified catalytically active human 
telomerase suggest that the telomerase construct may exist as 3 dimers of each 
of these components (Cohen et al. 2007). However, these studies result from in 
vitro reconstitution of recombinant telomerase components or purified 
telomerase and therefore may not be truly reflective of the in vivo active 
enzyme complex. 
Given the tumourigenic properties of telomerase expression, it is not surprising 
that it is highly regulated on multiple levels. Firstly, both hTERT and hTR 
transcription are highly regulated processes. Both genes show balance of 
multiple layers of transcriptional regulation at their promoters. For example, 
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hTERT expression is repressed by transcription factors such as AP1, p53 and 
RUNX2 and activated by c-Myc, SP1 and STAT3 (Kanaya et al. 2000; Kyo et al. 
2000; Konnikova et al. 2005; Takakura et al. 2005; Isenmann et al. 2007). Of all 
of these transcriptional regulators probably the most important link with 
senescence regulation comes from p53 and c-Myc. Given that p53 is a key 
effector of induction of the senescence pathway it is logical that it should also 
act as a negative transcriptional regulator of the main mechanism of senescence 
bypass.  
c-Myc’s role in senescence and telomere maintenance by telomerase is well 
studied. Overexpression of c-Myc is common in cancer playing a regulatory role 
in the cell cycle (Wang et al. 2008), angiogenesis and cell migration (Meyer et 
al. 2008; Herold et al. 2009). c-Myc therefore presents an attractive target for 
anti-cancer therapy. A recent study found that the potent anti-cancer drug 
butein causes a decrease in telomerase expression and inhibits cell proliferation 
through the suppression of c-Myc expression (Moon et al.). Recent evidence that 
further chromatin remodelling is required before c-Myc can access the hTERT 
promoter for activation (Bazarov et al. 2009) suggests chromatin modification 
may also play a factor in the lack of hTERT expression increases in these cell 
lines. Aside from hTERT, another down-regulated c-Myc target that may play a 
role in telomere maintenance is hnRPA3. It was recently shown that hnRPA3 
binds the single stranded telomere repeat in vitro, protects against nuclease 
activity and inhibits extension by telomerase (Huang et al. 2008). C-Myc 
therefore clearly plays an important role in the regulation of telomere 
maintenance by telomerase. Consistent with this, in melanoma, c-Myc 
overexpression has been shown to be required for the bypass of oncogene 
induced senescence (Zhuang et al. 2008). Similarly, c-Myc repression has been 
shown to induce cellular senescence and tumour regression in osteosarcoma, 
hepatocellular carcinoma and lymphomas (Wu et al. 2007).  
hTERT is further regulated by alternative splicing. Several splice variants of 
hTERT exist where only the full length variant is active. hTERT has been shown 
to have at least 6 different splice variants where three main alternative splice 
forms have been extensively studied to date, known as the ,  and /   forms. 
All the splice variants produce truncated inactive forms of the protein, however, 
there is evidence that the  variant may function as a dominant negative form 
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(Colgin et al. 2000; Yi et al. 2000). This suggests a further level of post-
transcriptional regulation through regulatory feedback loops from alternative 
splice variants. A more recent study utilized sequential RT-PCR of primer pairs 
covering the entire full-length hTERT mRNA in a panel of cDNAs from 5 normal 
and tumour tissues. Upon examination of the resulting fragments the study 
highlighted a further 6 novel alternative splice forms and therefore the potential 
for up to 12 alternatively spliced variants of hTERT (Saeboe-Larssen et al. 2006). 
These observations further highlight the importance of the strict regulation of 
the telomerase enzyme to prevent senescence bypass and lead to potential 
tumorigenesis. The importance of this mechanism is further emphasised by their 
observation in different forms of human cancers. A study of malignant breast 
tumours and their surrounding tissues showed that expression of full-length 
hTERT correlated with telomerase activity in breast tumours (Zaffaroni et al. 
2002). However, in surrounding normal tissue and benign lesions the study 
interestingly showed that expression of the full-length splice variant alone was 
not sufficient for telomerase activity. This suggests that further regulatory 
mechanisms for the inhibition of telomerase activity are present and active in 
these cells. Further studies of melanoma cells, typical carcinoids, large cell 
neuroendocrine carcinomas and small cell lung cancers have highlighted 
requirement of the full length hTERT splice variant for telomerase activity and 
the potential importance of alternative splicing as a telomerase regulatory 
mechanism in vivo (Zaffaroni et al. 2005; Lincz et al. 2008). As negative 
regulators of telomere maintenance by telomerase, the induction of the 
dominant negative splice variants of telomerase make and attractive target for 
anti-cancer therapy. The role of splice variants of hTERT in response to therapy 
has been implicated in recent studies of breast cancer. One study highlighted 
shifts in splice variants away from negative forms after treatment of breast 
cancer with tamoxifen, potentially highlighting a primary mechanism of 
resistance induction in cancer cells surviving treatment (Strati et al. 2009).  
A further layer of regulation to senescence bypass by telomerase is given by 
post-translation protein modification. Phosphorylation of telomerase by AKT and 
PP2A have been observed to enhance telomerase activity in breast cancer and 
melanoma cells (Li et al. 1997; Kang et al. 1999). In addition, the recent 
observation that decreased activity of telomerase in highly differentiated T-cells 
is due to the decreased activity of AKT further highlights the importance of the 
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mechanism in vivo (Plunkett et al. 2007). Phosphorylation also presents a 
mechanism by which telomerase activity can be down regulated upon 
senescence induction as the phosphorylative actions of the tyrosine kinase c-ABL 
have been found to repress telomerase activity rather than activate it  
(Kharbanda et al. 2000). As c-ABL is frequently activated in response to DNA 
damage this represents a further feedback loop by which senescence bypass via 
telomerase activation could be repressed upon the induction of the damage 
associated pathway of senescence. 
The importance of repressing telomerase activity to prevent senescence bypass 
is further highlighted by recent evidence of the involvement of the TGF  
downstream target SMAD3 in the suppression of telomerase during cancer 
induction (Li et al. 2007). SMAD3 is a known c-Myc inhibitor and as such its 
activation would repress the transcription of hTERT. As TGF  is a member of the 
secretory senescence pathway, it is possible that such secretion acts as a 
regulatory mechanism to prevent senescence bypass through telomerase 
telomere maintenance. The repression of telomerase activity after activation of 
both the damage associated and secretory senescence pathways highlights 
intrinsic mechanisms by which cells attempt to respond to and prevent the 
bypass of senescence through telomere maintenance by telomerase. 
1.4.2 Telomere maintenance by alternative lengthening of 
telomeres 
There are however, cells that maintain their telomeres without the reactivation 
of the telomerase enzyme. Such cells are said to use the alternative lengthening 
of telomeres mechanism or ALT. Currently, the underlying molecular 
mechanisms of ALT are poorly understood.  
Existing assays for ALT rely on phenotypic cellular traits. These include 
heterogeneous telomere lengths ranging from 3 kb to 50 kb (Henson et al. 2002), 
small nuclear foci called ALT-associated PML bodies (APBs) (Reddel 2003) and an 
abundance of extrachromosomal telomeric DNA, known as t-circles (Fajkus et al. 
2005). The actual role of these markers in the mechanisms by which these cells 
maintain their telomeres is yet to be fully understood. The current standard 
assay for ALT identification is primarily focused on the identification of ALT 
unique form of the APBs. However, the role of APBs in ALT is still under debate. 
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These nuclear structures contain the PML protein and SP100 of normal 
promyleocyclic leukaemia bodies (PML bodies) (Yeager et al. 1999) as well as 
telomeric DNA repeats, telomere binding proteins TRF1 and 2, RAD51, RAD52 
and replication factor A. RAD51, RAD52 and Replication factor A have well 
characterised roles in recombination and DNA synthesis (Benson et al. 1998) and 
therefore in combination with the TRF1 and 2 highlight a possible role for APBs 
in telomeric maintenance. Further APB characterization has highlighted that 
proteins such as NBS1, PML, TRF1, TRF2, TIN2, RAP1, MRE11 and RAD50 are 
required for APB construction and other molecules, such as BRCA1, hRAP1, SP100 
and 53BP1, simply associate with APBS (Wu et al. 2003; W-Q Jiang 2007). These 
complex and multiple interactions of APBs are indicative of a possible higher 
order structure in APB construction rather than their production as a byproduct 
of telomere maintenance by ALT. The association of molecules with various DNA 
interacting abilities such as the helicases BLM (Stavropoulos et al. 2002) and 
WRN (Johnson 2001) and DNA damage signaling and repair proteins like MRE11 
and RAD50 (in complex with NBS1) gives further weight to their potential for 
direct involvement in telomere maintenance (Zhu 2000). Evidence for this direct 
role is, however, still under debate with some evidence ALT telomere 
maintenance failing in their absence (Jiang et al. 2005) but also evidence of ALT 
in cells without any APBs (Fasching et al. 2005).  
Regardless of the direct involvement of APBs, the most prevalent theory as to 
the mechanism through which ALT cells maintain their telomeres is by 
homologous recombination. The use of fluorescently tagged telomeres has 
demonstrated the copying of telomeres from one chromosome to another 
(Dunham et al. 2000). In addition, through the introduction of a telomere tag it 
has also been shown that intra-telomere recombination can also be utilized by 
ALT cells (Muntoni et al. 2009). Investigation of the telomere recombination 
rates of ALT cell lines reveals higher rates in ALT in comparison to telomerase 
positive cells whilst non-telomeric regions show no significant rate differences, 
adding weight to the concept that this could be the mechanism behind telomere 
maintenance by ALT (Bechter et al. 2003; Londono-Vallejo et al. 2004). Further 
suggested models of telomeric recombination that could result in the observed 
telomere heterogeneity, as shown in Figure 1.3, and add further evidence to the 
theory (Muntoni et al. 2005).  
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Certain telomere binding proteins have also been implicated to play roles within 
the homologous recombination mechanism. This provides opportunities for the 
recruitment of the homologous recombination machinery to the telomeres. For 
instance, WRN is a helicase which when mutated causes the premature aging 
disease Werner Syndrome (Multani et al. 2007). It has been shown to interact 
with members of the shelterin complex, well known telomere interacting 
proteins, such as TRF1, TRF2 and POT1 (Smogorzewska et al. 2004) and as such 
could be seen to potentially have a role in telomere maintenance. However, 
their role may be more complex than previously thought. Patients with a defect 
in the WRN gene suffer rapid telomeric shortening. This suggests that the 
removal of active WRN affects the cell’s ability to stabilise the telomeres to 
their natural gradual degradation rate. WRN has also been successfully used as a 
tool to investigate spontaneous escape from the cell crisis resulting from short 
telomere lengths. Laud et al.demonstrated that cells deficient in WRN are 
capable of senescence escape and telomere maintenance through the ALT 
pathway (Laud et al. 2005). This shows that WRN may not be essential for ALT 
but that its expression and regulation could still play some role at the telomeres 
in ALT cells. 
Such cross-talk with other telomeric interacting proteins is not the only 
consideration that the homologous recombination theory has suggested. A study 
in 2005 examined minisatellite sequences which have known mutations created 
by homologous recombination. (Jeyapalan et al. 2005) The results showed a 
much higher level of minisatellite instability of one of these minisatellites, 
MS32, in ALT cell lines but not in normal or telomerase positive cell lines. This 
suggests that the increase in homologous recombination in ALT may have far 
reaching effects in the genome and may not simply affect the pathways involved 
in this one particular process. The alteration of genomic information in ALT cells 
could have far reaching effects and possibly allow the involvement of other 
relevant pathways through alterations in their regulation and expression.  
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Figure 1.3 - Telomeric heterogeniety achieved through asymetric telomere recombination 
and net gain through intertelomeric strand invasion. (A) Model proposed by Cesare and 
Reddel by which ALT cells would achieve heterogeneity in their telomeric lengths via 
recombination(B) Secondarily a further model is proposed by which telomeres would 
achieve an overall net gain of telomere length through the utilisation of other telomeres as a 
template strand for DNA synthesis, Image taken from Cesare and Reddel, 2010. Nat. Rev. 
Gen., 11(5) 319-330. 
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Further theories on the mechanisms behind ALT also exist. Evidence is growing 
for the role of the small telomeric circles, t-circles, in telomere maintenance. 
Homologous recombination has been found to create a small deletion 
approximately the size of t-circles (Wang et al. 2004). T-circles are present in 
high abundance extrachromasomally in ALT cell lines which may suggest a 
potential “rolling circle” mechanism of telomeric maintenance (Natarajan et al. 
2002) or maintenance mechanisms that could involve the integration of t-circle 
to telomeres or by use of the t-circle as a template (Tomaska et al. 2004). 
Further evidence is supplied in studies that show that even the smallest of t-
circles are active and capable of the rolling circle mechanism of telomeric 
maintenance (Hartig et al. 2004). This suggests that homologous recombination 
may not be solely responsible for the maintenance of the telomeres in ALT cell 
lines. As discussed previously, the interactions of telomere associated and 
homologous recombination associated proteins with other pathways supplies the 
opportunity for potential cooperation of mechanisms to a common goal.  
The interaction of t-circles as part of other ALT TMMs has become a distinct 
possibility since a recent study showed that Nbs1 is required for the production 
of t-circles (Compton et al. 2007). Nbs1 is well characterised as a foundational 
protein in APBs (Wu et al. 2003) and therefore their requirement for t-circle 
production suggests that there is a more complex set of interactions required for 
the full ALT TMM to occur. 
The use of ALT for telomere maintenance is predominantly found in cells of 
mesenchymal origin. However, even within mesenchymal tumour subtypes the 
frequency of ALT varies greatly, for example 77% of malignant fibrous 
histiocytomas use ALT whereas only 6% of rhabdomyosarcomas (Henson et al. 
2005). ALT has also been shown to correlate with patient outcome and prognosis 
however the exact correlation of ALT with outcome and prognosis varies 
depending upon tumour type. Studies of bone and soft tissue sarcomas show an 
improved survival for patients with ALT or telomerase negative tumours 
(Terasaki 2004). Osteosarcomas in particular show strongly favourable outcome 
with ALT (Ulaner et al. 2003; Sanders et al. 2004). Conversely, liposarcomas 
utilizing ALT have increased linkage to mortality (Costa et al. 2006).  Study of 
metastatic potential of mouse embryonic fibroblasts provides some evidence for 
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why some ALT tumours may have more favourable outcome than others (Chang 
et al. 2003). Telomerase reconstitution in subcutaneous ALT tumours led to a 
high metastatic ability whilst tumours that remained as ALT were unable to 
undergo metastasis. A lower metastatic potential could be one explanation for 
the prognostic implications of TMM and why some osteosarcomas, bone and soft 
tissue sarcomas have a more positive prognosis with ALT. However given the 
complexity of the ALT phenotype it is likely that other factors are also involved. 
Telomere maintenance by either telomerase or ALT is an essential step in the 
bypass of senescence, however the reason that a cell utilizes one mechanism 
rather than another is unknown. Examination of the molecular differences 
between the two mechanisms has shown that chromatin modifications may play 
a role in the decision. Methylation at the hTR promoter in ALT cell lines has 
been shown to be responsible for the repression hTR expression in ALT (Hoare et 
al. 2001) and similarly methylation and hypoacetylation of the hTERT promoter 
of ALT cells lines is suggestive of epigenetic suppression of hTERT expression in 
ALT cells  (Atkinson et al. 2005).  Such active regulation of the promoter of the 
two components of telomerase in ALT cells is suggestive of a regulatory network 
initiating and maintaining the choice of TMM during neoplasia. The details of 
such a regulatory network are currently not explored.  
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1.5 Aims of this Study 
As a major block to tumorigenesis an understanding of the regulatory networks 
surrounding the process of cellular senescence is required. Although the roles of 
individual molecules such as p53 and p16 during senescence induction have been 
well defined, the regulatory mechanisms surrounding the larger processes of 
senescence are currently poorly understood. The understanding of the regulatory 
networks involved in senescence bypass through mechanisms such as telomere 
maintenance may also improve current understanding as to how tumours perturb 
the process of senescence and achieve immortalization.  Furthermore, the 
degree to which bypassed senescence pathways remain latently expressed in 
human tumours and their potential impact on clinical factors such as patient 
outcome is completely unexplored. The investigation of these regulatory 
networks and latent senescence signaling may therefore facilitate the improved 
targeting of therapeutics and reveal novel diagnostic and prognostic biomarkers. 
It was therefore the specific aim of this study to investigate regulatory networks 
surrounding senescence signaling and bypass and assess the potential impact 
upon clinical factors such as outcome. 
Through the application of gene expression and miRNA microarray profiling, 
kinome siRNA and virtual drug screening the following questions were addressed: 
 What molecular differences exist between cells utilizing different TMMs 
for senescence bypass?  
 
 Do miRNAs have a regulatory role in senescence bypass and signaling? 
 
 Does latent senescence signaling exist in human tumours and how can it 
be measured? 
 
 Can such measures be used to assess the impact of latent signaling on 
clinical factors such as outcome and response to therapy? 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Tissue Culture Reagents and Consumables 
Minimum Essential Medium (MEM) Invitrogen 
RPMI 1640 growth medium Invitrogen 
Dulbeccos modified Eagles MEM Invitrogen 
L-glutamine (200mM) Invitrogen 
Trypsin (2.5%) Invitrogen 
Foetal calf serum (Batch ID) Autogen Bioclear 
96-well plates Iwaki 
12-well plates Iwaki 
28 cm2 flasks Nunc 
75 cm2 flasks Iwaki 
150 cm2 flasks Nunc 
500 cm2 triple-flasks Nunc 
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2.1.2 Cell Lines 
Human cell lines used in this study: 
Cell Line Source 
Telomere 
Maintenance 
Mechanism 
Age and Sex 
of Donor 
Known 
Mutations  
SK-LU-1 lung 
adenocarcinoma 
ATCC 
ALT 60 years, 
Female 
CDKN2A, 
CDKN2A(p14), 
KRAS, TP53 
KMST6 
immortalised lung 
fibroblast 
CCR 
ALT 9 weeks, 
Female 
TP53 
Wi38-VA13/2RA 
(WI38-SV40) 
immortalised lung 
fibroblast 
CCR 
ALT 3 months 
gestation, 
Female 
SV40 antigen 
renders TP53 
null 
SUSM1 carcinogen 
transformed liver 
fibroblast 
CCR 
ALT Fetal human 
fibroblasts, 
unknown 
TP53 
SAOS-2 
osteosarcoma 
ATCC 
ALT 11 years, 
Female 
RB1, TP53 
U20S osteosarcoma ATCC 
ALT 15 years, 
Female 
CDKN2A 
A2780 ovarian 
carcinoma 
ECACC 
Telomerase Unknown, 
Female 
PTEN 
HT1080 
fibrosarcoma 
 
ATCC 
Telomerase 35 years, 
Male 
CDKN2A, 
CDKN2A(p14), 
IDH1, NRAS 
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Cell Line Source 
Telomere 
Maintenance 
Mechanism 
Age and Sex 
of Donor 
Known 
Mutations  
5637 bladder 
carcinoma 
ATCC 
Telomerase 68 years, 
Male 
RB1, TP53 
C33a cervical 
carcinoma 
ATCC 
Telomerase 66 years, 
Female 
RB1, TP53, 
PTEN, 
PIK3CA, 
MSH2, FBXW7 
WI38 lung fibroblast ECACC 
None 3 months 
gestation, 
Female 
None 
documented 
IMR90 lung 
fibroblast 
ECACC 
None 16 weeks, 
Female 
None 
Documented 
 
2.1.3 Primary Cell Cultures 
Primary cells used in this study: 
Human mesenchymal stem cells (hMSCs): Primary hMSC aspirates isolated by 
centrifugation at 700 g for 15 min at 4 °C over a Ficoll-Hypaque gradient 
(Sigma). 
 
Human Tumour Biopsies 
The table in Appendix II details all of the current information on file for the 
mesenchymal tumours used in this study.  
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2.1.4 Luciferase Reporter Plasmid Vectors 
pGL3 hTERT 24/9: hTERT reporter vector; contains the firefly luciferase gene 
driven by a 576bp fragment of the hTERT promoter, constructed by Sharon Burns 
and Rosalind Glasspool. 
 
pSGG MYEOV: MYEOV reporter vector; contains the firefly luciferase gene driven 
by 1072bp fragment of the MYEOV promoter, constructed by Switchgear 
Genomics. 
2.1.5 Antibodies 
KAT2A/GCN5 Rabbit polyclonal Abcam (ab18381) 
E2F1 Rabbit polyclonal Active Motif (39313) 
HDAC5 Rabbit polyclonal Active Motif (40970) 
PKC alpha Rabbit polyclonal Abcam (ab32376) 
Anti-Rabbit IgG HRP-linked Antibody New England Biolabs (7074) 
ERC antibody Abcam (ab50132) 
 
2.1.6 Kits, Reagents and Enzymes 
Kit/Reagent Supplier 
Lipofectamine 2000 Invitrogen 
Passive lysis buffer Promega 
Luciferase assay system Promega 
Protein assay reagent Biorad 
Nucleospin II RNA extraction kit Macheray-Nagel 
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Kit/Reagent Supplier 
RNeasy lipid tissue RNA extraction kit Qiagen 
RNeasy mini kit Qiagen 
GeneAmp RNA PCR core kit Roche 
Taq PCR core kit Qiagen 
Hotstar Taq DNA polymerase Qiagen 
DyNAmo SYBR Green qPCR kit Finnzymes 
ECL detection reagents for western 
blotting 
Amersham 
Restriction endonucleases and buffers Invitrogen 
E.coli Top10 competent cells Invitrogen 
S.O.C. medium Invitrogen 
Plasmid Maxi Prep kit Qiagen 
Qiaquick Spin Miniprep kit Qiagen 
Multimark protein molecular weight 
marker 
Invitrogen 
NuPAGE Novex 4-12% BIS-TRIS gels Invitrogen 
NuPAGE MES SDS running buffer Invitrogen 
NuPAGE MOPS SDS running buffer Invitrogen 
NuPAGE antioxidant Invitrogen 
NuPAge transfer buffer Invitrogen 
RNAseZap Ambion 
Agilent RNA 6000 Nano reagents & 
supplies 
Agilent Technologies 
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Kit/Reagent Supplier 
RNA 6000 Nano Chips Agilent Technologies 
Nuclear Extraction Kit Active Motif 
TRANSAM c-Myc Active Motif 
Recombinant c-Myc Active Motif 
Gene expression microarray kits and 
reagents 
Agilent Technologies 
MiScript miRNA qPCR kit Qiagen 
 
2.1.7 Chemicals 
2.1.8 General laboratory supplies and reagents 
Provided by Beatson Institute Central Services: 
LB-Medium (Luria-Bertani Medium) 
Sterile Distilled Water 
Sterile phosphasphate buffered saline (PBS) 
Sterile PBS + EDTA (PE) 
10x TBE electrophoresis buffer (Tris Borate/EDTA) 
Sterile glassware and measuring pipettes 
 
General: 
 Supplier 
Ampicillin Sigma 
Kanamycin Sigma 
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 Supplier 
Falcon Tubes 50 & 15ml Becton Dickson 
Universal containers 5ml, 20ml & 
100ml 
Bibby Sterilin 
Microcentrifuge tubes 1.5ml & 0.5ml Eppindorf & Abgene 
Cell scrapers Corning 
Pipette tips Gilson & Griener 
Plastic stripettes 1ml, 5ml, 10ml, 25ml 
& 50ml 
Corning 
X-ray film Fujifilm 
Nitrocellulose membrane Millipore 
 
2.1.9 Oligonucleotide Primers for qPCR 
Oligonucleotide primers given in a 5’ to 3’ direction. 
hTERTF: 5’- CTGCTGCGCACGTGGGAAGC, 
hTERTR: 5’- GGACACCTGGCGGAAGGAG,  
s15F: 5’-TTCCGCAAGTTCACCTACC, 
s15R: 5’-CGGGCCGGCCATGCTTTACG,  
MYEOVF: 5’-TGGGAGGACACGCAAGTT, 
MYEOVR: 5’-CCAGCAGCCAAAGCAAAG,  
WNT5BF: 5’-AGGAGGGAGGTTGTGGTT,  
WNT5BR: 5’-GAACCGTGGAGGATGAAG, 
DSC54F:  5’-ACCCTTCTACGAAATGGA,  
DSC54R:  5’-ACTGTGGCTTATTCCCAT,  
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NSUN5F:  5’-TGAGACCACACTCAGCAG,  
NSUN5R: 5’-GAGAGGACAGGCATCTTC 
GAPDHF: 5’ACCACAGTCCATGCCATCAC,  
GAPDHR: 5’TCCACCACCCTGTTGCTGTA 
TCEAL7F: 5’GAAGGAAGAGCTGGTTGAT 
TCEAL7R: 5’GACCCCTTATCTCTTCCAA 
ChipTERTF:  5’TCCCCTTCACGTCCGGCATT 
ChipTERTR:  5’AGCGGAGAGAGGTCGAATCG 
2.1.10 Oligonucleotides for siRNA 
Target Gene Supplier 
TCEAL7 Dharmacon 
 
2.1.11 Equipment 
Medical Air Technologies Bio-MAT class II microbiological safety cabinet 
Scharfe Systems Casy-1 cell counter 
Forma Scientific CO2 H2O jacketed incubator 
Olympus CK2 phase contrast microscope 
Sigma 4K15/ Beckman GS-6R bench top centrifuges 
Bio-Rad sub-cell GT electrophoresis gel tank/model 200 power supply 
M.J. Research PTC-200 Peltier thermal cycler 
Beckman J6-MC centrifuge 
Beckman Microfuge-R refrigerated micro-centrifuge 
Turner Biosystems Veritas Luminometer 
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Molecular Devices 96 well colorometric plate reader 
Kodak X-Omat 480 RA film processor 
Syngene Gene Genius bioimaging system  
SBeckman DU650 spectrophotometer 
Atto AE 6450 polyacrylamide gel electrophoresis tank 
Atto AE 6675 semi-dry blotting apparatus 
Novex XCell SureLock Elecrophoresis Cell 
Agilent 2100 Bioanalyzer, Agilent Technologies 
IKA LabChip vortexer, Agilent Technologies 
Nanodrop, Agilent Technologies 
Ribolyser, Hybaid 
2.2 RNA Methods 
2.2.1 RNA extraction 
RNase-free filter pipette tips were used throughout RNA extraction and 
microcentrifuge tubes were pre-treated with Diethyl dicarbonate (DEPC) water. 
Prior to extraction all surfaces and pipettes were wiped with RNaseZap (Ambion) 
to remove RNases.  
Total RNA was purified from cultured cells using the NucleoSpin RNA II kit as per 
the manufacturers’ instructions.  In brief, approximately 1 x106 cells were lysed 
by addition of 350µl of buffer RA1 and vigorous vortexing.  This lysis buffer 
contains large amounts of chaotropic ions, which inactivate RNases and create 
appropriate binding conditions which favour adsorption of RNA to the silica 
membrane.  The lysate was homogenised by passing it 10 times through a 20 
gauge needle and was then applied to a NucleoSpin filter which contains the 
silica membrane.  Contaminating DNA, which is also bound to the silica 
membrane, was removed by treatment with DNase-1 solution for 15 minutes at 
room temperature.  Salts, metabolites and macromolecular cellular components 
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were removed in washing steps and the pure RNA was eluted under low ionic 
strength conditions with RNase-free water.  
Total RNA was extracted from fresh frozen tumour samples using RNeasy lipid 
tissue RNA purification kit as per manufacturors instructions. In brief, 
approximately 100 g of fresh frozen tissue were homogenised in 350 l of tissue 
lysis/binding solution using a 20 second pulse at speed setting 5.5 on a Hybaid 
Ribolyser. This lysis buffer contains the required concentration of chaotropic 
ions to facilitate bind of nucleic acids to the silica membrane of spin columns in 
combination with a low concentration of detergent to maximise tissue breakup 
and cellular disruption.  350 l of 100% ethanol was then added to create 
optimial nucleic acid binding conditions. The solution was then applied to a 
RNAqueous filter cartridge which contains the silica membrane optimised for 
capturing low RNA concentrations. Contaminating salts, metabolites and 
macromolecular cellular components were removed in washing steps and the 
pure RNA was eluted under low ionic strength conditions with RNase-free water. 
 
2.2.2 RNA quality assessment 
RNA quality and quantity was analysed using the RNA 6000 Nano Assay reagents, 
RNA Nano LabChips and Agilent 2100 Bioanalyzer, as per manufacturors 
instructions. In brief, prefiltered RNA matrix gel combined with RNA dye 
concentrate in an RNAse free microcentrifuge tube, vortexed well and 
centrifuged for 10 minutes at 13000 g. Gel dye was added to the RNA chip and 
pressurised to force the gel through the chip’s capillaries. 5 l of RNA 6000 Nano 
marker was then added to the ladder well and all sample wells on the chip. This 
low molecular weight RNA complex gives the bioanalyser software software a 
common reference point in all RNA samples for comparison. 1 l of RNA 
standards were then added to the ladder well and 1 l of each RNA sample 
added to their respective wells. The RNA labChip was then vortexed for 1 minute 
on the IKA LabChip vortex, Agilent technologies. The Agilent 2100 Bioanalyser 
electrodes were washed with RNase ZAP followed by DEPC-treated water before 
insertion of the LabChip for analysis using the 2100 Bioanalyser software. The 
samples are then filtered through the gel-dye electrophoretically allowing size 
and quality assessment in relation to the provided standards.   
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2.2.3 Gene expression microarray hybridisation, washing and 
scanning 
RNA for each tumour sample was amplified and labelled using the Agilent Low 
RNA Input Linear Amplification Kit PLUS, One-Colour and hybridised to Agilent 
whole human genome 4 x 44K gene expression arrays as per manufacturers’ 
instructions. Raw data was extracted from scanned images using Agilent Feature 
Extraction software (Agilent Technologies, Santa Clara, CA).  
 
2.2.4 miRNA expression microarray hybridisation, washing and 
scanning 
miRNA Microarrays were performed by S. Hoare using Agilent’s miRNA Microarray 
System and Human miRNA Rel 12.0 (8 x 15K) arrays as per manufacturers 
instructions (Agilent Technologies, Santa Clara, CA). 100ng of RNA was 
dephosphorylated, DMSO added and then denatured. Samples were labelled 
using T4 ligase and Cyanine 3-pCp, vacuum dried and resuspended in 
hybridisation buffer mix containing blocking reagent. Samples were denatured 
and hybridised overnight for 20hrs @ 55oC and 20rpm.  Slides were washed then 
scanned using an Agilent DNA microarray scanner with the miRNA default 
settings. Data was extracted from scan files using Agilent Feature Extraction 
software version 10.5.1.1 (Agilent Technologies, Santa Clara, CA). 
2.2.5 cDNA synthesis by reverse transcriptase PCR 
cDNA was prepared using the GeneAmp RNA PCR core kit (Roche).  RNA was 
quantitated and quality assessed using the Agilent 2100 Bioanayser and adjusted 
to 1μg in RNase-free dH2O. Only RNA with an RNA integrity number of 9 or above 
was used for cDNA synthesis.  Reactions were prepared in a PCR workstation 
(Labcaire) using RNase-free tubes and tips, which were UV crosslinked prior to 
use.  A reaction mix was made up with 4µl of 10x Buffer, 8.8µl MgCl2, 8 µl 
dNTPs, 2 µl random hexamers, 0.8µl of RNAse inhibitor, 1µl of reverse 
transcriptase (RT) and 1ug of RNA per sample, made up to 40µl with dH20.  For 
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each sample a no RT control mix was also prepared.  Samples were then 
incubated at 25ºC for 10 minutes, 48ºC for 30 minutes and 95ºC for 5 minutes 
using a Peltier Thermal Cycler (PTC-200) DNA Engine (MJ Research).  1ul of cDNA 
was used in subsequent PCR reactions.    GAPDH specific PCR was performed for 
RT-PCR reaction products and no RT controls to determine the quality of cDNA 
produced and to check for DNA contamination of the RNA. 
2.2.6 Polymerase Chain reaction 
Polymerase Chain Reaction (PCR) master mixes were made using reagents from 
the Qiagen Taq-core kit. Reaction mixes were prepared in a PCR workstation 
(Labcaire) and all equipment was UV crosslinked before use.  Reactions typically 
contained 1 l template cDNA along with final concentrations of master-mix 
components as follows: 1x PCR buffer; 0.5 M each primer; 0.2mM each of dATP, 
dTTP, dCTP, dGTP; 1 unit Taq polymerase.  Reaction volumes were made up to 
25 L with sterile distilled H20 and run on a Peltier Thermal Cycler (PTC-200) DNA 
Engine (MJ Research) according to the cycling conditions detailed below.  PCR 
products were analysed by agarose gel electrophoresis.  Typically 7 μl was 
loaded onto a 1% agarose gel containing Gel Red (SUPPLIER) for UV visualisation 
of DNA. 
2.2.6.1 Cycling conditions 
RT-PCR 
1. 25°C for 10 min 
2. 48°C for 30 min 
3. 95°C for 5 min 
4. 4°C forever 
GAPDH  
1. 94°C for 45 sec 
2. 60°C for 45 sec 
3. 72°C for 2 min 
4. Repeat 29 times from step 2  
5. 4°C forever 
 
2.2.7 Quantitative polymerase chain reaction (qPCR)  
q-PCR master mixes were made using the Finnzymes DyNAmo SYBR green qPCR 
kit.  The 2x reaction mix provided contained pre-mixed SYBR green dsDNA 
binding dye, buffer, Taq polymerase and dNTPs. Typical reactions therefore 
consisted of 1x SYBR green reaction mix, 0.5 M each primer and 1 l DNA made 
up to a 20 l volume with dH20.  Reaction mixes were prepared in a PCR 
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workstation (Labcaire) and all equipment was UV crosslinked before use.  All 
reactions were set up in triplicate alongside a no-DNA control.  A known 
concentration range (100 ng – 10 pg) of 5 genomic DNA standards were also set 
up in triplicate producing a standard curve to which the PCR product is 
compared and quantified.  Reactions were run on an Opticon 2 DNA Engine from 
MJ Research according to the cycling conditions detailed below.  The average 
value of the triplicate reactions was taken as the concentration of PCR product. 
2.2.7.1 Cycling conditions 
DSC54  
1. 94°C for 10 min 
2. 95°C for 30 sec 
3. 60°C for 45 sec 
4. 72°C for 30 sec 
5. 80°C for 10 sec 
6. Plate read 
7. Repeat 34 times from step 2  
MYEOV  
1. 94°C for 10 min 
2. 95°C for 30 sec 
3. 58°C for 45 sec 
4. 72°C for 30 sec 
5. 82°C for 10 sec 
6. Plate read 
7. Repeat 34 times from step 2  
NSUN5  
1. 94°C for 10 min 
2. 95°C for 30 sec 
3. 60°C for 45 sec 
4. 72°C for 30 sec 
5. 84°C for 10 sec 
6. Plate read 
7. Repeat 34 times from step 2  
S15  
1. 94°C for 10 min 
2. 95°C for 30 sec 
3. 55°C for 45 sec 
4. 72°C for 30 sec 
5. 82°C for 10 sec 
6. Plate read 
7. Repeat 34 times from step 2  
 
TCEAL7  
1. 94°C for 10 min 
2. 95°C for 30 sec 
3. 55.2°C for 45 sec 
4. 72°C for 30 sec 
5. 82°C for 10 sec 
6. Plate read 
7. Repeat 34 times from step 2  
 
WNT5B  
1. 94°C for 10 min 
2. 95°C for 30 sec 
3. 56°C for 45 sec 
4. 72°C for 30 sec 
5. 82°C for 10 sec 
6. Plate read 
7. Repeat 34 times from step 2  
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hTERT  
1. 94°C for 15 min 
2. 95°C for 30 sec 
3. 69°C for 45 sec 
4. 72°C for 1 min 
5. 87.5°C for 10 sec 
6. Plate read 
7. Repeat 34 times from step 2  
 
CHIPTERT  
1. 94°C for 15 min 
2. 95°C for 30 sec 
3. 62°C for 45 sec 
4. 72°C for 30 sec 
5. 88 °C for 10 sec 
6. Plate read 
7. Repeat 39 times from step 2  
 
 
 
2.2.8 qPCR validation of miRNA expression in mesenchymal 
tumours 
miRNA qPCR was performed by S. Hoare according to MiScript protocol (Qiagen, 
Crawley, West Sussex), in which 250ng-1ug of RNA is transcribed into cDNA by 
addition of a polyA tail, using oligo dT primers with an additional unique 
sequence. Quantitative-PCR was then carried out using the universal primer to 
this sequence and the unique miRNA primer and visualised with SYBR green. Q-
PCR was tested for each tumour set with a range of small non-coding miRNA 
primers (Qiagen). Using the most uniform expression of a control RNA across a 
tumour type lead to the selection of RNU1A for liposarcomas, MPNST and 
synovial sarcoma normalisation whereas RNU6B was used for mesothelioma 
normalisation. A selection of Q-PCR reactions was carried out for the specific 
miRNA, and these were normalised to the controls. Universal RNA (Stratagene, 
La Jolla, CA) was used for standards in each case. Q-PCR was carried out on a 
Chromo4 machine (Bio-RAD Laboratories Ltd., Hemel Hempstead, UK). Average 
results from at least 2 reactions were plotted as box-plots using Minitab (version 
15). 
2.3 DNA techniques 
2.3.1 Transformation of cells with Plasmid DNA 
Transformation of plasmid DNA was performed by adding 1µl of plasmid DNA to 
50µl of competent E. coli TopTen cells and incubating for 30 minutes on ice. The 
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bacteria were then heat shocked by placing in a 42oC water bath for 30 seconds 
and then transferred to ice for 2 minutes. 100µl of S.O.C media was added and 
the bacteria were incubated on a shaker at 37oC for 1 hour. 800 µl of S.O.C. 
media was added and 100-300 µl was then spread onto Agar plates containing 
ampicillin and incubated overnight at 37oC to allow growth of discrete colonies. 
Individual colonies were then removed from Agar plates using a sterile 10 l 
pipette tip and placed in 10 ml LB-media containing ampicillin. Cultures were 
incubated on a shaker at 37oC overnight. 
2.3.2 Glycerol stocks 
1 ml glycerol stocks were prepared by combining 500 l of fresh bacterial 
culture with 500 l of 50 % sterile glycerol. Glycerol stocks were stored at -70 oC 
in 1.5 ml sterile microcentrifuge tubes. 
2.3.3 Small scale preparation of plasmid DNA 
Mini-preparation of DNA from small volumes of bacterial culture was performed 
using the QIAprep Spin Miniprep Kit (Qiagen) as per manufacturers’ instructions.  
In brief, 10 ml of overnight culture was pelleted at 2500rpm for 10 minutes and 
the supernatant discarded.  The pellet was subjected to alkaline lysis followed 
by neutralisation then centrifugation at 13000rpm to remove cell debris.  
Supernatant was transferred to a spin filter containing a silica-gel membrane to 
which DNA was specifically adsorbed in the presence of high salt.  Following a 
wash step to remove salts DNA was eluted in 50 μl of distilled water. 
2.3.4 DNA sequencing 
Sequencing of plasmid DNA was performed by Beatson Molecular Services. 
2.3.5 Large scale preparation of plasmid DNA 
Maxi-preparation of plasmid DNA was performed using the Qiagen Plasmid 
Maxiprep kit as per manufacturers’ instructions.  In brief, 500ml-1L of bacterial 
culture was harvested by centrifugation at 4000rpm for 10 minutes and alkaline 
cell lysis performed.  Cell lysates were cleared by centrifugation at 4000rpm for 
30 minutes at 
Kyle Lafferty-Whyte, 2010  Chapter 2,48 
selectively binds plasmid DNA under appropriate low-salt and pH conditions.  
Following wash steps in medium salt buffer plasmid DNA was eluted in high salt 
buffer and precipitated by adding 0.7 x volume (10.5ml) of isopropanol and 
with 5ml of 70% ethanol then centrifuged again at 4000rpm for 15 minutes.  
Finally the pellet was air-dried at 37 ºC for 10 to 15 minutes and redissolved in a 
200 μl of TE buffer. DNA concentrations were then analysed using a Nanodrop 
Spectrometer, Agilent Technologies, and adjusted to 1μg/μl. 
2.3.6 Restriction Digests 
Restriction endonuclease digests using up to 2µg of plasmid DNA were performed 
in 20µl reactions containing 1 L of each restriction endonuclease (typically 
10U/ L) diluted with 1x restriction endonuclease buffer. Reactions were made 
up to 20 µl with sterile distilled water and incubated at 37oC for a minimum of 1 
hour. 
2.3.7 UV gel documentation 
Analysis and photography of Gel Red (Cambridge bioscience)/ethidium bromide 
agarose gels visualised under UV was performed using gene genius bioimaging 
system by syngene. 
2.3.8 Western blotting 
Fifteen micrograms of protein equivalents were separated on 10% Bis–Tris gels 
using NuPAGE MES running buffer (Invitrogen, Renfrewshire, UK), and then 
blotted onto nitrocellulose membrane (Millipore, Watford, UK) and blocked in 
phosphate buffered saline Tween-20 containing 5% nonfat dried milk. Membranes 
were probed with the following antibodies: HDAC5 rabbit polyclonal (Active 
Motif, Rixenstart, Belgium), PKCa rabbit polyclonal and KAT2A/GCN5 rabbit 
polyclonal (both from Abcam, Cambridge, UK) and secondary anti-rabbit IgG 
horseradish peroxidase-linked antibody (New England Biolabs UK, Hitchin, UK). 
After visualization, membranes were stripped of bound primary and secondary 
antibodies by submerging in 1% SDS and 0.2m glycine (pH 2.5) and shaken for 1 h 
at room temperature, and rinsed and reblocked before probing with loading 
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control antibody extracellular signal-regulated kinase 1 rabbit polyclonal 
(1:3000) (Santa Cruz Biotechnology, Heidelberg, Germany). 
2.3.9 Maintenance and Storage of mammalian cell lines 
The ALT cell lines used were SKLU (lung adenocarcinoma), SUSM1 (liver 
fibroblasts), KMST6 (lung fibroblasts), WI38-SV40 (SV40 immortalized lung 
fibroblasts), SAOS (osteosarcoma) and U2OS (osteosarcoma). Telomerase-
positive cells used were C33a (cervical carcinoma), HT1080 (fibrosarcoma), 
A2780 (ovarian carcinoma) and 5637 (bladder carcinoma). Normal cell strains 
used were WI38 (normal lung fibroblasts) and IMR90 (normal lung fibroblasts). 
Bone marrow hMSCs were isolated as described earlier (Serakinci et al., 2006) 
and cultured using Dulbecco’s modified Eagle’s medium with low glucose plus 
Glutamax supplemented with 17% Hyclone fetal bovine serum (Thermo Fisher 
Scientific, Waltham, MA, USA) at 5% CO2. 
2.3.10 Transient transfection of siRNAs 
Whole kinome siRNA library screen from Applied Biosystems (Applied Biosystems 
Inc, Foster City, CA USA) in SKLU cells. In brief, 50 nM of siRNA or non-coding 
siRNA control (Applied Biosystems Inc, Foster City, CA USA) were co-transfected 
with 250ng of hTERT reporter plasmid in 96 well plates (Thermo-Fisher 
Scientific, Rochester, NY, USA) using lipofectamine 2000 (Invitrogen, Paisley, 
UK) according to manufacturer’s instructions. Cell lysis was achieved using 
passive lysis buffer (Promega, Madison, WI, USA). TCEAL7 siRNA transfections 
were performed using Dharmacon Smartpools (Thermo-Fisher Scientific, 
Rochester, NY, USA) in 75 cm2 flasks. TCEAL7 siRNA transfections for c-Myc 
activity were performed in 125 cm2 flasks. pCMV-XL4:TCEAL7 overexpression 
plasmid was purchased from Origene (Origene Technologies Inc., Rockville, MD, 
USA) and all transfections were performed in 75 cm2 flasks.  All transfections 
were performed in triplicate. 
2.3.11 Luciferase reporter assay 
Luciferase assay system (Promega, Madison, WI, USA) was used to determine 
luciferase activities according to manufacturer’s instructions. 
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2.3.12 Nuclear extract purification and Trans-AM c-Myc 
activity assay 
Nuclear extracts of approximately 8 x108 cells of each of the six ALT cell lines 
(WI38-SV40, KMST6, SKLU, SUSM1, SAOS and U2OS) and four telomerase-positive 
cell lines (A2780, C33a, HT1080 and 5637) were extracted in triplicate using an 
Active motif nuclear extraction kit (Active Motif, Rixenstart, Belgium) as per the 
manufacturer’s instructions. c-MYC DNA-binding ELISAs (Active Motif) were 
performed on three separate occasions with four technical replicates of each 
cell line as per the manufacturer’s instructions. A standard curve of 5, 2.5, 1.25 
and 0.625 ng/well recombinant c-MYC protein (Active Motif) was run on each 
assay to allow relative quantification. Results of all ALT and telomerase-positive 
cells were grouped and a t-test was carried out using Minitab (version 14). 
2.3.13 c-Myc Chromatin ImmunoPrecipitation 
ChIP assays were performed as per manufacturers’ instructions (Millipore, 
Watford, UK) as previously published (Bilsland et al. 2009).  
2.3.14 Telomerase activity assay 
The TRAPeze XL kit was used for TRAP assay according to the manufacturer’s 
instructions (Millipore, Watford, UK) and was performed by S. Hoare as 
previously published (Bilsland et al. 2009). 
2.4 Bioinformatic Methods 
2.4.1 Gene expression microarray Data normalisation and quality 
control 
All array data was then imported into GeneSpring GX (version 7.3.1, Agilent 
Technologies, Santa Clara, CA) and tumour data was normalised to the 70th 
percentile and the cell line and hMSC data normalised to the 50th percentile. 
Further quality control involved filtering based on flag values where only those 
genes that had non-absent flag values for at least half of the ALT and telomerase 
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samples were included in downstream analysis. DU145 and HT29 gene expression 
microarrays were perfomed by L. Hanley. 
2.4.2 Deposit of microarray data to GEO 
Fully MIAME compliant gene expression data resulting from this study was 
deposited with GEO under the following accession numbers: GSE14533 and 
GSE17118. 
2.4.3 miRNA expression microarray Data normalisation and 
quality control 
Raw miRNA microarray data was imported into BRB array tools and the following 
quality control and normalisation filters were applied: signal intensity threshold 
of 10, probes labelled as absent excluded, arrays normalised to the median of 
the entire array using the median array as a reference. Furthermore, genes 
where less than 20% of the data had a fold change of less than 1.5 from its 
median expression or where more than 50% of the data was missing were also 
excluded.  
2.4.4 Hierarchical clustering 
Gene Expression Hierarchical clustering was performed using Genespring GX 
(version 7.3.1) using Spearman correlation and average linkage, merging 
branches with similarity less than 0.01. Hierarchical clustering of NCI60 
expression data was performed by importing the median normalized data from 
BRB-array tools into Partek.  miRNA hierarchical clustering was performed within 
BRB-array tools using Pearson correlation and average linkage.  
2.4.5 Telomere Maintenance Gene expression signature 
generation Gene selection 
Within GeneSpring GX, the 1305 gene signature was generated from cell line 
expression profiles using a WELCH ANOVA with a false discovery rate of 0.05 and 
the Benjamini and Hochberg multiple testing correction to test for significant 
differences in gene expression between the two telomere maintenance 
mechanism groups.  A similar analysis in liposarcoma samples generated no 
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results therefore to generate the refined 297 gene signature a Fishers Exact Test 
using a p-value of ≤0.05 was performed using the liposarcoma expression profiles 
to test for significant association of gene expression with telomere maintenance 
mechanism.  From this analysis 422 genes were also present within the 1305 
signature.  Those genes with fold change values in the same direction for both 
cell line and liposarcoma data (i.e. an increased or decreased expression in ALT 
compared to telomerase positive) were included in the refined signature. 
2.4.6 Mesenchymal tumour miRNA signature generation 
The binary tree prediction method (utilising the compound covariate predictor 
algorithm) in BRB array tools in combination with leave-one-out cross-validation 
was used to identify miRNAs whose expression patterns had the ability to 
distinguish between tumour types. 
2.4.7 Survival Analysis 
Kaplan-Meier plots of survival and Log Rank (Cox Regression) tests adjusting for 
age and sex were performed using SPSS (v15, SPSS Inc, Chicago, Illinois, USA). 
miRNAs with significant hazard ratios were highlighted using BRB array tools 
“find genes correlated with survival” tool which develops an expression based 
predictor of survival risk group as previously described by Bair and Tibshirani 
(Bair et al. 2004).  
2.4.8 Senescence scoring of gene expression data 
Gene expression data was filtered to show only values associated with 
senescence signature gene lists using BRB array tools. Filtered data was then 
exported to Excel and normalised to median after which genes were scored as 
“senescent” or “non-senescent” depending on their gene expression levels 
relative to the median and their known expression pattern during senescence 
signaling (see Table 1). For example, expression of the proliferation-associated 
gene KI67 below median would be marked “senescent” but above median 
expression would not. The overall senescence score was then calculated as a 
percentage of the genes receiving a “senescent” score over the total number of 
genes in a particular senescence signature. Median, and maximum and minimum 
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values plotted using Excel. As such, a senescence score could be summarized by 
the following formula:  
Score = ((number of proscescent genes)/(Number of genes in pathway))*100 
Senescence scoring of drug treated breast cancer cells was performed by L. 
Hanley and included for completeness. 
2.4.9 Correlations of senescence signature rankings 
To assess the correlations of senescence scores given to each individual sample 
by each signature the scores for each tumour were placed into Minitab (v15, 
Minitab Inc, Coventry, UK) and rankings for each signature score were used for 
Pearson correlations. 
2.4.10 Regression Analysis of Senescence scores and 
compound GI50 data 
Regression analysis was performed using the stat package of Perl and exporting 
results to Excel.  
2.4.11 Predicted compound activity mapping 
This was performed by Cancer Research Technologies UK through the use of 
graph-theory connectivity indices to build a decision tree model of predicted 
activities. Compounds showing significant regressions for any of the three scores 
were then aligned with their predicted activity in Excel. 
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3 Senescence bypass by telomere maintenance 
is a regulated by a gene expression network with a 
central role for c-Myc and TCEAL7 and highlights a 
mesenchymal stem cell origin for ALT 
3.1 Introduction 
As previously discussed, for a cell to become fully tumourigenic it must bypass 
replicative senescence and this is usually achieved through telomere 
maintenance.  
Most cancers utilise the telomere rebuilding activities of the ribonucleoprotein 
telomerase. Telomerase activity is strictly regulated in normal cells and only 
occurs in specific normal cell types including germ line cells and activated 
lymphocytes (Artandi et al. 2006). To obtain telomerase activity cells must 
express both genetic components hTERT, which encodes the catalytic subunit, 
and hTR which encodes the RNA template molecule used for reverse 
transcription of telomeres. The senescence bypass effect of telomerase activity 
is exemplified by its frequent ectopic expression leading to the creation of 
immortalised cell lines (Morales et al. 1999; Yang et al. 1999).  
However, around 10% of cancers utilise the recombination based mechanism 
known as the alternative lengthening of telomeres (ALT). ALT is predominantly 
found in tumours of mesenchymal origin, however even within this group of 
tumours, the predominance of ALT varies in individual types of tumours from 
77% ALT in MFH to 6% in Rhabdomyosarcomas (Ulaner et al. 2004; Henson et al. 
2005). Furthermore the prognostic implications of ALT for different tumour 
types varies from being linked with good prognosis in osteosarcomas (Ulaner et 
al. 2003) and poor prognosis in liposarcomas (Costa et al. 2006; Cairney et al. 
2008). The molecular mechanisms behind telomere maintenance by ALT are 
currently not well elucidated. Cells utilising the ALT mechanism use both inter 
and intra telomere recombination to maintain their telomere lengths and have 
increased rates of telomeric exchange (Dunham et al. 2000; Londono-Vallejo et 
al. 2004; Muntoni et al. 2009) ALT is currently characterised by a combination of 
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the presence of ALT associated PML bodies (APBs), lack of detectable telomerase 
activity, presence of extrachromosomal T-circles and heterogenous telomere 
lengths.  
The telomere maintenance mechanism (TMM) used by a tumour is not usually 
considered nor investigated during the course of a study and as a result, the 
molecular details of the decision between telomere maintenance mechanisms is 
currently poorly understood. To this end gene expression microarrays were 
utilised to explore the transcriptional differences between TMMs in cell lines and 
mesenchymal tumour biopsies for which the TMM had been previously 
established. 
3.2 Results 
3.2.1 Gene expression analysis distinguishes telomerase and ALT 
cell lines 
To investigate the presence of a telomere maintenance mechanism (TMM) 
specific gene expression signature expression profiles, 4 ALT (SKLU1, KMST6, 
WI38-SV40, SUSM1) and 4 telomerase positive cell lines (5637, A2780, C33a, 
HT1080) were investigated using Agilent whole human genome 1-colour 
microarrays.  A detailed description of the quality control measures and the 
normalisation options applied can be found in Chapter 2, however boxplots show 
that the normalised data was equally spread and comparable between the 2 
groups (Figure 3.1a) with virtually equal medians of 0.78 and 0.79 for ALT and 
telomerase positive cell line groups respectively. 
A Welch ANOVA was used to find significant differences in gene expression 
between the 2 groups with aim of exploring the possibility that expression of 
individual genes within these large profiles was responsible for defining either 
telomerase positive or ALT cells (Figure 3.1b, left panel).  A list of 1307 probes 
corresponding to 1305 differentially expressed genes with an adjusted p-value 
≤0.05 was generated (For all gene lists associated with this work see Appendix I).  
Focusing on the expression values for individual genes within the larger 1305 
gene signature it was clear that where expression was high in the ALT cell lines 
it was low in the telomerase positive cell lines and vice versa (Figure 3.2a).   
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Figure 3.1 - Gene expression analysis of ALT and telomerase positive cell lines. (A) 
Boxplots show distribution of normalised data in ALT and telomerase positive cell line 
groups.  Grey boxes define 25 and 75% quartiles, while error bars represent the 1st and 99th 
percentiles of the distribution.  Dots represent outliers, black line represents the median, 
while the cross represents the mean of the distribution. (B) Overview of signature 
generation from cell line and liposarcoma tissue samples.  A refined 297 gene signature 
was generated from a combination of the 1305 gene cell line signature and the 6719 gene 
liposarcoma signature.  This signature shows a potential mesenchymal stem cell origin for 
ALT and is involved in telomerase gene regulation. 
Kyle Lafferty-Whyte, 2010  Chapter 3,57 
 
Figure 3.2 - Gene expression profiling distinguishes telomerase positive and ALT cell lines 
and is suggestive  of a mesenchymal stem cell origin for ALT. (A) Scatter plot representing 
normalised microarray expression values for the 1305 gene signature in ALT (blue) and 
telomerase positive (red) cell lines relative to overall median expression value.  Each dot 
represents the mean gene expression values for a gene, while error bars represent the 
standard error. (B) Hierarchical clustering of the cell line data using the 1305 signature 
accurately separates telomerase positive (red) from ALT (blue) cell lines. (C) Hierarchical 
cluster ing cell line, mortal fibroblast and hMSC samples using the 1305 signature whereby 
hMSC and mortal fibroblasts cluster more closely to ALT than Telomerase positive cell 
lines. All clustering performed using the Spearman correlation, average linkage and 
merging branches with a similarity correlation of 0.001 or less. 
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Furthermore, hierarchical clustering of the cell lines based on this signature 
accurately separated out ALT and telomerase positive cell lines into 2 separate 
groups (Figure 3.2b), suggesting that the genes responsible for defining 
telomerase or ALT or those involved in regulating the decision of which TMM to 
activate have been present within this signature. 
3.2.2 Clustering using the 1305 gene signature is suggestive of a 
mesenchymal stem cell origin for ALT 
The fact that ALT is predominantly found in tumours of mesenchymal origin 
prompted further investigation into whether ALT was a function of the cell of 
transformation and if mesenchymal stem cells could be the potential cell of 
origin for ALT tumours.  To this end, supervised hierarchical clustering analysis 
using the 1305 gene signature was performed to investigate any relationship 
between telomerase positive, ALT and normal fibroblast cell lines and hMSC 
(Figure 3.2c).  The signature accurately separated out telomerase positive and 
ALT cell lines, normal fibroblasts and hMSC.  However, while the telomerase 
positive cell lines clustered together on a separate branch the ALT cell lines, 
normal fibroblasts and hMSC all clustered together.  Normal fibroblasts were 
found to be more directly related to hMSC than ALT, however fibroblasts and 
hMSC were found to be equally related to the ALT cell lines, suggestive of a 
mesenchymal stem cell origin for ALT.  This may be as predicted, however this 
was the first time any direct association between mesenchymal stem cells and 
ALT had been documented. 
Analysis of the signature revealed several genes associated with stem cell 
maintenance and self-renewal processes were differentially expressed between 
telomerase positive and ALT cell lines.  Four of these genes with strong 
differences in expression were chosen for validation by quantitative PCR (Figure 
3.3a).  Three of these were significantly up-regulated in ALT cell lines and 
barely expressed in telomerase positive.  DSC54 is a novel mesenchymal stem 
cell protein for which little information exists; WNT5b is a well-known regulator 
of stem cell function implicated in oncogenesis and development; MYEOV is 
overexpressed in myeloma and has a role in promoting invasion and 
proliferation.  The final gene NSUN5 is a proliferation associated nucleolar 
antigen, deletion of which may contribute to the premature aging effects of the  
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Figure 3.3 - qPCR Validation of the 1305 gene expression signature highlights a stem cell 
link (A) Expression levels of DSC54, WNT5B, MYEOV and NSUN5 were validated by 
quantitative PCR in telomerase positive cell lines 5637, A2780, C33a and HT1080 (black 
bars) and ALT cell lines WI38-SV40, KMST6, SKLU, SUSM1 (grey bars) cell lines. Each bar 
represents the mean and standard error of triplicate reactions from a representative 
experiment normalised to GAPDH. (B) Expression values for DSC54, WNT5B and MYEOV in 
various normal tissues extracted from publicly available microarray expression data 
(GSE3239), compared to those for ALT and telomerase positive cell lines and hMSC.  Dots 
represent the median while error bars represent the maximum and minimum normalised 
expression values. 
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developmental disorder Williams syndrome.  NSUN5 was significantly up-
regulated in telomerase positive compared to ALT cell lines. 
To further explore the link between ALT and mesenchymal stem cells the 
expression of these genes within a variety of normal tissues of differing 
embryonic origin and human mesenchymal stem cells (hMSC) was explored. To 
this end publicly available gene expression profiles from normal fibroblasts, 
smooth muscle, stromal, ectoepithelial, epithelial and endothelial tissues were 
downloaded (GSE3239) and expression of DSC54, WNT5b and MYEOV in these 
tissues was compared to that of hMSC, telomerase positive and ALT cell lines 
(Figure 3.3b).  No comparable data was available for NSUN5 in this dataset and 
therefore this gene could not be included in the analysis.   
Consistent with the Q-PCR validation expression, all 3 genes showed higher 
expression in ALT than telomerase positive cell lines.  When comparing all of the 
expression patterns, DSC54 was only high in ALT cell lines and hMSC, consistent 
with a mesenchymal stem cell origin for ALT.  WNT5b on the other hand showed 
varying expression across the different tissue types and cell lines with highest 
expression in hMSC, ALT and mesenchymally derived tissues and lowest 
expression in telomerase positive and epithelial tissues.  MYEOV distinguished 
ALT from telomerase positive cell lines, however a similar low level of 
expression was seen across the various other tissue types. 
3.2.3 Refinement of the 1305 gene signature using liposarcoma 
gene expression improves separation of ALT and 
telomerase positive liposarcomas and suggests a 
mesenchymal stem cell origin for ALT in this mesenchymal 
malignancy 
Liposarcomas are tumours of mesenchymal origin in which telomere 
maintenance mechanism is highly prognostic (Costa et al. 2006).  In order to 
refine the cell line derived signature with data from primary tumours, the power 
of the 1305 gene expression signature to distinguish telomerase positive and ALT 
in liposarcomas was investigated.  Gene expression profiles were generated for a 
group of 17 previously characterised liposarcoma samples, of which 9 were ALT 
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and 8 were telomerase positive.  Unsupervised clustering showed some split in 
the samples depending on their TMM, which was not improved when the 1305 
gene signature was applied.  Furthermore, hMSC did not cluster with any 
liposarcoma samples, but clustered together on a separate branch (Figure 3.4 a 
& b).   
Although the 1305 signature did not improve clustering, the liposarcoma 
samples, for the most part, clustered together according to their telomere 
maintenance mechanism.  The obvious separation between ALT and telomerase 
positive tumours in the clustering diagram suggested that differences in gene 
expression exist between the 2 groups, although no significant differences were 
found.  In order to explore this further a Fisher’s exact test was used to test for 
any association between gene expression level and telomere maintenance 
mechanism.  From this analysis 8227 probes corresponding to 6719 genes were 
found to be significantly associated with TMM in ALT and telomerase positive 
liposarcoma samples (Figure 3.1b right-hand panel). 
To further refine this large signature the overlap, with the 1305 gene signature 
determined from the cell lines was examined.  Of these 1305 genes 422 genes 
were also present in the liposarcoma signature and therefore had a significant 
association with telomere maintenance mechanism in liposarcoma and cell lines.  
Further refinement of the signature was carried out by examining the direction 
of gene expression in telomerase positive and ALT tumours in comparison to the 
cell line data.  297 of the 422 genes had gene expression that was comparable to 
the cell line data, 152 genes up in ALT, down in telomerase positive and 145 
genes down in ALT, up in telomerase positive (Figure 3.1b centre panel). 
Hierarchical clustering of ALT and telomerase positive liposarcoma samples using 
this refined 297 gene signature showed a clear separation between the 2 groups 
with all but 2 ALT samples clustering on one branch while all telomerase positive 
samples clustered together on a separate branch (Figure 3.4c).  Furthermore, 
consistent with the hypothesised mesenchymal stem cell origin for ALT seen 
within the cell line data, hMSC clustered with the ALT liposarcomas using this 
refined signature rather than as a separate group when the 1305 signature was 
applied (Figure 4 b & c). 
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Figure 3.4 - Hierarchical clustering of ALT and telomerase positive liposarcoma sample and 
hMSC distinguishes telomerase positive from ALT and highlights an hMSC origin for ALT. 
Liposarcoma samples were previously determined as ALT (blue) or telomerase positive 
(red) by classical methods.  Hierarchical clustering of these samples and hMSC (green) was 
performed using the Spearman correlation, average linkage and merging branches with a 
similarity correlation of 0.001 or less using (A) all genes (B) 1305 gene signature or (C) the 
refined 297 gene signature.  
(D) Network analysis of the 297 gene signature shows hTERT regulation. Signaling network 
of known direct interactions between genes from the 297 gene signature drawn using the 
analyse network building algorithm within Metacore.  Green arrows represent positive, red 
negative and grey unspecified interactions.  Red and blue circles next to network objects 
represent expression data.  Red: up in ALT and down in telomerase positive liposarcoma 
samples and cell lines; Blue: down in ALT and up in telomerase positive liposarcoma 
samples and cell lines.  The network highlights that a number of molecules activated by c-
Myc have reduced expression in ALT cells and those inhibited by c-Myc have increased 
expression in ALT cells. This is suggestive of lower c-Myc activity in cell using ALT. 
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Further validation of the refined signature was achieved by applying it back to 
the cell line data for hierarchical clustering.  As predicted it accurately 
separated out telomerase positive from ALT cell lines (data not shown), further 
validation that this refined signature held true and no power was lost by 
reducing gene number. 
3.2.4 The refined 297 gene signature is involved in telomerase 
gene regulation and highlights lower c-MYC activity in ALT 
Given the ability of the refined 297 gene signature to separate liposarcomas by 
TMM it was logical that the genes within the signature may have comprised of 
functional regulatory networks involved in aspects of TMM.  In order to explore 
this, network modelling using Metacore from GeneGo was performed. Using the 
direct interactions and transcriptional regulation algorithms within the software, 
a candidate network indicating possible interactions between genes from the 
297 signature, mined from published data, was produced.  A regulatory network 
involving hTERT and telomeric DNA was revealed by this analysis (Figure 3.4d).  
Expression data from the 297 gene signature was converted to fold change in 
ALT over telomerase positive, uploaded into Metacore analytical suite and 
overlaid on the direct interactions network.  As can be seen from Figure 3.4d, by 
combining interactions between known signaling pathways and experimentally 
defined levels of expression for regulatory genes this approach allowed for 
predictions relating to hTERT regulation and repression in ALT cells.  hTERT 
expression was reduced in ALT cells and tumours in relation to telomerase 
positive samples.  Consistent with this, expression of E2F1 a known repressor of 
hTERT, was up-regulated in ALT samples, whereas chromatin modifying enzymes 
with roles in gene activation such as GCN5 were down-regulated in ALT, in 
agreement with the known decreased association of acetylated histones and low 
hTERT expression in ALT cell lines (Atkinson et al. 2005). The analysis also 
indicated that c-Myc regulation may contribute to the signature. Although c-Myc 
was not itself differentially expressed, 21 signature genes including hTERT were 
predicted transcriptional targets of c-Myc. 
Interestingly, most signature genes expected to be activated by c-Myc were 
repressed, while those expected to be inhibited were mainly up-regulated in ALT 
relative to telomerase positive samples, suggesting that c-Myc activity may be 
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suppressed in ALT. c-Myc is a known hTERT transcriptional activator (Hao et al. 
2008) and therefore decreased activity of c-Myc in ALT cells would serve as a 
mechanism of down-regulating hTERT transcription.  
3.2.5 Validation of the Gene expression network highlights the 
highlights protein level differences and lower c-Myc activity 
in ALT  
To validate the gene expression differences shown by the network analysis 
western blotting of three proteins in the network was undertaken, HDAC5, PKC  
and GCN5. The results shown in Figure 3.5A demonstrate that the expression 
differences highlighted in this network were also seen at the protein level. 
The network analysis also suggested lower c-Myc activity in ALT cells compared 
to telomerase positive cells. Additional validation of the network was 
undertaken through the functional examination of c-Myc activity levels using 
DNA binding activity ELISAs. The results of the DNA binding ELISAs confirmed 
that this is indeed the case, as a significantly lower level of c-Myc activity was 
observed in the ALT cell lines (p=0.015) (Figure 3.5B).  
3.2.6 Telomerase positive cells have increased binding of c-Myc 
at the hTERT promoter but show no change in binding 
partner expression. 
To establish the direct regulatory role of c-Myc at the hTERT promoter in these 
cell lines chromatin immunoprecipitation (ChIP) using a c-Myc antibody and qPCR 
for the hTERT promoter in the resulting pull-down was performed (Figure 3.6A). 
Although the levels of c-Myc binding at the hTERT promoter varied between cell 
lines overall the telomerase positive cell lines had a higher level of c-Myc 
present at the hTERT promoter than ALT cell lines. This was consistent with the 
decreased c-Myc activity in ALT cells.  
3.2.7 c-Myc regulatory factors expression patterns do not explain 
lower c-Myc activity in ALT  
Relative levels of Myc/Max versus Mad/Max binding have previously been 
observed to regulate the hTERT promoter chromatin environment, raising the  
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Figure 3.5 - The TERT regulatory network is shown at the protein level and predicted c-Myc 
activity is confirmed as significantly lower in ALT.  
(A) Western blotting shows protein level differences in 3 proteins of the 297 gene network. 
15 g of cell extracts were run on NuPAGE 4-12% Bis-Tris gels, transferred to Millipore 
nitrocellulose membrane and probed with appropriate antibodies. Blots were then stripped 
and reprobed with ERK1 loading control. Panels shown are representative panels of 2 
separate blots. 
(B) c-Myc activity ELISA shows significantly lower activity in ALT cells. Interval plot shows 
the average of 6 ALT cell lines (WI38-SV40, KMST6, SKLU, SUSM1, SAOS and U2OS) and 4 
telomerase cell lines (A2780, C33a, HT1080 and 5637) on 3 separate occasions with 4 
replicates of each cell line.  Crosshairs show mean expression for each group and error 
bars show 95% confidence intervals of the mean, p-value = 0.015 
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Figure 3.6 - c-Myc shows increased binding at the hTERT promoter in telomerase positive 
cells while common c-Myc binding partner expression is unaltered between ALT and 
telomerase positive cells.  
(A) ChIP analysis of the hTERT promoter was completed using an antibody against c-Myc 
performed in duplicate. Each immunoprecipitate was quantified in triplicate by quantitative 
PCR analysis and related back to an input sample in each experiment to normalize the data. 
Error bars show standard error.  
(B) Gene expression microarray data for the ALT cell lines (SKLU, SUSM1, KMST6, WI38-
SV40) and the telomerase positive cell lines (HT1080, C33a, 5637, A2780) shows little 
expression differences between c-Myc binding partners Mad and Max. Error bars show 
standard error. c-Myc expression is significantly decreased in ALT (p = 0.036) and 
telomerase cell lines (p = 0.041) compare to mortal and MSC cells. 
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interesting possibility that E-boxes might play a role in establishment of 
epigenetic silencing of telomerase in ALT. Investigation of whether the 
difference in c-Myc binding at the hTERT promoter could be accounted for by 
expression differences in Mad and Max was therefore the logical next step. No 
significant difference in expression of c-Myc itself or Mad and Max was observed 
between the ALT and telomerase positive cell lines (Figure 3.6B). Given the lack 
of differences in expression of c-Myc, Max, or Mad between ALT and telomerase 
cell lines that could explain the decrease of c-Myc activity observed in ALT, 
investigation of other possible mechanisms for c-Myc regulation were 
undertaken. 
3.2.8 Differential expression of c-Myc inhibitor TCEAL7 in ALT 
and telomerase positive cell lines  
The transcription elongation factor A (SII)-like protein TCEAL7 had recently been 
shown to inhibit c-Myc activity through the competitive binding of E-Boxes 
(Chien et al. 2008). Such competitive inhibition would allow regulation of c-Myc 
transcriptional activity without the need for a down regulation in expression. 
TCEAL7 expression was therefore examined to assess whether it could 
potentially be regulating c-Myc activity in ALT and telomerase positive cells. 
Figure 3.7A shows RT-qPCR for TCEAL7 in the ALT and telomerase positive cell 
lines.  Three of the four ALT cell lines had high levels of TCEAL7 expression 
whereas all of the telomerase positive cells had little or no expression of the 
gene. To investigate whether TCEAL7 and c-Myc could directly interact co-
immunoprecipitations for c-Myc and TCEAL7 were performed. Neither pull-down 
of c-Myc with TCEAL7 antibodies nor TCEAL7 with c-Myc antibodies in any of ALT 
or telomerase positive cell lines was observed (data not shown). This suggested 
Kyle Lafferty-Whyte, 2010  Chapter 3,69 
 
Figure 3.7 - TCEAL7 expression is increased in ALT cell lines and mesenchymal tumours.  
(A) S15 normalised qPCR of TCEAL7 of telomerase positive cell lines (HT1080, A2780, 5637, 
C33A) and ALT cell lines (SKLU, KMST6, WI38-SV40, SUSM1). Error bars show standard 
error of triplicate experiments.  
(B) Interval plot of gene expression microarray data for TCEAL7 of 3 mesenchymal tumour 
types (liposarcoma, peritoneal mesothelioma and malignant peripheral nerve sheath 
tumour) previously submitted to GEO under accession number GSE17118. Crosshairs show 
mean expression and error bars show 95% confidence intervals drawn using Minitab (v.15).  
P-Value = 0.053 
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 that TCEAL7 and c-Myc do not directly interact and TCEAL7 regulation of c-Myc 
activity in ALT is through competitive inhibition.  
Given that the functional network was generated using a combination of cell line 
and liposarcoma data and as ALT is predominantly found in tumours of 
mesenchymal origin in vivo (Ulaner et al. 2004; Henson et al. 2005) it was 
decided to examine the expression levels of TCEAL7 in a larger cohort of 
mesenchymal tumours. To this end, gene expression microarray data was 
generated for two further mesenchymal tumour types: peritoneal mesotheliomas 
and MPNST. Figure 3.7B shows that when combined TCEAL7 expression in the 
ALT mesenchymal tumours was higher than telomerase positive tumours (p-value 
= 0.053). This suggested that TCEAL7 could regulate c-Myc activity both in vitro 
and in vivo.  
3.2.9 Perturbation of TCEAL7 expression levels in ALT and 
telomerase positive cells leads to changes in hTERT 
expression, c-Myc activity and telomerase activity. 
To investigate the effects of altering TCEAL7 expression levels in ALT cells siRNA 
knockdowns using a pool of three different siRNAs were performed. Figure 3.8A 
shows that in all 4 ALT cell lines TCEAL7 expression was significantly reduced in 
comparison to non-coding siRNA controls. Subsequent examination of the effect 
of TCEAL7 knockdown on c-Myc activity in ALT cells using transcription factor 
binding ELISAs was undertaken. Figure 3.8b shows that SKLU and KMST6 showed 
negligible changes in c-Myc activity. As SKLU and KMST6 were seen to express 
less TCEAL7 than the other two cell lines it is possible that TCEAL7 is not the 
main c-Myc regulatory factor in these cells lines. WI38-SV40 and SUSM1 however, 
showed an increase in c-Myc activity over control transfections of 9 and 2 fold 
respectively. This suggested that in the ALT cell lines with high levels of TCEAL7 
expression c-Myc activity is inhibited by TCEAL7. As lower levels of c-Myc binding 
at the hTERT promoter in ALT cells had also been observed, investigation of 
whether TCEAL7 expression knockdown and whether the resulting changes in c-
Myc activity were sufficient to alter the expression of hTERT in ALT cells was 
performed. Although not always reaching significance, RT-qPCR of full length 
hTERT in ALT cells (Figure 3.8B) showed that in WI38-SV40 and SUSM1 hTERT 
expression also increased as a result of TCEAL7 knockdown. The decrease in  
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Figure 3.8 - Knockdown of TCEAL7 expression leads to increases in c-Myc activity and 
increased hTERT expression in ALT cells. TCEAL7 knockdown using a pool of 3 
independent TCEAL7 siRNAs (Dharmacon) or non-coding siRNA control were performed in 
duplicate for each secondary assay in each ALT cell line. (A) qPCR of TCEAL7 expression 
expression was normalised to S15 expression before taking fold of control transfections. 
(B) hTERT expression was normalised to S15 expression before taking fold of control 
transfections. c-Myc activity was measured using transcription factor ELISA assays (Active 
Motif) performed in duplicate with at least 6 replicates from two separate transfections. 
Recombinant c-Myc (Active Motif) was used to create a standard curve for relative 
quantification. Error bars show standard error of triplicate experiments. 
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hTERT expression in SKLU and KMST6 also suggested active E-box dependent 
regulation of telomerase, though c-Myc activity was relatively unaffected. 
Therefore, additional mechanisms for c-Myc suppression may also be present in 
these cell lines. One possibility is that TCEAL7 knockdown preferentially relieves 
Mad rather than c-Myc targeting to E-boxes in these cells resulting in further 
reduction of hTERT expression. 
As telomerase positive cells were seen to express little to no TCEAL7 the effects 
of TCEAL7 overexpression was investigated in these cells. A cDNA overexpression 
construct was transfected into the four telomerase positive cell lines and the 
expression of TCEAL7 was analysed by RT-qPCR compared to an empty vector 
control. In all four cell lines TCEAL7 expression was significantly increased in 
comparison to empty vector control (Figure 3.9A). The effect of TCEAL7 
overexpression on hTERT expression was then investigated using RT-qPCR (Figure 
3.9B). All four cell lines showed decreased hTERT expression after TCEAL7 
overexpression. HT1080 showed the smallest decrease in hTERT expression (p = 
0.7993) and this may be due to the fact that HT1080 showed the highest level of 
c-Myc binding at the hTERT promoter (Figure 3.6A) and therefore higher levels 
of TCEAL7 may be required to successfully compete with this. The effect of 
TCEAL7 overexpression on telomerase activity levels in these cells was then 
investigated using the TRAP assay (Figure 3.9B). Three of the four telomerase 
positive cell lines showed decreased telomerase activity over control after 
TCEAL7 overexpression. Although the cell line 5637 had shown decreased levels 
of hTERT gene expression, telomerase activity in this cell line increased with 
TCEAL7 overexpression. 5637 cells have relatively low levels of hTERT 
transcription and the down regulation of hTERT expression may trigger a 
regulatory feedback loop to maintain basal telomerase activity through, for 
example, post-transcriptional mechanisms such as alternative RNA splicing or 
hTERT phosphorylation. Regardless, taken together the current results clearly 
indicated that TCEAL7 is a novel regulator of hTERT expression and telomerase 
activity in both ALT and telomerase positive cell lines. 
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Figure 3.9 - Overexpression of TCEAL7 expression leads to decreases in c-Myc, hTERT 
expression and telomerase activity in telomerase positive cells. TCEAL7 cDNA 
overexpression plasmid (Origene) or empty vector control plasmid was tranfected into 
telomerase positive cells in duplicate for each secondary assay. (A) qPCR of TCEAL7 
expression was normalised to S15 expression before taking fold of control transfections. 
(B) hTERT expression was normalised to S15 expression before taking fold of control 
transfections. Telomerase activity (black) was measured using TRAP assay performed in 
duplicate for two separate transfections. Error bars shows standard error of triplicate 
experiments. 
Kyle Lafferty-Whyte, 2010  Chapter 3,74 
3.2.10 Functional Validation of 297 gene expression network 
using siRNA kinase screen highlights 106 hTERT regulatory 
kinases in ALT cells 
Network analysis of the 297 gene liposarcoma signature identified a number of 
kinases that contribute to the regulation of hTERT in ALT cells, such as PKC-
alpha and TK1 (Figure 3.4). Kinases have previously been observed to regulate 
hTERT promoter activity in telomerase positive cells (Bilsland et al. 2009). It was 
therefore hypothesized that the regulation of hTERT in ALT cells may have a 
further layer of regulation through hTERT regulatory kinases.  
To investigate this an siRNA kinase screen was undertaken using an hTERT 
promoter luciferase reporter construct in the ALT cell line SKLU. 3 separate 
siRNAs for 719 kinases and kinase-related genes were investigated. The cut-off 
for hit assessment was a >2 fold change in hTERT promoter activity in at least 
2/3 siRNAs. This resulted in 106 kinases that met the criteria (Figure 3.10). 
Examination of the regulatory effect of these hits showed that 89 were hTERT 
activators and 17 were hTERT inhibitors. This disproportionate number of 
telomerase activators may be reflective of the strict regulation of telomerase 
expression in ALT cells highlighted by the gene expression network. Alteration of 
one of the multiple regulatory systems preventing telomerase expression in ALT, 
in this case phosphorylation by kinases, may the majority of the time be 
insufficient to overcome the larger repressive network effect. This interesting 
result indicates that SKLU cells retain many active signaling components, which 
may be required for hTERT expression in telomerase positive cells. In the 
context of the ALT phenotype, it is likely that their effects on telomerase are 
muted by additional regulatory systems including epigenetic changes at the 
hTERT promoter and the altered gene expression networks previously observed 
in this study. It will be of interest to investigate the potential roles of the 
inhibitory kinase hits identified here in these processes in future studies. 
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Figure 3.10 - siRNA kinase screen highlights 106 kinases with hTERT regulatory factors. 
Kinases with two siRNAs that induce a two fold or more change in hTERT promoter activity 
in the same direction over promoter-less control plasmid. Each point indicates the average 
change in promoter activity of 2 or more different siRNAs for each kinase assayed in 
triplicate, error bars show standard error of triplicate repeats.  
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3.2.11 Transcriptional Regulation networks of 106 hTERT 
regulatory kinases highlights c-Myc as top regulator. 
As these kinases have the potential to regulate TERT expression they represent a 
further level of the TERT regulatory network. Transcriptional regulation of these 
kinases themselves therefore represents a further potential level of regulation in 
the TERT regulatory network. To this end the transcriptional regulation network 
inference algorithm in Metacore was applied. This analysis returned several 
networks centered on statistically significant transcription factor regulators of 
the hits, including a number with known hTERT regulatory functions (Table 3.1). 
Union of the networks surrounding the hTERT transcriptional activators STAT3, 
SP1 and c-Myc (Figure 3.11A) and repressors p53 and the Androgen receptor 
(Figure 3.2B) highlighted the interplay between multiple candidate pathways 
which may influence the expression of hTERT in ALT cells. For example, in 
Figure 3.11A, the kinase SYK expression was activated by c-Myc which in turn 
activated the transcription factor STAT3. SYK also negatively regulated SP1 
through binding. The negative regulation of an hTERT activating transcription 
factor may highlight the potential for such complex networks to self-regulate 
the exact levels of different signaling pathways contained within them.  
Interestingly, c-Myc regulated the largest percentage of kinase hits in this study 
(Table 3.1) showing that not only is c-Myc itself involved with telomerase 
regulation in ALT but that its downstream kinases themselves are regulators of 
telomerase expression. 
3.3 Discussion  
Senescence presents a major block to tumour progression and therefore cells 
require a mechanism of senescence bypass senescence if they are to become 
fully tumorigenic. The induction of senescence through telomere attrition, 
known as replicative senescence, is one mechanism by which cellular 
proliferation is regulated. To bypass this mechanism most tumours utilize the 
telomere rebuilding enzyme telomerase. However, a small proportion of tumours 
utilize an intra- and inter- telomere recombination based mechanism known as 
the alternative lengthening of telomeres or ALT 
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No. Network % of hits 
regulated 
p-Value 
1 c-Myc 17 1.50E-48 
2 HNF4-
alpha 
15 2.42E-40 
3 p53 14 1.28E-37 
4 SP1 13 6.67E-35 
5 STAT3 11 1.73E-29 
 
 
 
 
 
Table 3.1 - Transcriptional regulation of 106 hTERT regulating kinases 
shows known hTERT regulating transcription factors and c-Myc as top 
regulator. 
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Figure 3.11 - Transcriptional regulation networks highlight synergistic regulation of hTERT 
regulatory kinases by known hTERT transcriptional regulators. Merged networks of the top 
5 transcriptional regulators of 106 siRNA kinase screen hits of known hTERT transcriptional 
activators (A) and repressors (B). Green lines between objects indicate an activating 
interaction whereas red lines indicate an inhibitory reaction. Overlaid line colours (red, 
green or blue) indicate transcriptional networks generated for each transcription factor 
before network merge. Symbols on the lines indicate the following: TR = transcriptional 
regulation, +P = phosphorylation, B = binding and ? = unknown mechanism. Blue circles 
next to kinases indicate an hTERT activating kinase and red circles indicate an hTERT 
inhibiting kinase 
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 (Dunham et al. 2000; Muntoni et al. 2009). The molecular mechanisms 
regulating the decision to activate telomerase or ALT during tumourigenesis are 
currently poorly understood. Lack of expression of the telomerase genes hTR and 
hTERT is associated with chromatin remodelling at the promoters, suggesting 
that forced repression of these genes may cause the cells to utilise the ALT 
mechanism for immortalisation (Atkinson et al. 2005).  In this section of the 
study, gene expression profiling of telomerase and ALT cell lines and 
liposarcomas was utilised to investigate other signaling pathways and networks 
that may be operating to control the ALT phenotype and the decision to activate 
telomerase or ALT for immortalization and senescence bypass.  
 A gene expression signature was uncovered with the power to distinguish 
telomerase positive and ALT through hierarchical clustering methods in tumour 
cell lines (Figures 3.1B, 3.2A & 3.2B).  Further refinement of this signature using 
gene expression profiles from liposarcoma tissue samples revealed a 297 gene 
signature that had significant association with TMM (Figure 3.1B).  By combining 
clinical samples with cell line profiles some of the underlying biology of ALT in 
vivo and in vitro was uncovered.  Network analysis of interactions within the 
refined signature highlighted a signaling network involved in repression of hTERT 
in ALT liposarcoma samples and cell lines (Figure 3.4D).  
Validation of the functional network was undertaken using a number of different 
approaches. Initially, western blots of 3 of the molecules in the network 
confirmed that this pattern was also 3 observed at the protein level and qPCR 
confirmed the differential expression of 4 genes at the mRNA level (Figure 3.5A 
& 3.3A). The functional network of interactions also highlighted the potential for 
lower c-Myc activity in cells using the ALT mechanism. Therefore examination of 
the relative activity levels of c-Myc was undertaken to further validate the 
patterns observed in the functional gene expression network. Upon direct 
investigation using c-Myc activity ELISAs, a lower level of c-Myc activity in ALT 
was confirmed (Figure 3.5B) and through the use of ChIP differential c-Myc 
binding at the hTERT promoter in ALT and telomerase positive cells was also 
confirmed (Figure 3.6A). 
The role of c-Myc in cell cycle regulation and senescence signaling makes it a 
key transcriptional regulator during the processes of immortalisation and 
senescence bypass. c-Myc is well documented as a regulator of telomerase and 
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therefore its potential as a key regulator of the molecular differences between 
TMMs is an interesting consideration. 
Gene activation by c-Myc binding at DNA E-boxes occurs as a dimer with binding 
partner Max (Amati et al. 1993). The activities of Max in turn are antagonised by 
dimerisation with Mad and the resulting binding of Mad/Max to E-boxes within 
promoter regions leads to gene repression (Ayer et al. 1993). Furthermore, Mad 
has been found to dimerise with and recruit the histone demethylase RBP2 to E-
boxes in the hTERT promoter and repress transcription through chromatin 
remodelling (Engels et al. 2006). The expression levels of Mad and Max in ALT 
and telomerase positive cells may therefore have an influence on the activity of 
c-Myc and telomerase expression. However, investigation of the expression of 
these factors in the gene expression microarray data (Figure 3.6B) showed no 
expression difference in c-Myc, MAD or MAX able to explain the decreased c-Myc 
activity observed in ALT cell lines.  
As the expression patterns of c-Myc’s regulatory molecules Mad and Max were 
unable to account for the decreased c-Myc activity, less well characterized c-
Myc regulatory mechanisms were investigated. A literature search revealed 
TCEAL7 as a competitive inhibitor of c-Myc DNA binding. TCEAL7 is a member of 
the transcription elongation factor A (SII)-like gene family and is relatively 
poorly studied. The expression of TCEAL7 is epigenetically silenced in epithelial 
ovarian cancer and forced expression of TCEAL7 in ovarian tumour cell lines 
induced apoptosis (Chien et al. 2005). Furthermore, TCEAL7 has been observed 
to have decreased expression in a variety of human tumours (Chien et al. 2008) 
and recently polymorphisms in the gene have been associated with reduced risk 
of invasive serous ovarian cancers (Peedicayil et al. 2009). The role of TCEAL7 in 
cancer risk may be due to its function as a regulator of cyclin D1 expression and 
c-Myc activity (Chien et al. 2008). TCEAL7 binds to E-boxes of gene promoters 
and thereby competitively inhibits gene activation by Myc-Max complexes. Such 
competitive inhibition would effectively decrease c-Myc activity without the 
need for decreased c-Myc expression and it is for this reason that TCEAL7 was 
suggested as a potential mechanism for c-Myc activity regulation in ALT. Through 
RT-qPCR of ALT and telomerase positive cell lines it was found that ALT cells 
expressed a high level of TCEAL7 whereas telomerase positive cells expressed 
little or no TCEAL7 (Figure 3.7A). As ALT is predominantly seen in 
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mesenchymally derived tumours and not just liposarcomas (Ulaner et al. 2004; 
Henson et al. 2005) the investigation of TCEAL7 expression was expanded to 
include 2 further mesenchymal tumour types: peritoneal mesotheliomas and 
malignant peripheral nerve sheath tumours (MPNST). The analysis of the 
resulting combined mesenchymal tumour cohort showed that TCEAL7 expression 
was increased in ALT tumours compared to telomerase positive tumours (p = 
0.053) suggesting that TCEAL7 overexpression may be a c-Myc regulatory 
mechanism both in vitro and in vivo (Figure 3.7B). Furthermore, through the use 
of knockdown and overexpression of TCEAL7 in ALT and telomerase positive cell 
lines respectively it was shown that TCEAL7 could regulate c-Myc activity, hTERT 
expression and telomerase activity (Figures 3.8 & 3.9). This was consistent with 
the fact that c-Myc is a known hTERT transcriptional activator (Zeller et al. 
2003; Hao et al. 2008) and may show a further mechanism by which the decision 
to activate either ALT or telomerase is influenced. As the majority of human 
tumours utilize telomerase as a telomere maintenance mechanism the 
decreased expression of TCEAL7 in a wide variety of human tumours (Chien et 
al. 2008) is consistent with TCEAL7’s potential role as an hTERT regulator 
through c-Myc.  
The gene expression network also highlighted PKC  as a known hTERT regulatory 
molecule (Chang et al. 2006) and kinases have previously been seen to play a 
role in regulation of telomerase in telomerase positive cells (Bilsland et al. 
2009). Through the use of a siRNA kinase hTERT luciferase reporter screen the 
kinome was probed for hTERT regulatory kinases in ALT cells with the aim of 
further investigating the role of kinases in ALT. 106 kinases through which hTERT 
promoter activity was regulated were highlighted (Figure 3.10). A greater 
proportion of hits which were hTERT activators, such that their knockdown 
resulted in decreased hTERT expression, were observed which may reflect the 
strict hTERT regulatory conditions present within ALT cells. This finding would 
suggest that knockdown of a single molecule would in most cases be insufficient 
to overcome the effects of the entire network. It is for this reason that 
decreases in hTERT promoter activity may be easier to achieve than increases.  
Through the use of transcriptional regulation network building algorithms it was 
discovered that the 106 kinases were regulated by known hTERT regulating 
transcription factors (Table 3.1). Furthermore, merging networks of known 
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hTERT activating or repressing transcription factors highlighted cooperating 
interactions between these factors (Figure 3.11). The regulation of the 
transcription factors themselves by upstream hTERT regulatory kinases 
highlighted further potential mechanisms by which they could regulate hTERT 
promoter activity. The data presented here therefore highlights the fact that 
the complex network of interactions by which the expression of telomerase is 
regulated in ALT cells further extends to kinase regulation, consistent with 
previous data in telomerase positive cells (Bilsland et al. 2009). Furthermore, 
the top transcriptional regulator of the 106 kinase hits was c-Myc. This further 
emphasized the potential key role that c-Myc may play in the decision between 
the two telomere maintenance mechanisms through telomerase regulation and 
its potentially central role in senescence signaling regulation during 
immortalization and bypass.  
The functional validation of the candidate network further highlighted the 
importance of a global analysis of gene expression.  Where significant expression 
of one gene may be of importance in certain circumstances, it is more likely, as 
evidenced by the gene expression network and the complex transcriptional 
networks between the 106 hTERT regulatory kinases, that small changes in a 
combination of genes in a signaling pathway are responsible for defining a 
phenotype.  By investigating signaling networks on a global scale an increased 
understanding of the biology underlying the ALT phenotype and its regulation in 
mesenchymal malignancies has been achieved. Such improved understanding of 
the mechanisms by which tumours bypass senescence help to further 
investigations into senescence induction in human tumours. 
In addition to the hTERT regulatory network a number of stem cell related genes 
were also highlighted within the 1305 gene signature.  The possibility that the 
decision to activate either telomerase or ALT is made at the cellular level was 
an interesting hypothesis to consider.  Cancer biology in many ways parallels 
that of stem cell biology, as pathways regulating the self-renewal phenotype and 
replicative lifespan of stem cells, such as WNT signaling (Fevr et al. 2007), are 
commonly deregulated in cancer.  With the growing interest in stem cells as the 
cell of origin for certain tumours, investigating the potential origin for ALT 
immortality may improve the understanding of the regulation of senescence 
bypass by telomere maintenance.  The preponderance of ALT in mesenchymal 
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malignancies prompted an investigation of any relationship between human 
mesenchymal stem cells (hMSC) and ALT or telomerase positive cell lines and 
liposarcoma tissues.  hMSCs are an adult stem cell population with limited 
replicative lifespan and no detectable telomerase activity (Zimmermann et al. 
2003), which is due at least in part to active repression of the telomerase genes 
at the chromatin level, similar to the situation in ALT cell lines (Serakinci et al. 
2006; Cairney et al. 2008). hMSCs do not however display characteristic 
molecular markers of ALT (Bernardo et al. 2007; Zhao et al. 2008). It is 
therefore possible that hMSCs upon transformation could become either ALT or 
telomerase positive tumours. There is however a need for accurate models of 
the molecular details of the decision between these two mechanisms, such as 
this, before manipulation of the resulting telomere maintenance mechanism can 
be achieved.   
Hierarchical clustering showed that the expression profile of the signature genes 
in hMSC was more closely related to ALT than to telomerase positive cell lines 
with the larger signature and also to ALT liposarcomas when the refined 297 
gene signature was utilised, suggesting a mesenchymal stem cell origin for ALT 
(Figures 3.1C & 3.4C).   
Mesenchymal stem cells are known to be potential targets for transformation in 
vitro.  Lack of any telomere maintenance mechanism in these cells may be a 
tumour suppressor mechanism as transduction with hTERT has been shown to 
extend their lifespan and induce neoplastic characteristics following long term 
culture in vitro and tumour formation in vivo (Serakinci et al. 2004).  In addition 
several studies have shown the ability of MSCs to transform spontaneously 
following long term culture in vitro in murine systems (Miura et al. 2006; Zhou 
et al. 2006), although the situation in human systems remains unclear with 
conflicting reports suggesting that the capacity for spontaneous transformation 
may be dependent on the tissue of origin (Rubio et al. 2005; Wang et al. 2005; 
Miura et al. 2006; Bernardo et al. 2007).  More recently several studies have 
linked hMSC with mesenchymal malignancies including Ewing’s sarcoma (Tirode 
et al. 2007; Riggi et al. 2008) and malignant fibrous histiocytoma (Matushansky 
et al. 2007).  Stem-like tumour initiating cells have also been isolated from 
various mesenchymal tumours (Gibbs et al. 2005; Wu et al. 2007).  Taken 
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together this data suggests that the stem cell origin for cancer extends to 
mesenchymal malignancies.   
Although the preponderance of ALT in mesenchymal tissues has been 
documented previously on numerous occasions, this was the first time the link to 
a mesenchymal stem cell origin for ALT had been made.  Furthermore, this was 
not simply reflective of the mesenchymal origin of ALT cell lines as both the ALT 
and telomerase positive liposarcoma samples were mesenchymally derived and 
only the ALT liposarcomas cluster with hMSC. The significance of this association 
is unknown at present, but certainly warrants further investigation.   
The observations of differential c-Myc activity between ALT and telomerase 
positive cells may potentially be linked to potential cell of transformation, in 
this case hMSCs and ALT. Exploration of the expression levels of c-Myc and it’s 
regulatory factors Mad and Max showed no significant difference in the 
expression levels of Mad or Max between ALT or telomerase positive cells (Figure 
3.6B).  
In conclusion, this analysis has highlighted a gene expression signature capable 
of distinguishing telomerase positive from ALT in cell lines and liposarcoma 
tissue samples.  This signature contained a regulatory signaling network 
involving hTERT repression in ALT and is indicative of a novel hMSC origin for 
ALT. A candidate network also highlighted differences in c-Myc activity, further 
investigation of which highlighted the potentially key role of c-Myc in the 
decision between ALT and telomerase TMMs during senescence bypass. A better 
understanding of the regulation of senescence bypass through TMM in the cell of 
origin will increase knowledge of the biology underlying these tumour types and 
may highlight novel areas for therapeutic intervention. Furthermore, these 
investigations show that regulation of senescence bypass by telomere 
maintenance involves a complex network of interactions involving gene 
expression differences, transcription factors and kinases, all of which present 
attractive targets for intervention. To make full use of these gene expression 
networks further understanding of the regulatory mechanisms behind them, such 
as chromatin modifications, miRNA regulation and post-translational protein 
modifications, is required however. 
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4 miRNA regulation of senescence signaling 
during tumourigenesis. 
4.1 Introduction 
Telomere maintenance mechanisms (TMMs) are utilised by tumour cells to 
bypass telomere induced replicative senescence. Data in the previous chapter 
highlighted the complex gene expression networks regulating the decision 
between telomere maintenance mechanisms. Furthermore, the previous chapter 
also showed that these networks are in part regulated by the actions of kinases, 
c-Myc and TCEAL7.  The coordination of these multiple changes to gene 
expression and pathway signaling requires regulation at many different 
molecular levels and in coordination with the regulation of the larger 
senescence program. For instance multiple chromatin modifications, such as 
methylation of K9 H3 (Narita et al. 2003), are required to establish the 
senescence-associated heterochromatin foci during senescence induction 
(Atkinson et al. 2007; Zhang et al. 2007) and have also been seen to play a role 
in telomere maintenance mechanisms (Cairney et al. 2008).  Of the many ways 
to regulate gene product expression, miRNAs are relatively poorly understood. 
These short non-coding molecules ranging in size from 19-22 nucleotides are 
highly conserved and regulate protein expression through interactions with the 
3’ untranslated region (UTR) of mRNA (Lee et al. 1993; Wightman et al. 1993).  
Mammalian miRNAs are produced in two main stages. Initially miRNAs transcripts 
(known as primary miRNAs) are transcribed by RNA polymerase II and then are 
then processed in the nucleus by the RNase type III protein Drosher to form 
precursor miRNA hairpin molecules (Kim et al. 2009). The miRNAs are then 
exported from the nucleus to the cytoplasm where they are further processed by 
another RNase type III protein, Dicer, to form the mature 19-22 nucleotide single 
stranded miRNA. The mature miRNAs are then bound onto Argo proteins to form 
the final functional RNA induced silencing complex (RISC) (Wahid et al. 2010). 
miRNA genes have been observed in both coding and non-coding genes in both 
exonic and intronic regions where the majority of miRNAs are found in intragenic 
regions (Kim et al. 2009, Lagos-Quinata et al. 2001, Lau et al. 2001). 
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The binding of a miRNA to the 3’UTR causes inhibition of translation through 
steric hindrance or degradation of the mRNA, depending on the degree of 
complementarity between the two sequences (Engels et al. 2006). The ability of 
miRNAs to regulate a variety of target genes allows them to induce changes in 
multiple pathways and processes such as development (Harfe 2005), apoptosis, 
proliferation and differentiation (Bartel 2005). Furthermore, recent observations 
in breast cancer particularly implicate miRNA expression as having a pivotal role 
in tumour progression. The expression of some miRNAs, such as the mir-200 
family, have been observed to suppression metastasis whereas others, such as 
mir-373 and mir-520c, are considered pro-metastic miRNAs (Shi and Guo 2009). 
As such miRNA expression has the potential to regulate entire pathways in 
normal developmental processes as well as being potentially hijacked for use in 
the establishment and progression of cancer.      
MiRNAs could therefore facilitate the complex cellular changes required to 
establish the senescent phenotype. Identification of the mRNA sequences that 
miRNAs regulate is mainly derived using bioinformatics techniques. The ability of 
each miRNA to target genes is based on sequence complementarity to 3’UTRs of 
known mRNAs. Furthermore each miRNA has the potential to regulate on 
average 1000 gene targets (Griffiths-Jones 2004; Griffiths-Jones et al. 2006; 
Griffiths-Jones et al. 2008). It is this large number of potential targets across 
different biological pathways that give miRNAs the power to potentially induce 
complex cell phenotypes, like senescence. 
To investigate whether miRNAs could play a role in the complex regulatory 
networks of senescence signaling and bypass an initial investigation of 12 miRNAs 
with known experimental evidence for a role in senescence induction was 
performed. Using publicly available gene expression data for cells induced to 
senescence by various stimuli, the potential of these 12 senescence associated 
miRNAs (SA-miRNAs) to regulate the patterns of differential gene expression was 
assessed. After establishing the potential of miRNAs to regulate the larger 
process of senescence, their potential role in senescence bypass by regulation of 
telomere maintenance mechanisms was investigated.  Using miRNA microarray 
profiling the associations of miRNA expression with telomere maintenance 
mechanisms and survival in mesenchymal tumours were explored. 
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4.2 Results 
4.2.1 Identification of 12 SA-miRNAs and Pathway mapping of 
their miRNA targets shows cell cytoskeletal, cell cycle and 
proliferation regulation potential 
Although the gene targets of miRNAs can be identified theoretically by 
computational algorithms, it is unclear exactly which potential target genes they 
modulate and to what extent this affects the associated functions of these 
genes. The identification of miRNAs with the ability to regulate a complex 
phenotype, like senescence, is therefore not possible using purely bioinformatic 
techniques. For this reason the literature was searched for miRNAs with 
experimental evidence of a role in senescence induction. To this end, database 
searches of the terms “miRNA” and “senescence”, using pubmed and ISI web of 
knowledge (accessed 18 Nov 2008) were performed. The literature search 
highlighted 6 studies with direct evidence for regulation of senescence by 
miRNAs. Two main approaches were used in these studies: microarray based and 
comprehensive functional genomics; and the investigation of candidate 
senescence genes and the miRNAs regulating them. The 6 studies highlight a 
total of 12 senescence-associated miRNAs (SA-miRNAs). Each miRNA has the 
ability to bind between 953 and 2351 sites on mRNA 3’ UTRs (see Table 4.1) and 
in addition some 3’UTRs potentially have multiple complementary sites for a 
given miRNA. To add to the complexity, in reality this set of miRNAs may only be 
a subset of the total number of miRNAs that play a role in senescence 
regulation.  
Before the full impact of miRNAs’ role in the regulation of senescence bypass by 
TMMs could be fully understood, a measure of their ability to regulate the larger 
process of senescence must be gained. To this end, mapping of the signaling 
pathways regulated by the SA-miRNAs (shown in Table 4.1) was performed. 
Furthermore, through this approach it was hypothesised a better understanding 
of the biological mechanisms by which miRNAs can cooperate to create the 
complex senescence phenotype would be gained. The free, publicly available 
Sanger miRNA database contains a registry of computationally calculated gene 
targets for each known miRNA. The current version of the database (mirBase 
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targets v5, 25 Aug 2008) was downloaded and queried using Microsoft Access, in 
order to generate lists of theoretical gene targets for the 12 SA-miRNAs. As the 
computational method of assigning gene targets to miRNAs cannot assess the 
level of complementarity required for a biological effect, it was decided to 
include all theoretical targets in the analysis, as a representation of the 
maximum regulatory effect these miRNAs could have. The signaling pathways 
that these gene targets are involved in were explored using the systems biology 
tool Metacore from Genego (Genego Inc, St Joseph, MI).  
The top 5 pathways regulated by the SA-miRNAs are shown in Table 4.2. Two of 
these maps are involved in cytoskeletal remodelling and are highly saturated 
with gene targets of the SA-miRNAs (Figure 4.1). Senescent cells are seen to 
undergo changes in morphology, becoming large and flattened (Berube et al. 
1998), which would require significant cytoskeletal remodelling. Such 
widespread cellular modifications would be associated with the alteration of 
many different pathways and processes that all contribute to the maintenance 
of the actin cytoskeleton. Due to their ability to bind a number of different gene 
targets miRNAs provide a mechanism by which such widespread changes could be 
induced.  
Changes in the processes involved in DNA synthesis in early S-phase are also 
potentially regulated by the SA-miRNAs (Figure 4.2). Of the objects on this map  
59% are potentially regulated by the SA-miRNAs and in particular members of the 
MCM and ORC complexes. The ORC and MCM complexes are responsible for the 
initiation of DNA replication by assembly of the pre-replication complexes and 
ensure that the process only occurs once during the cell cycle (Bell et al. 2002). 
Recently the ORC complex was reported to be able to interact with the telomere 
binding protein TRF2 and affect telomere homeostasis (Tatsumi et al. 2008). 
Replicative senescence relies on the shortening of telomeres to induce a DNA 
damage checkpoint response that blocks their progression into S-phase (di 
Fagagna et al. 2003). Since senescence involves irreversible cell cycle arrest, SA-
miRNA regulation of cell cycle mechanisms strengthens their possible role in 
senescence regulation. 
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Number Senescence 
Associated 
miRNA 
Number of 
predicted 
complementary 
sites in the 
transcriptome 
References 
1 hsa-let-7f 1018 Wagner et al., 2008 
2 hsa-miR-499 2157 Wagner et al., 2008 
3 hsa-miR-373 1057 Voorhoeve et al., 2006 
4 hsa-miR-372 953 Voorhoeve et al., 2006 
5 hsa-miR-371 2205 Wagner et al., 2008 
6 hsa-miR-369-5P 1107 Wagner et al., 2008 
7 hsa-miR-34c 2351 Kumamoto et al.,2008 
8 hsa-miR-34b 1086 Kumamoto et al.,2008 
9 hsa-miR-34a 1296 Tazawa et al., 2007, He et al., 
2007, Kumamoto et al.,2008 
A hsa-miR-29c 1199 Wagner et al., 2008 
B hsa-miR-217 993 Wagner et al., 2008 
C hsa-miR-20a 1275 Poliseno et al., 2008 
Table 4.1 - Senescence associated miRNAs from the literature and the number of 
computationally derived mRNA 3’ untranslated regions each can target. (Note  some mRNAs 
may contain multiple binding sites) Numbering denotes the thermometer number 
representing particular miRNA’s targets on Figures 4.2, 4.3 and 4.4. 
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  Pathway Map % of objects on the map that 
are SA-miRNA targets 
1 The role of TGF and WNT in Cytoskeletal 
remodelling 
44% (49/111) 
2 Cytoskeletal remodelling general process 42% (43/102) 
3 Cell Cycle: The start of DNA replication 
in early S-phase 
59%(19/32) 
4 Regulation of transcription in the CREB 
pathway 
50% (21/42) 
5 Development EGFR signaling via small 
GTPases 
41% (13/32) 
Table 4.2 - The top 5 pathways regulated by all 12 SA-miRNAs with the percentage of the 
map that consists of SA-miRNA gene targets . Gene target lists for each SA-miRNA were 
input to Metacore and the pathway maps which were commonly regulated were examined. 
Pathways are ordered by the number of SA-miRNA targets on each map. The presence of 4 
regulatory pathways involving different aspects of cellular signaling and only one cell cycle 
pathway shows that there is more to senescence than just cell cycle regulation. SA-miRNAs 
therefore present a mechanism by which a variety of the required cellular pathway changes 
could be regulated. 
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Figure 4.1 - SA-miRNA regulation of the Cytoskeletal remodelling and the role of TGF and WNT 
biological pathway map. Red thermometers show an object that can be regulated by a SA-
miRNA with thermometer numbering corresponding to that seen in Table 2.1.Multiple 
thermometers denote that the object is a target of multiple SA-miRNAs. Green arrows 
represent positive, red negative and grey unspecified interactions. Boxes on lines denote the 
type of regulation where P = phosphorylation; B = binding; Tr = transcriptional regulation, Cm 
= covalent modification, T = transformation and Z = catalysis. 
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Figure 4.2 -SA-miRNA regulation of Cell cycle and DNA replication in early S phase 
biological map. Red thermometers show an object that can be regulated by a SA-miRNA 
with thermometer numbering corresponding to that seen in Table 2.1.Multiple 
thermometers denote that the object is a target of multiple SA-miRNAs. Green arrows 
represent positive, red negative and grey unspecified interactions. Boxes on lines denote 
the type of regulation where P = phosphorylation; B = binding; Tr = transcriptional 
regulation, Cm = covalent modification, T = transformation and Z = catalysis 
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The transcription factor CREB is also potentially regulated by SA-miRNAs (Figure 
4.3). CREB is a known regulator of cellular growth and proliferation through its 
transcriptional regulation of genes such as the oncogene c-fos (Ahn et al. 1998) 
and regulators of the cell cycle such as cyclin D1 (Lee et al. 1999) and cyclin A 
(Desdouets et al. 1995). Alteration of molecules regulating CREB by SA-miRNAs 
would therefore confer another mechanism to alter the cell growth and 
proliferation pathways towards a senescent state.  
EGFR and its proliferative signaling are not conducive to a senescent cellular 
environment. Consistent with this, EGFR is repressed at the chromatin level 
during senescence (Narita et al. 2003) and this analysis showed to be potentially 
regulated by the 12 SA-miRNAs (Table 4.2). The ability of SA-miRNAs to further 
repress these signals provides a cell entering senescence another regulatory 
mechanism by which to ensure their silencing.  
The multiple pathway alterations discussed suggest that these SA-miRNAs are 
potentially regulating many of the necessary steps required to create a fully 
senescent cell, from changes in the cellular cytoskeleton to alteration of 
multiple pathways regulating cell cycle and proliferation signals. Senescence can 
be stimulated by more than one mechanism however, including induction by 
telomere attrition (replicative senescence), oncogenes, drugs and cellular 
stress. It remains unclear whether the same pathway alterations and miRNAs are 
involved in each of the different stimuli or whether each stimulus takes a 
different route to the same endpoint of a senescent cell, as depicted in Figure 
4.4.  
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Figure 4.3 - SA-miRNA regulation of Transcription and the CREB pathway biological 
map. Red thermometers show an object that can be regulated by a SA-miRNA with 
thermometer numbering corresponding to that seen in Table 2.1.Multiple 
thermometers denote that the object is a target of multiple SA-miRNAs. Green arrows 
represent positive, red negative and grey unspecified interactions. Boxes on lines 
denote the type of regulation where P = phosphorylation; B = binding; Tr = 
transcriptional regulation, Cm = covalent modification, T = transformation and Z = 
catalysis. 
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Figure 4.4 -– Potential mechanisms of miRNA regulation in Senescence and their potential. 
A small subset of miRNAs, such as the 12 SA-miRNAs that we have identified, may be 
acting as master regulators of the senescent phenotype. However it is also possible that 
individual types of senescence induction may require different miRNAs to create the same 
cellular changes due to the different stimuli and therefore signaling pathways involved. 
Overlaps in the biological pathways or miRNAs could therefore be utilised to discover 
novel drug targets for senescence induction 
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4.2.2 Investigation of SA-miRNA regulation of different 
senescence stimuli 
In order to investigate the potential of SA-miRNAs to regulate the different 
senescence stimuli previously published publicly available gene expression data 
was utilised. This allowed the exploration of the potential roles of miRNAs to 
regulate the differentially expressed gene lists from replicative senescence in 
hMSCs (Wagner et al. 2008), drug induced replicative senescence by a 
telomerase inhibitor (Damm et al. 2001), cellular stress by Ethanol or tert- 
butylhydroperoxide exposure (Pascal et al. 2005) and oncogene induced 
senescence by BRAFE600 (Kuilman et al. 2008).  
Each of the datasets queried showed some potential to be regulated by the SA-
miRNAs as shown in Table 4.3. Using the results of these 4 analyses, the 
potential of SA-miRNAs to regulate pathways with gene expression changes for 
each stimulus was further explored. The differences and similarities in SA-
miRNAs and their targeted pathways between stimuli were also investigated. 
4.2.2.1 Replicative senescence  
By reanalysing the publicly available gene expression data from the study by 
Wagner and colleagues, it was possible to examine the pathways during 
replicative senescence that could be regulated by SA-miRNAs (Table 4.4a) 
(Wagner et al. 2008). Wagner et al measured gene expression changes at 
different population doublings of hMSCs from early passage into replicative 
senescence. Gene lists of 2 fold or more changes in expression between early 
and late passage hMSCs were constructed. Filtering of these lists to only those 
genes theoretically regulated by the SA-miRNAs led to the construction of 2 lists: 
85 gene targets with increased expression and 49 gene targets with expression in 
late passage compared to early passage hMSCs. The pathways associated with 
each gene list were then individually explored using Metacore. 
Looking initially at the pathways that have gene targets with increased 
expression in Table 4.4a, it was observed that 3 of the 5 maps on the list were 
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Table 4.3 - Regulation of gene expression signatures of different types of senescence 
induction.  
Ticks represent the ability of that SA-miRNA to theoretically regulate one or more genes within 
the signature. All four senescence induction signatures are regulated by at least 5 SA-
miRNAs. These differences in SA-miRNA regulation may represent the differing need for 
regulation of SA-miRNA target genes by different stimuli. The regulation of all of the 
senescent signatures studied by microRNAs hsa-mir-499 and hsa-mir-34c may demonstrate 
their potential as regulators of core senescence genes required by all senescence stimuli. 
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Table 4.4 -Top 5 biological pathway maps that contain SA-miRNA gene targets shown in 
order of p-value. 
(A)Wagner et al microarray data was reanalysed and all genes with a 2 fold or more 
difference between early passage and late passage hMSCs were selected. These lists were 
then filtered selecting only gene targets of the 12 SA-miRNAS and biological pathways 
maps analysed using Metacore from Genego.  
(B)Damm et al published differentially expressed gene signatures which were filtered 
selecting only gene targets of the 12 SA-miRNAS and biological pathways maps analysed 
using Metacore from Genego 
b 
a 
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 involved with apoptosis and survival through the FAS and TNFR1 signaling 
pathways or in a p53 dependent manner. In all 3 maps the only molecules that 
the SA-miRNAs are regulating are BRE and c-FLIP. BRE is known to suppress the 
apoptotic pathways through binding and inhibition of the FAS receptor (Li et al. 
2004) and the TNF-alpha receptor (Gu et al. 1998). C-FLIP is a potent inhibitor of 
apoptosis through its binding and resulting inhibition of the adaptor protein 
FADD (Irmler et al. 1997). Although the SA-miRNAs are only regulating 2 
molecules involved in the survival and apoptosis signaling pathways, regulation 
of the absolute levels of such signals may be one of the mechanisms by which 
the SA-miRNAs ensure the cells enter senescence rather than apoptosis. 
The second most significant pathway with increases in gene expression during 
replicative senescence is cytoskeletal remodeling centering on the role of 
intermediary filaments. As discussed previously, changes in the cellular 
morphology of senescent cells would require significant changes to the 
cytoskeleton of the cell. Changes in expression of key genes regulating many of 
these processes would therefore be required. The SA-miRNAs provide one 
potential mechanism by which these changes could be regulated. 
Changes to the immune response and the IL1 signaling pathway during 
replicative senescence are also potentially regulated by the SA-miRNAs. The 
concept of the involvement of IL1 and other pro-inflammatory networks in the 
induction of senescence is concurrent with the current findings (Hardy et al. 
2005; Morandi et al. 2008; Sasaki et al. 2008). The regulation of these pro-
inflammatory networks by miRNAs may provide a mechanism by which the 
secretory senescence pathway is regulated.  
Table 4.4 also shows that all 12 SA-miRNAs can also target genes with expression 
2 fold or more decreased during replicative senescence. Four out of the 5 
pathways that contain SA-miRNA gene targets with decreases in expression are 
involved in various aspects of cell cycle regulation (Table 4.4a). These include 
DNA replication in early S-phase and the roles of APC, the SCF complex and 
ESR1. Regulation of key molecules in the multiple processes governing the cell 
cycle during senescence induction is critical. The SA-miRNAs regulate a subset of 
molecules (CDK2, EMI1, Cyclin B, SKP2, and CDC18L) that are involved in 
regulation of these multiple cell cycle pathways. This allows the SA-miRNAs to 
affect the cell cycle regulatory process as whole rather than at just one 
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checkpoint or stage. These 12 SA-miRNAs that therefore exemplify the potential 
of miRNAs to play a regulatory role in this aspect of replicative senescence. 
The remaining pathway containing gene targets down-regulated during 
replicative senescence is involved in dCTP/dUTP metabolism. Since senescent 
cells are no longer cycling, changes in metabolism will logically follow. SA-
miRNAs may only be regulating a small part of cellular metabolism, the 
metabolism of 2 nucleotide units, however these metabolic changes may have 
far reaching effects. Furthermore, changes in dATP, ATP and TTP metabolism 
are seen further down in the list of pathways, 6, 7 and 9 respectively, which are 
not discussed here. It may therefore be the case that the SA-miRNAs are able to 
regulate the changes in metabolism required to establish senescence or that 
only changes to a few molecules or processes are required. 
The regulation of cellular survival, pro-inflammatory and cytoskeletal 
remodeling cellular processes would all logically be required to create the 
senescent cell phenotype. This analysis shows that these processes can 
theoretically be regulated by the SA-miRNAs, during replicative senescence, 
highlighting their potential to regulate the absolute levels and timings of these 
complex signaling cascades to create a senescent cell.  
4.2.2.2 Drug induced replicative senescence 
Replicative senescence results from the shortening of telomeres during each 
round of the cell cycle (Harley et al. 1990). Many cancer cells reactivate the 
enzyme telomerase, which has the ability to maintain telomeres and therefore 
overcome this barrier to tumorigenesis (Deng et al. 2008). Application of a drug 
that inhibits telomerase would, in theory, activate such cells’ natural 
senescence pathways, potentially including the actions of the SA-miRNAs. To 
explore this hypothesis the differentially expressed genes published by Damm 
and colleagues were interrogated for potential SA-miRNA regulation (Damm et 
al. 2001).  
Damm and coworkers investigated senescence resulting from treatment of lung 
carcinoma cells with the telomerase inhibitor BIBR1532. The published genes 
lists were filtered to include only those genes regulated by the 12 SA-miRNAs. 
This resulted in a list of 76 down-regulated SA-miRNA gene targets and 49 up-
regulated gene targets (Table 4.4b). Pathway analysis was then performed to 
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investigate the potential effects of SA-miRNA regulation in drug induced 
replicative senescence. 
As seen previously during the analysis of replicative senescence, the pathways 
associated with gene targets showing increased expression involve a variety of 
different cellular mechanisms. Two of these pathways are involved in the 
regulation of cellular signaling by the molecules PTEN and Activin A. The dual 
specificity phosphatase PTEN is a tumour suppressor gene and regulates cellular 
proliferation and survival through its ability to bind p53 in the nucleus (Chang et 
al. 2008). Activin A is a member of the TGF  superfamily and is involved in the 
regulation of cell growth and apoptosis (Takabe et al. 1999). Both molecules are 
commonly deregulated in cancers (Jeruss et al. 2003; Jiao et al. 2007) reflecting 
their importance in regulation of cell proliferation processes. Alterations in 
these signaling pathways could therefore be beneficial to the establishment of a 
senescent cell phenotype. The theoretical regulation of these processes by the 
SA-miRNAs demonstrates further mechanisms by which SA-miRNAs can cause the 
complex signaling pathway changes required to induce senescence.  
Two further pathways associated with gene expression increases in this dataset 
that show potential regulation by the SA-miRNAs involve EGFR and the ERBB 
family. As previously discussed, regulating signaling from the ERBB family of 
tyrosine kinases is an important step in senescence induction due to their role in 
the regulation of cellular proliferation. The presence of this map demonstrates 
that SA-miRNAs are a potential regulatory mechanism of these pathways during 
drug induced replicative senescence as well as natural replicative senescence.  
The remaining pathway associated with increased gene target expression is 
involved with changes in metabolism regulated by the transcription factor AP-1.  
Closer inspection of the SA-miRNA targets on this map (Figure 4.5) highlights the 
role of AP-1 in regulation of p21 and the apoptosis molecules c-fos and FASR. 
The involvement of c-fos and FASR in pathways regulated by the SA-miRNAs has 
been highlighted earlier in this study. This demonstrates that regulation of the 
diverse cellular proliferation and apoptosis signaling pathways affected by these 
molecules is an important step in senescence establishment, under both natural 
replicative senescence and when artificially drug induced. SA-miRNA regulation 
could therefore provide a mechanism by which the absolute levels and timings of 
these signals can be controlled. 
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Figure 4.5 - SA-miRNA regulation of transcription and the role of AP1 in regulation of 
cellular metabolism pathway biological map during drug induced senescence. Red 
thermometers show an object that can be regulated by a SA-miRNA with thermometer 
numbering corresponding to that seen in Table 2.1.Multiple thermometers denote that the 
object is a target of multiple SA-miRNAs. Green arrows represent positive, red negative and 
grey unspecified interactions. Boxes on lines denote the type of regulation where P = 
phosphorylation; B = binding; Tr = transcriptional regulation, Cm = covalent modification, T 
= transformation and Z = catalysis. 
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 The biological pathway map analysis of the decreases in gene expression for 
telomerase inhibited cells returned results very similar to that of the down-
regulated genes in natural replicative senescence. Four of the 5 maps are 
involved with the regulation of various aspects of the cell cycle including the 
role of APC, the DNA damage response checkpoint, regulation of ESR1 and 
chromosome condensation in prometaphase (Table 4.4b). As with the cell cycle 
pathways seen in replicative senescence, the regulation of cell cycle following 
telomerase inhibition would be a critical step in senescence induction. Targeting 
these multiple pathways to cell cycle control gives SA-miRNAs comprehensive 
regulation of the process. 
The remaining map is involved with metabolism of folic acid. As previously 
discussed, changes in metabolism will be required in cells undergoing 
senescence. However, this may also reflect metabolic changes involved in the 
metabolism of BIBR1532, independent of senescence, that the SA-miRNAs are 
also able to regulate. The ability of SA-miRNAs to target not just the down-
regulation cell cycle aspects of senescence but also the metabolic changes 
demonstrates the flexibility and complexity of their action. 
Looking at the pathway analysis of both replicative and drug induced senescence 
shown in Table 4.4, highlights the fact that the down-regulated pathways in both 
cases are cell cycle and metabolism related whilst the up-regulated pathways 
differ between the two stimuli. However, looking at the functions of the up-
regulated pathways in both cases reveals a common apoptosis regulatory signal. 
Cells in replicative senescence appear to be signaling apoptosis survival through 
FAS and TNFR1 pathways or in a p53 dependant manner whereas the telomerase 
inhibited cells are using the actions of Activin A and PTEN for this purpose. Thus 
the SA-miRNAs are potentially using different cellular mechanisms by which to 
achieve the same goal. The SA-miRNA regulation of the cellular signals behind 
drug induced and natural replicative senescence are therefore stimuli specific 
whilst remaining focused towards the common outcome of creating the complex 
senescent cell phenotype.  
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4.2.2.3 Oncogene induced senescence (OIS) 
Telomere erosion leading to the activation of DNA damage signaling cascades is 
not the only method of senescence induction. Oncogene induced senescence 
(OIS) can be caused upon either the loss of tumour suppressor genes like PTEN 
(Chen et al. 2005) or activation of oncogenes such as MEK, RAS and BRAFE600 (Lin 
et al. 1998; Michaloglou et al. 2005; Courtois-Cox et al. 2006). Recent evidence 
suggests that senescence induction by these stimuli is dependent upon IL-6 
mediated inflammatory responses without which the cells bypass senescence and 
continue proliferating (Kuilman et al. 2008). The same study also used gene 
expression microarrays to examine differentially expressed genes between cells 
that bypass and cells that undergo OIS, revealing a signature of 20 genes shown 
in Table 4.5. Seven of these genes, including IL-6, can theoretically be regulated 
by SA-miRNAs.  
Due to the small size of the initial signature, and hence the small number of 
target genes, analysis of the biological pathways underlying the SA-miRNA 
regulation was not statistically feasible. However, the SA-miRNAs regulate 
nearly 30% of the OIS signature revealed by Kuilman et al, including the key 
molecule IL-6 (Table 4.5). This may demonstrate the principle that large 
numbers of gene alterations are not always required for senescence induction, 
just well targeted ones. The multiple regulation of 3 of the genes in particular 
(C20orf26, CD55 and IL6) by the SA-miRNAs may show that within this signature 
these genes require the strictest regulation to ensure the successful induction of 
senescence, although further validation is required to test this theory. 
The analysis of differentially expressed genes during oncogene induced 
senescence, although limited by the size of gene list, still highlights the 
potential of SA-miRNAs to regulate key molecules required for this form of 
senescence induction. Furthermore, the regulation of inflammatory networks 
shown in this study to be key to senescence induction was also highlighted 
during the analysis of replicative senescence. This common regulation of pro-
inflammatory secretory senescence genes in response to 2 different senescence 
stimuli by SA-miRNAs is suggestive of its importance in senescence as a whole. 
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Table 4.5 - 20 Differentially expressed genes upon induction of oncogene induced 
senescence highlighted by Kuilman et al. Also shown are the SA-miRNAs that can 
theoretically regulate 7 of these genes, brackets show the number of theoretical 3’UTR 
binding sites that each SA-miRNA has for that gene. 
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4.2.2.4 Cellular stress induced senescence 
Senescence can also be induced by many different types of cellular stress such 
as UV-B (Debacq-Chainiaux et al. 2005), hydrogen peroxide (Frippiat et al. 
2001), tert-butylhydroperoxide (t-BHP) or ethanol exposure (Dumont et al. 
2002). Pascal and colleagues used a combination of differential display RT-PCR 
and low density DNA arrays to investigate genes involved in senescence induction 
by ethanol or t-BHP (Pascal et al. 2005). They revealed signatures of genes 
increasing and decreasing in expression for both ethanol and t-BHP, many of 
which overlapped. Table 4.6 highlights the potential of the SA-miRNAs as 
regulators of stress induced senescence by both treatments. 75% of the genes 
theoretically regulated by SA-miRNAs overlap between the two treatment types. 
This may suggest that these target genes are those that are core to senescence 
induction by SA-miRNA regulation. 
 Of all the overlapping genes shown in Table 4.6 four have roles in regulation of 
the actin cytoskeleton, namely ARHGAP24, ARPC2, MACF1 and S100A4 (Belot et 
al. 2002; Katoh et al. 2004; Daugherty et al. 2008). In the previous analysis of 
this chapter, cytoskeletal remodelling has always been associated with genes 
showing increased expression levels. Here however, two of the molecules, 
ARHGAP24 and ARPC2 show decreased expression. This may therefore represent 
specific molecules that require negative regulation in the context of stress 
induced senescence. Alternatively this may represent down-regulation of genes 
required to create the necessary senescence-associated cytoskeletal alterations. 
This demonstrates the potential of SA-miRNAs to regulate similar processes 
through different mechanisms dependant on stimuli. 
Cell cycle regulation has in both replicative and drug induced senescence been 
strongly negatively regulated. Two of the overlapping down-regulated genes, 
RAD17 and CDC37L1 (Table 4.6), common to both ethanol and t-BHP treatments 
have roles in the cell cycle. RAD17 specifically is involved in cell cycle arrest 
caused by DNA damage signaling (Dahm et al. 2002). The DNA damage caused by 
reactive oxygen species in cellular senescence may therefore be activating 
similar mechanisms of senescence induction as that seen in replicative 
senescence. These gene targets highlight the fact that the SA-miRNAs are able  
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Table 4.6 - SA-miRNA targets showing alterations in gene expression after stress induced 
senescence by either tert-butylhydroperoxide (t-BHP) or Ethanol (EtOH) and the direction of 
their alteration, blank cells infer no effect. Also shown is the SA-miRNAs that can 
theoretically regulate these genes, brackets show the number of theoretical 3’UTR binding 
sites that each SA-miRNA has for that gene 
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to induce similar mechanisms Usingstimuli specific target genes. The flexibility 
of the SA-miRNA mechanism of action allows them to remain specific enough for 
a cell to respond to a particular stimuli whist general enough to focus pathway 
changes in those cells to create the senescent cell phenotype. 
Two of the overlapping genes, EWSR1 and LOXL2, have previous evidence of 
senescence association. The EWS fusion protein has recently been reported as a 
repressor of senescence (Hu et al. 2008) and therefore its down-regulation by 
SA-miRNAS would provide a mechanism by which to prevent it inhibiting 
senescence induction. LOXL2 however has been used as a marker of senescent 
cells due to its increased expression during senescence (Muller et al. 2006). 
These senescent associated genes can theoretically be regulated by SA-miRNAs 
and this may therefore present a mechanism by which their roles in senescence 
induction are controlled. 
The remaining overlapping genes may still have roles in senescence. These genes 
may be involved in senescence induction through previously identified or 
potentially novel unidentified pathways, which analysis of the individual gene 
function does not elucidate. Their inclusion into larger data sets of potential 
senescence associated genes for systems biology analysis may help to elucidate 
their role. 
MiRNA regulation of stress induced senescence can therefore be seen to 
potentially transcend treatment type and incur changes in core senescence 
genes. Furthermore, regulation of additional treatment specific genes gives SA-
miRNAs the potential to alter diverse cellular pathways required to respond to 
different stimuli.  
Given the combined evidence of the potential of miRNAs to regulate the 
induction of senescence presented here; it is possible to hypothesise that 
perturbation of miRNA expression may play a role in tumorigenesis, senescence 
bypass mechanisms such as telomere maintenance and hence impact patient 
survival. To investigate this hypothesis miRNA expression patterns in human 
mesenchymal tumour biopsies was examined using miRNA microarrays. 
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4.2.3 Unsupervised hierarchical clustering of miRNA expression 
profiles shows improved separation of mesenchymal 
tumours over gene expression microarray profiles 
Before examination of the relationships of individual miRNAs with clinical 
factors, the ability of miRNAs to distinguish between tumour types was 
compared to that of gene expression data from the previous chapter. After 
quality control filtering of data from miRNA expression microarrays for 20 
peritoneal mesotheliomas, 18 liposarcomas, 17 MPNST and 10 synovial sarcomas, 
as described in Chapter 2, 325 miRNAs were used for unsupervised hierarchical 
clustering (Figure 4.6A). Although the majority of peritoneal mesotheliomas 
clustered together the other tumour types were poorly separated. Comparison of 
unsupervised hierarchical clustering of gene expression data for peritoneal 
mesotheliomas, MPNST and liposarcomas from the previous chapter (Figure 4.6B) 
showed a similar distinct clustering of peritoneal mesotheliomas. The clustering 
pattern of the miRNA expression profiles highlighted known histological 
similarities, for example the observation that the MPNST and synovial sarcomas 
were clustered on the same branch. The spread of the liposarcomas throughout 
the dendrogram was also consistent with the known heterogeneity of this tumour 
type. This data suggested that miRNA expression patterns were not only of use 
for examining the different underlying routes to tumourigenesis between tumour 
types but were potentially more discriminatory than mRNA profiling.  
As unsupervised hierarchical clustering of miRNA expression profiles of the 
tumour types was suggestive of different miRNA expression profiles for each 
tumour type but insufficient for complete separation; binary tree prediction 
analysis was used to investigate whether subgroups of miRNAs were able to 
improve the separation of these mesenchymal tumour types. These subgroups 
may be reflective of these individual tumour types route to tumourigenesis and 
therefore could be utilised to further explore the role of miRNAs in senescence 
bypass in each tumour type.  
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Figure 4.6 - Unsupervised hierarchical clustering of mRNA and miRNA highlights similar 
tumour biology but is unable to completely distinguish between tumour types. 
Unsupervised hierarchical clustering of miRNA (A) and gene expression (B) microarray 
data. Raw data was imported into BRB arraytools normalised and quality control filtered. 
Clustering was performed using a centred Pearson correlation algorithm and average 
linkage 
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4.2.4 Binary Tree prediction analysis highlights 87 miRNAs that 
improve separation of mesenchymal tumours in hierarchical 
clustering 
To investigate miRNA subgroups whose expression patterns were able to 
distinguish between tumour types the binary tree prediction method (using the 
compound covariate predictor algorithm) within BRB array tools was utilised. 
Through a multi-step process this method builds a hierarchical tree which 
divides the tumour types by groups of differentially expressed miRNAs. Each 
node of the tree provides a list of miRNAs whose expression patterns could 
therefore be used to distinguish between tumour types. This analysis highlighted 
3 lists of miRNAs with the ability to distinguish between tumour types (Figure 
4.7A) with an average misclassification rate, by “leave-one-out cross-validation” 
technique, of 14.7%. The resulting binary tree consisted of 3 nodes with the first 
node being 72 miRNAs able to distinguish between mesotheliomas and the 3 
other tumour types. This large number of miRNAs with differential expression 
patterns in this tumour type was consistent with the high degree of separation 
observed between mesotheliomas and other tumour types in the hierarchical 
clustering. Furthermore, 37 miRNAs able to distinguish between liposarcomas 
and the remaining two tumour types (MPNST and synovial sarcomas) and a 
further 12 miRNAs able to distinguish between MPNSTS and synovial sarcomas 
were identified. Closer examination of these lists revealed a number of 
overlapping miRNAs between nodes. By taking only those miRNAs unique to an 
individual node the list was reduced to a core set of 87 miRNAs with the ability 
to distinguish between tumour types (Appendix I). Hierarchical clustering using 
this 87 miRNA signature showed improved separation of the three tumour types 
(Figure 4.7B). Synovial sarcomas and MPNSTs showed a similar clustering pattern 
to that seen in unsupervised clustering (Figure 4.6A), further emphasising the 
degree of similarity of these tumour types. With the exception of one sample, 
the previously diverse liposarcomas were now contained within one major 
cluster suggesting that the miRNAs within the signature may have some 
biological significance for this tumour type. Furthermore, examination of the 
liposarcomas by histological subtypes highlighted a branch of 9 myxoid and 
myxoid-round cell tumour samples (Figure 4.7B*). This 87 miRNA signature was  
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Figure 4.7 – Binary Tree prediction analysis highlights an 87 miRNA signature able to 
distinguish tumour types. Compound covariate prediction analysis with leave-one-out 
cross-validation was performed using BRB-Array tools. The resulting three nodes of 
miRNAs (A) were then examined for overlaps leading to a list of 87 unique miRNAs present 
at only one node. (B) Supervised hierarchical clustering using the 87 miRNA signature 
shows improved clustering of tumour groups. * indicates a cluster of myxoid and myxoid 
round-cell liposarcomas. 
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therefore not only able to group a previously diverse tumour type but further 
split that tumour type into histological subtypes.  
4.2.5 Tumour type specific miRNAs show prognostic significance 
and correlation with telomere maintenance mechanism 
Given the potential biological significance of these miRNAs the next step of the 
analysis was to explore whether miRNAs of prognostic significance existed within 
the 87 miRNA signature. Hazard ratios were calculated for each miRNA using BRB 
array tools, as detailed in Chapter 2. MiRNAs with a significant hazard ratio 
(p≤0.05) were then adjusted for age, sex and grade using Mantel Cox regression 
in SPSS.  The number of miRNAs for each tumour type with a significant hazard 
ratio varied from 14 in liposarcomas to 5 in synovial sarcomas (Table 4.7) a 
number of these showed independent prognostic significance when adjusted for 
grade, age and sex (Table 4.7 & Figure 4.8). Comparison of these prognostic 
miRNAs and the 87 miRNAs able to distinguish between tumour types showed 
that 13 of the prognostic miRNAs were also found in the 87 miRNA signature. 
This data therefore suggested that miRNAs have implications in overall tumour 
biology as well as prognostic implications in individual tumour types. 
Furthermore, examination of the lists of prognostic miRNAs showed miR-let7g 
was prognostic in both MPNST and synovial sarcomas. This commonly prognostic 
miRNA further highlighted the similarity between these two tumour types 
previously suggested by the hierarchical clustering (Figure 4.6 and Figure 4.7) 
potentially extends to miRNA regulatory mechanisms. Additionally, to directly 
investigate the potential impact of the 12 SA-miRNAs upon survival the list of 
significant miRNAs for prognosis was examined. 3 of the SA-miRNAs were found 
to also have prognostic significance in the mesenchymal dataset. miR-20a, 34a 
and 29c miRNAs in liposarcomas, mesotheliomas and MPNST respectively showed 
prognostic significance indicating that the regulation of senescence signaling by 
through SA-miRNAs may be an important factor in patient outcome in these 
tumour types. 
In the previous chapter, complex layers of transcriptional and kinase regulation 
of the decision between different TMMs (see chapter 3) were highlighted. In 
addition to this the prognostic implications of TMMs in liposarcomas and 
peritoneal mesotheliomas have been documented  
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Table 4.7 - miRNAs with significant associations with outcome in mesenchymal tumours. 
MicroRNAs with significant hazard ratios for liposarcomas, mesotheliomas, MPNST and 
synovial sarcomas were identified using BRB array tools. Mantel Cox regression was used 
to adjust for age, sex and grade. * indicates comparisons that could not be adjusted for 
grade due to missing information. 
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Figure 4.8 - Survival analysis of miRNA expression patterns highlights tumour specific 
prognostic miRNAs. Kaplan-Meier plots of miRNAs with a significant hazard ratio after 
adjustment for grade, age and sex from Table 4.7, plotted using SPSS (v.15) (A) and (B) 
show prognostic miRNAs, in liposarcomas. (C) shows the independent prognostic miRNA in 
peritoneal mesothelioma. (D) and (E) shows prognostic miRNAsi. Solid lines show high 
expression whereas dotted lines indicate low expression of respective miRNAs. P values 
are the result of Mantel-Cox survival analysis after adjusting for grade, age and sex. 
Mesotheliomas were not adjusted for grade due to missing information. 
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(Ulaner et al. 2003; Costa et al. 2006; Cairney et al. 2008; Villa et al. 2008). The 
investigation into the role of miRNAs in the regulation of telomere maintenance 
in these tumour types may provide a biological explanation for differences in 
prognosis. Table 4.8 shows 48 miRNAs with significant differences in expression 
between tumours using either ALT or telomerase as a TMM. Examination of these 
miRNAs and those that are prognostic for each tumour type revealed overlaps in 
both liposarcomas and peritoneal mesotheliomas. Furthermore, differential 
expression of the two arms of miR-193a hairpin (-5p and -3p) that are prognostic 
or differentially expressed by telomere maintenance groups suggested that both 
aspects of the miR-193 precursor may be being processed and acting 
synergistically upon different aspects of cellular signaling to incur the same 
prognostic endpoint. Common regulation of telomere maintenance mechanisms 
between tumour types was also suggested by the common differential of 
expression of 3 miRNAs in these tumours. MicroRNAs miR-181b and miR-39a* 
were differentially expressed in liposarcomas and MPNSTs and miR-338-3p in 
liposarcomas and mesotheliomas suggesting that these miRNAs may have key 
roles in telomere maintenance transcending tumour type. 
Further value in some miRNAs that were not found to be independent of age, sex 
and grade was observed when overlaps between prognostic and TMM associated 
miRNAs were examined. miR-21* and miR-324-5p show significant hazard ratios 
but were not independently prognostic. However these miRNAs were also 
differentially expressed between TMM in liposarcomas (Table 4.7 & 4.8). TMM 
has previously been associated with poor outcome in liposarcomas (Costa et al. 
2006; Cairney et al. 2008) and the expression patterns of these two miRNAs 
supported their role in both processes. miR-21* had a high hazard ratio, implying 
that expression of the miRNA was associated with poor outcome and this miRNA 
was expressed 4 fold higher in ALT liposarcomas. miR-324-5p had a low hazard 
ratio and ALT liposarcomas had a 4 fold lower expression of this miRNA. These 
results suggested that the prognostic implications of these miRNAs in 
liposarcomas could be due to their potential role in the regulation of TMM.  
In peritoneal mesothelioma only miR-96 overlapped between the prognostic and 
TMM miRNAs (Table 4.7 & 4.8). The expression pattern of miR-96, having a high 
hazard ratio and 5 fold lower expression in ALT tumours, was consistent with the 
known poorer prognosis of mesotheliomas with higher telomerase activity 
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Table 4.8 - miRNAs with significant expression differences between telomere maintenance 
mechanisms. Significant expression differences were identified using an ANOVA in 
Genespring GX (version 10) 
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(Villa et al. 2008). Furthermore, after adjustment for age and sex miR-96 was 
the most significant prognostic miRNA (p= 0.034) coupled with a high level of 
significance for TMM (p = 0.003) suggesting that regulation of TMM by miR-96 
may be an important prognostic factor in this tumour type.    
No overlaps between the prognostic and significant telomere maintenance 
miRNAs were observed in MPNST (Table 4.7 & 4.8). Due to the presence of only 1 
ALT synovial sarcoma in the cohort examination of miRNAs associated with 
telomere maintenance mechanism was not statistically feasible in this tumour 
type. 
Interestingly no SA-miRNAs had significance in TMMs. This suggested that SA-
miRNAs may play a role in the regulation of senescence signaling but not the 
decision between TMMs in mesenchymal tumours. 
A selection of miRNAs from each tumour type with significant associations with 
survival or telomere maintenance were selected for validation by qPCR (Figure 
4.9). Although not always reaching statistical significance, the expression 
patterns of each miRNA echoed that seen in the microarray data when 
comparing high and low expression for survival, or ALT and telomerase for TMM. 
The confirmation of these expression differences by a second methodology 
showed that they are not simply an artefact of the microarray and are 
differentially expressed between these groupings in these tumour types. These 
validated individual miRNAs associated with telomere maintenance or survival in 
these tumour types therefore represent attractive targets for future functional 
studies. 
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Figure 4.9 - qPCR validation of miRNA expression patterns confirms patterns observed in 
microarray data. Box plots represent the average of at least 2 Qiagen MiScript qPCR 
experiments normalised to non-coding small RNAs. Tumours are grouped according to the 
hazard ratio groupings in the original microarray analysis for miRNAs significantly 
associated with survival in liposarcomas (A), mesotheliomas (C), MPNST (E) and synovial 
sarcomas (G). Tumours are grouped by TMM in liposarcomas (B), mesotheliomas (D) and 
MPNST (F).  
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4.3 Discussion 
As knowledge of the complexities of the signaling pathways involved with 
senescence induction and bypass grows there is a need for an improved 
understanding of the regulation of these signaling pathways. miRNAs present a 
relatively poorly explored mechanism of gene regulation. Due to their ability to 
simultaneously regulate many different genes on a variety of pathways miRNAs 
represent a potentially important senescence regulatory mechanism. Through 
examination of the pathways regulated by 12 miRNAs with previously published 
evidence of senescence regulation and miRNA microarray data for mesenchymal 
tumours the potential impact of miRNA regulation of senescence bypass was 
investigated. 
Literature searches revealed a set of 12 miRNAs with experimental evidence for 
roles in the regulation of senescence induction. When looking at the individual 
SA-miRNAs some miRNAs have more support for their roles in senescence than 
others (Table 4.1).  The evidence for a regulatory role of the mir-34 family of 
miRNAs in senescence is growing and has stemmed from the investigation of p53 
and its role in senescence. A number of studies have identified the miR-34 
family, particularly miR-34a, as downstream effectors of p53 involved in the cell 
cycle (Bommer et al. 2007). Recent research has found that up-regulation of 
miR-34a in various cancer cell lines leads to cell cycle arrest, increased 
expression of β-galactosidase (He et al. 2007) and down-regulation of E2F family 
target genes (Tazawa et al. 2007). Furthermore, drug treatment of various 
cancer cell lines with the MDM2 inhibiting drug Nutlin-3, leading to p53 
activation, induced up-regulation of primarily miR-34a and later miR-34b and 
miR-34c (Kumamoto et al. 2008). Reports of a pro-apoptotic effect induced by 
miR-34a (Chang et al. 2007; Raver-Shapira et al. 2007) may demonstrate that its 
expression alone is not responsible for senescence.  
The potential role of hsa-miR-20a in senescence regulation was discovered 
through investigation of the candidate senescence associated gene LRF (Poliseno 
et al. 2008). LRF is a transcriptional repressor of the MDM2 inhibitor p19ARF 
(Pomerantz et al. 1998; Maeda et al. 2005). The overexpression of miR-20a in 
mouse embryonic fibroblasts induced senescence by lowering LRF protein levels 
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and in turn increasing p19ARF levels. The fact that investigation of two different 
senescence-associated genes, p53 and LRF, yields only two different SA-miRNAs 
may be a reflection of the range of signaling pathway changes that these 
molecules contribute to in the induction of the senescent phenotype.  
Genome-wide analysis of changes in miRNA expression or investigations of those 
miRNAs that allow senescence bypass were alternative approaches used in SA- 
miRNA identification. The use of microarrays identified miRNAs hsa-miR-371, 
hsa-miR-369-5p, hsa-miR-29c, hsa-miR-499 and hsa-let-7f as significantly up-
regulated in senescent human mesenchymal stem cells (hMSCs) when compared 
to early passage hMSCs (Wagner et al. 2008). miRNA hsa-miR-271 was also seen 
to be significantly up-regulated by this study but overall had very low expression 
levels. These varying levels of miRNA expression may suggest different 
requirements for alterations in their target gene pathways.  
MiR-372 and miR-373 were identified as miRNAs whose expression was able to 
bypass RAS-induced senescence in the presence of wild-type p53 (Voorhoeve et 
al. 2006). The expression of these miRNAs would therefore not be conducive to 
senescence and were included in this analysis as examples of miRNAs whose 
targets may increase in expression during senescence. 
These reports in combination with the observation of significant associations of 
miR-34a, miR-29c and 20a with survival in mesenchymal tumours presented here 
provide experimental evidence for the molecular mechanisms by which miRNAs 
may act in the context of senescence and their biological importance. Recent 
reports of the regulatory effects of miRNAs miR-17-5P and miR-24 on senescence 
regulators p21 and p16, may offer further miRNAs with a role in senescence 
(Fontana et al. 2008; Lal et al. 2008). However, lack of β-galactosidase and 
H2AX analysis or the expected alterations to senescence induction prevent 
whether these miRNAs play a direct role in senescence from being established 
purely from these initial observations. For this reason they were not included in 
the SA-miRNA cohort. 
The regulation of different senescence induction stimuli by SA-miRNAs was found 
to vary as shown in Table 4.3. In this study, evidence of the potential SA-miRNAs 
regulation of core sets of senescence genes regardless of induction mechanism is 
presented. This analysis highlighted common up-regulation of apoptosis signaling 
Kyle Lafferty-Whyte, 2010  Chapter 4,122 
and pro-inflammatory gene regulation targeted by SA-miRNAs between different 
senescence stimuli. SA-miRNA targeted down-regulation of cell cycle processes 
across the induction mechanisms was also observed. This evidence taken in 
combination with the large degree of overlap between treatment types in stress 
induced senescence was suggestive of key cellular changes that the SA-miRNAs 
can facilitate during senescence induction. To date, this is the first report of 
predicted miRNA regulation of common pathways regardless of senescence 
stimulus.  
2 SA-miRNAs, hsa-miR-499 and hsa-miR-34c, were shown to regulate all of the 
senescence types examined suggested that these particular SA-miRNAs may act 
as master regulators for senescence induction. Alterations in different biological 
signaling pathways by the remaining 10 SA-miRNAs could then tailor the cellular 
response to suit the alterations required by specific stimuli. This hypothesis 
requires further laboratory validation, however the fact that both miRNAs 
already have experimental evidence to show they are senescence regulators 
adds some weight to the theory. However, no significant associations with 
survival or TMM were observed in the mesenchymal miRNA microarray data. This 
suggests that although potential regulators of senescence signaling regardless of 
stimulus these miRNAs are not utilised by mesenchymal tumours to perturb the 
senescence programme and become immortalised.  
Further exploration of the potential miRNAs as regulators of senescence bypass 
through TMMs and their impact on survival was undertaken utilizing miRNA 
expression microarray data for 4 mesenchymal tumour types, liposarcomas, 
MPNST, synovial sarcomas and peritoneal mesotheliomas. Mesenchymal tumours 
are a diverse group of tumours with varying median survivals. Senescence 
associated molecules such as p16, Ki67 and p53 have previously been linked with 
outcome in many of these tumour types (Kourea et al. 1999; Watanabe et al. 
2001; Borczuk et al. 2005; Oda et al. 2005). In addition, the complex regulatory 
networks presented in the previous chapter and the known prognostic 
significance of TMMs in mesenchymal tumours further suggests the potential 
importance of miRNA regulation during tumourigenesis. 
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Previous analysis of miRNA expression patterns in liposarcomas, MPNSTs and 
synovial sarcomas has identified a number of differentially expressed miRNAs but 
failed to correlate the expression levels of any individually with survival 
(Subramanian et al. 2007; Guled et al. 2009). A recent publication highlighted 
the expression of 7 miRNAs significantly associated with histological subtype in 
mesotheliomas, two of which (miR17-5p and miR-30c) also correlated with 
survival (Busacca et al. 2009). However, for such a large and diverse tumour 
group relatively few miRNA investigations have been performed for example no 
known miRNA signatures for liposarcomas, MPNST and synovial sarcomas exist. 
This may be reflective of the rarity of these tumours and the difficulty in 
collecting sufficient numbers of tumours for statistically viable studies.  
For each tumour type a group of prognostic miRNAs were highlighted. 33% of the 
prognostic miRNAs overlapped with those in the 87 miRNA signature suggesting 
unique molecular differences that influence outcome between these tumour 
types (Table 4.7 & 4.8). These miRNAs therefore present a potential novel target 
for future clinical trials and mechanistic investigations.  
25, 14 and 9 miRNAs were significantly differentially expressed between 
telomere maintenance mechanisms in liposarcomas, peritoneal mesotheliomas 
and MPNST respectively were also highlighted (Table 4.7). 2 miRNAs (miR-21* 
and 324-5p) in liposarcomas and one miRNA (miR-96) in mesotheliomas which 
also had prognostic significance were also observed (Table 4.7 & 4.8). 
Agreement of the expression patterns in telomere maintenance mechanism 
groups and the hazard ratios in each tumour type of these overlapping genes 
suggested that the prognostic implications of these miRNAs may be due to their 
role in the regulation of telomere maintenance mechanisms, consistent with the 
known prognostic implications of telomere maintenance in both tumour types 
(Costa et al. 2006; Cairney et al. 2008; Villa et al. 2008). For example, miR-21* 
had a high hazard ratio, implying that expression of the miRNA was associated 
with poor outcome and this miRNA was expressed 4 fold higher in ALT 
liposarcomas. To date, there has been no published association between 
telomere maintenance and patient outcome in MPNSTs and the lack of overlap 
between prognostic miRNAs and miRNAs involved in telomere maintenance in 
this miRNA data may therefore reflect the possibility that telomere maintenance 
mechanism may not have a significant effect on patient outcome. There were 
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however a number of significantly different miRNAs for telomere maintenance 
suggesting that although not prognostic, telomere maintenance mechanism 
regulation may still be an important factor in biology of this tumour type. 
Although an increased incidence of ALT has previously been seen in synovial 
sarcomas (Henson et al. 2005) the mesenchymal tumour cohort contained only 1 
ALT tumour and examination of the role of miRNAs in telomere maintenance 
regulation for this tumour type was not possible. 
In this chapter, pathway mapping and theoretical gene target identification was 
used to create a biological framework by which to test the relevance of miRNAs 
in the regulation of senescence signaling. miRNAs were not only shown to 
potentially regulate genes previously seen to be involved in senescence but also 
regulate larger pathway alterations, such as cell cycle and cytoskeletal 
remodeling, that would logically be required to create the complex phenotype 
of the senescent cell. Commonly regulated pathways and cellular mechanisms 
between the senescence stimuli also demonstrated the potential of SA-miRNAs 
to regulate a core set of pathway modifications regardless of senescence 
induction mechanism. Furthermore, stimulus specific pathways by which SA-
miRNAs can regulate apoptosis survival signals in cells undergoing drug induced 
or natural replicative senescence were highlighted. Additionally, individual 
miRNAs that were differentially expressed between telomere maintenance 
mechanisms and with prognostic significance were identified. In depth 
examination of these miRNAs highlighted that that three of the SA-miRNAs had 
prognostic significance in specific mesenchymal tumour types suggesting that 
regulation of senescence signaling by these miRNAs may be an important factor 
in tumorigenesis and patient outcome and warrants future laboratory 
investigation. The combination of these findings suggests that miRNAs may 
present a real senescence signaling regulatory mechanism with potential for 
targeted therapies. Furthermore, regulation by miRNAs is a post-transcriptional 
event and therefore would provide a mechanism by which genes could remain 
transcribed but not translated. This may therefore facilitate the establishment 
of latent senescence signaling in human tumours; the impact of which is not 
currently understood. 
 
5 Scoring of damage or secretory associated 
senescence phenotypes in human tumour gene 
expression datasets and identification of a pro-
inflammatory signature correlating with survival 
advantage in peritoneal mesothelioma  
5.1 Introduction 
In the previous chapter significant associations between SA-miRNAs and survival in 
mesenchymal tumours was observed. Furthermore, previous data within this 
project highlighted the fact that telomere maintenance mechanisms for 
senescence bypass are highly regulated processes in these tumours (see chapter 3). 
This suggests that senescence signaling may have an impact on or be related to a 
cell’s route to tumorigenesis. Although the senescence program must be bypassed 
for cells to become fully immortalised it is currently unclear as to how much latent 
senescence signaling remains present in human tumours after this event. 
Therefore, latent senescence signaling dynamics during disease progression and in 
response to known senescence induction mechanisms have not been explored. To 
fully explore the associations between cellular senescence and larger tumourigenic 
processes it is necessary to look beyond single genes and instead utilise data from 
larger pathways. To this end, a scoring system that reduces the levels of latent 
senescence signaling in a human tumour present in gene expression microarray 
data to one quantifiable number was designed. It must be noted that this is one of 
the first times such an approach has been taken and as such this represents a pilot 
study in the field. The list of genes that have been used for the signatures, their 
assigned directions and even the scoring method itself may require further 
alterations in future studies. Therefore the results presented here are a first-pass 
hypothetical study into latent senescence signaling in vivo and in vitro. After 
validating the approach in datasets whereby senescence induction would be 
expected; the scoring system was applied to a mesenchymal data set and the 
expression pattern of latent secretory senescence signaling and associations with 
survival was explored.  
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5.2 Results 
5.2.1  Development of senescence scoring approach 
Bypass of senescence is a requirement for full transformation. However, many 
cancer cells retain the ability to induce the senescence program in response to 
genotoxic insults (Braig et al. 2006; Gewirtz et al. 2008). Theoretically, tumours 
must therefore retain latent senescence pathways, however their impact upon 
other factors such as patient survival and response to therapy are unclear. To 
explore these associations it was first necessary to design a method of quantifying 
the levels of latent expression of senescence signaling pathways in a human 
tumour. As gene expression changes in a number of well-defined senescence 
markers during senescence induction are documented, gene expression microarray 
data was used to gain a measure of the degree to which these markers were still 
signaling in a senescent manner. To this end, the published literature was mined 
for gene expression signatures and biomarkers of senescence (Table 5.1) and two 
sub-signatures were established. DAS biomarkers represent genes with known roles 
in senescence the damage associated senescence pathway and chromatin 
responses. Additionally, a modified secretory senescence (mSS) signature was 
created by combination of elements of the senescence messaging 
secretome/senescence associated secretory phenotype (SMS/SASP) signatures with 
a signature of 4 genes representing DNA damage and telomere dysfunction which 
increase in expression/activity in senescent cells and are detectable in serum of 
ageing human patients (Coppe et al. 2008; Jiang et al. 2008; Kuilman et al. 2009; 
Young et al. 2009). Given the reliance of the scoring procedure on the starting 
gene-lists and directions but also it’s inherent adapatability; future studies utilizing 
this method may choose to alter the content of the gene signatures to reflect 
current knowledge in the field. 
To assign senescence scores, data were imported and normalised to median using 
BRB array tools. Each gene was then scored as senescent or not depending on 
whether expression was in a pro-senescence direction (see Table 5.1) with 
reference to that gene’s median expression level. For example, expression of the 
proliferation-associated gene KI67 below median would be marked “senescent” but 
above median expression would not. The total percentage of genes receiving a 
“senescent” score was then calculated for each sample to give an overall 
Kyle Lafferty-Whyte, 2010  Chapter 5, 122 
senescence score. By this approach, the level of pro-senescence signaling in each 
pathway can be measured. Although very simple mathematically, taking the 
percentage of genes still signaling in a senescent manner provides a single 
continuous senescence measurement in human tumours incorporating the sum 
contributions of many pathways, something that has not previously been 
attempted. To attempt to validate the scoring approach in this pilot study, the 
scoring system was applied to a number of settings in which senescence would be 
predicted to occur. 
5.2.2 Validation of the Approach 
5.2.2.1 Senescence signaling pathways induced by radiation therapy 
The induction of cellular senescence in response to radiotherapeutic agents has 
been recently documented. Application of the scoring system in this context would 
therefore be expected to show increased senescence signaling post radiotherapy. 
To investigate this, the scoring system was applied to a publicly available dataset 
(GSE15781) which consisted of tumours and normal tissue of the colon before and 
after radiotherapy (Figure 5.1). Examination of all biomarkers showed that tumours 
had a higher level of senescence signaling compared to their respective normal 
tissues (score 69% and 56%, respectively) (Figure 5.1A). Furthermore, irradiated 
tumours had higher median levels of pro-senescence signaling than their non-
irradiated counterparts (score: 74 % in irradiated tumours compared with 69 % in 
non-irradiated). These results suggested that the scoring system was potentially 
able to capture increased senescence signaling resulting from radiotherapy. 
As well as measuring overall senescence signaling, the scores of the sub-signatures 
DAS and mSS were also explored. Irradiation of tumours causes high levels of DNA 
damage with the aim of causing cell necrosis or apoptosis (Ross 1999). Patterns in 
the data shown in Figure 5.1B highlighted that irradiated normal tissue have 
increased median DAS signaling compared to their non-irradiated counterparts, 
however the overall spread of the data was lower in the irradiated normal tissue 
(50 % - 87 % in non-irradiated normal compared to 37 % - 75 % in irradiated normal). 
Median DAS signaling in adenocarcinoma was unchanged by irradiation, although 
the minimum scores were at a higher level in irradiated tumours than their  
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Originating Senescence Signatures Genes Expression Direction in Senescence 
DAS Biomarkers 
(Campisi et al. 2007; Fridman et al. 2008; 
Sedivy et al. 2008) 
p16 Increase 
HMGA1 Increase 
HMGA2 Increase 
HIRA Increase 
ASF1a Increase 
H2AFY Increase 
H2AFY2 Increase 
PML Increase 
MMP3 Increase 
53BP1 Increase 
p21 Increase 
Ki67 Decrease 
mSS Biomarkers 
 (Coppe et al. 2008; Jiang et al. 2008; 
Kuilman et al. 2009; Young et al. 2009) 
IL6 Increase 
IL8 Increase 
PAI1 Increase 
IGFBP3 Increase 
IGFBP5 Increase 
IGFBP7 Increase 
IL1A Increase 
CXCR2 Increase 
IGF1 Decrease 
IGF2 Decrease 
WNT2 Decrease 
CAMP Increase 
STMN1 Increase 
EEF1A1 Increase 
IGF2R Increase 
TGFB1 Increase 
Table 5.1  - Gene expression changes and senescence signatures. 
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Figure 5.1 - Senescence scoring of public data sets. Datasets tested were: irradiated and non-
irradiated colorectal tumour and normal tissue (GSE15781); doxorubicin and 5-FU treated 
breast cancer cell lines (GSE1647); mesenchymal stem cells cultured to replicative senescence 
(GSE9593); a melanoma progression set (GSE4587). All sets were scored using (A) All markers 
from Table 1, (B) DAS markers, (C) mSS markers. Median senescence scores are shown with 
bars representative of the maximum and minimum values. In the case of the hMSC set, the 
time-course data are derived from the cells of a single donor without replication and therefore, 
no bars are shown 
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non- irradiated counterparts (62 % compared to 50 %) suggesting a trend in favor of 
higher DAS signaling in irradiated tumours.  
Interestingly, irradiation did not increase mSS signaling in tumours (score: 73% pre- 
and post-irradiation). In contrast, normal tissues showed a median increase of 6.7% 
(Figure 5.1C). Radiotherapy therefore appeared to specifically activate the DNA 
damage and chromatin aspects of senescence whilst not altering levels of the 
secretory senescence signaling pathway in tumours. This finding may present novel 
opportunities for improved senescence induction through therapeutic activation of 
secretory pathways in these tumours, however given the preliminary nature of this 
pilot study further validation of this result in other radiation treatment datasets 
may be required. 
5.2.2.2 Senescence scoring in drug treated breast cancer cells 
To assess the performance of the scoring approach in a further situation in which 
senescence induction would be expected, i.e. drug-induced accelerated 
senescence, a further the public data set (GSE1647), in which the authors 
investigated drug-specific toxicity-related expression profiles in a panel of breast 
cancer cell lines treated with chemotherapy drugs, was explored. Senescence was 
not directly assessed in this study, though each drug was administered at its IC50 
for each cell line (assessed by a mitochondrial dye conversion assay). For statistical 
robustness, the data for the 3 cancer cell lines ZR-75-1, ME16C, and MCF7 treated 
for 24 hours (leading to a total of 6 replicates per treatment) with either 
doxorubicin or 5-FU were pooled, both of which have previously been observed to 
induce the accelerated senescence phenotype in tissue culture (Bu et al. 2008; 
Sliwinska et al. 2009). 
Across all cell lines, the median basal senescence score was comparatively low 
(20%). As observed with radiotherapy of colon adenocarcinoma, treatment with 
either 5-FU or doxorubicin results in induction of the overall senescence score 
(Figure 5.1A, 5-FU score: 35%; doxorubicin score: 33%). DAS markers had basal 
expression of 14% in untreated cells. As expected, these genes were strongly 
induced, resulting in median scores of 45.5% and 41% for 5-FU and doxorubicin, 
respectively (Figure 5.1B). The mSS component also appeared to be induced by 24 
hour drug treatments, though more modestly than the DAS component, rising to 
31% and 28% from a basal level of 25%. Thus according to this scoring approach, 
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both radiotherapy and chemotherapy induced multiple senescence markers as 
expected, however mSS appeared to have a greater contribution in response to 
chemotherapeutics. 
5.2.2.3 Senescence signaling dynamics during replicative senescence 
Having shown that the scoring system highlighted increased senescence signaling 
after treatment with senescence inducing therapies, the scoring system was next 
applied to investigate replicative senescence of human mesenchymal stem cells 
(hMSCs). Passages 2 to 11 in hMSCs from the same patient, (publicly available 
dataset GSE9593) were scored for latent senescence signaling. This same dataset 
was also used in the previous chapter to assess miRNAs potential role in 
senescence. Prior to passage 11, at which time hMSCs were completely senescent, 
the authors of the study observed continuous changes in the cellular phenotype 
including gradual increases in cell size and senescence associated -galactosidase 
staining (Wagner et al. 2008). These phenotypic changes are consistent with known 
phenotypic changes during the process of replicative senescence onset. 
The analysis of all senescence markers in this data (Figure 5.1A) was consistent 
with these observations, indicating that senescence gradually increased with 
passage, albeit to a small degree. A plateau between passages 6 and 8 was evident 
when all markers were scored (score 79%). Strikingly, however, examination of the 
DAS and mSS signatures at this time point showed that this plateau was in fact a 
timed change in signaling type. Secretory senescence signaling remained level at 
75% until passage 6 at which point a slight reduction to 69% was observed. At this 
timepoint there was a corresponding sharp increase in DAS signaling (75 % to 92 %). 
A subsequent spike in secretory (mSS) expression (score 81%) occurred at passage 
7, followed by a return to base levels (Figure 5.1C). Examination of DAS markers at 
this time point (Figure 5.1B) showed a transient decrease in their expression at 
passage 7 (score 75% compared with 92% at passage 6) before returning to maximal 
levels. These changes in latent senescence signaling correspond to a transient 
change in the global expression profile of these cells observed between passages 6-
8 in the original analysis (Wagner et al. 2008).  
The dynamics of telomere shortening were not directly explored in the original 
study. However, passage 7 occurs immediately before the onset of the main 
plateau phase of growth, suggesting that a significant fraction of cells may have 
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undergone telomere dysfunction. DAS signaling spiked at P6, prior to the spike in 
mSS signaling at P7, raising the intriguing possibility that a threshold level of 
damage signaling triggers cells to communicate cellular stress to the surrounding 
microenvironment through the mSS pathway (Rodier et al. 2009). Furthermore, the 
spike in secretory signaling also correlated with a transient increase in expression 
of glycoprotein GPNMB/osteoactivin which was validated by QPCR in the original 
study (Wagner et al. 2008). GPNMB is an osteoclastic factor also implicated in 
endothelial cell adhesion and regulation of pro-inflammatory macrophage signaling. 
The increase of expression of GPNMB at this passage in combination with the 
observed increase in secretory senescence signaling is therefore consistent with the 
concept that signaling to the microenvironment is indeed increased at this time 
point (Sheng et al. 2008; Pahl et al. 2009). This was the first time such a temporal 
switch in senescence signaling had been documented, however the differential 
regulation of secretory and other senescence pathways during replicative 
senescence was also concurrent with other recent findings in human T-cells during 
senescence bypass (Degerman et al, 2010). 
5.2.2.4 Senescence scoring in a Melanoma progression dataset 
The above results suggested that the scoring system effectively captured increased 
activity of senescence pathways during both therapeutically induced and natural 
replicative senescence. The expression levels of latent senescence pathways are 
likely to be altered by the processes of transformation and tumour progression and 
may reflect the route to immortalisation in individual tumour types. To explore this 
hypothesis the changes in senescence signaling during tumour progression in a 
melanoma dataset (GSE4587) were explored. Figure 5.1 shows levels of senescence 
signaling in benign nevi (score 55%, for all markers). Interestingly, an increased 
senescence score was found in melanoma when compared to benign nevi, 
regardless of the type of senescence signaling explored (DAS score: 58% versus 50%; 
mSS score 75% versus 63%). Therefore, although transformation has been achieved 
in these melanomas some aspects of the senescence program still appeared to be 
active. Furthermore, the specific identities of induced senescence genes during 
tumour progression may point to the route of immortalisation for specific tumour 
types. Given that begign nevi are a well established model of senescence in vivo it 
may also be feasible that the scoring method is not accurately predicting 
senescence in these cells. Further validation would therefore be required. 
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Nonetheless, the promising results of the radio- and chemotherapeutic treatment 
datasets and the replicative senescence data make it possible to hypothesise that 
the scoring system could potentially be accurate and this could be a new 
observation in this tumour model. The lower level of scoring in the nevi could be 
because senescence has been established in the nevi the levels of actual signaling 
being triggered may be less than that caused by the constant trigger, and bypass, 
of the senescence signaling cascade caused by abberantly proliferating cells (such 
as primary tumours and metastasis).  
Comparison of primary melanoma and metastasis using all markers showed a slight 
increase in metastasis (melanoma score: 70%; metastasis score: 71.4%) (Figure 
5.1A). However, exploration of DAS and mSS revealed striking differences between 
the two tumour stages. Primary melanomas had a high contribution from mSS 
signaling and low levels of expression of the DAS biomarkers (75% and 58% 
respectively), while metastases had the opposite expression pattern (mSS score 
69%; DAS score 75%) (Figure 5.1B & C). These results may reflect the differing 
selection pressure upon these tumour stages whereby the pro-inflammatory 
microenvironment produced by the secretory senescence signaling pathway is 
advantageous to a primary tumour in processes such as angiogenesis but may 
prevent immune evasion by metastatic tumours. The low DAS senescence scores in 
primary tumours may be reflective of low levels of signaling shortly after 
immortalization and senescence bypass. After which, genomic instability may 
potentially increase during the process of tumour progression leading to higher 
levels of DAS senescence signaling pathways in metastasis. Furthermore, DAS 
related signaling pathways may be induced during bypass of anoikis. In summary, 
these results suggested that DAS signaling increases during tumour progression. 
However, these increases were clearly insufficient to induce full senescence and 
cell cycle arrest. 
5.2.3 Application of Scoring Approach 
5.2.3.1 Differential senescence signaling patterns in mesenchymal 
tumours 
The results above provided preliminary proof of concept that senescence scores 
obtained using these signatures conformed mostly to expectations, given current 
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understanding of replicative and accelerated senescence. The scoring system 
therefore provided an initial tool with which the potential role of latent 
senescence signaling in human tumours could be explored. To this end, the scoring 
system was applied to the mesenchymally derived tumour gene expression dataset 
(Figure 5.2). For this dataset all of the senescence biomarkers had identical median 
scores across all tumour types (46%) (Figure 5.2A). Dissection of individual 
senescence signaling pathways showed that DAS signaling was lowest in MPNST (42 
%) and mesotheliomas (46 %) and higher in liposarcoma (score: 50%) (Figure 5.2B).  
In contrast, mSS expression was higher in mesothelioma (score: 50%) than either 
MPNST or liposarcomas (44% and 47%, respectively) (Figure 5.2C). This suggests that 
even small changes in senescence signaling pathways can be detected using this 
scoring method and therefore allow for hypothesis driven investigations. For 
example, differences in latent senescence signaling could affect factors such as 
patient prognosis and response to therapy. In particular, the higher scores for DAS 
in liposarcoma and mSS in mesothelioma samples were interesting in light of the 
shorter median survival for patients presenting with peritoneal mesotheliomas (27 
months) compared to liposarcoma (99 months). These inverse signaling patterns 
further reinforce the concept that high levels of signaling of one of the two 
senescence pathways may be tolerable but both may be sufficient to induce full 
senescence and block transformation. Furthermore, the lower median survival of 
mesotheliomas in this example may suggest that the immune activatory signals 
given by the latent secretory senescence signaling may be advantageous to primary 
tumour proliferation similar to that observed previously in melanomas (Figure 5.1). 
Having observed interesting signaling dynamics in larger tumour types, the scoring 
system was next utilised to investigate latent senescence scores in individual 
tumour samples. For each senescence signature the scores for each tumour were 
ranked within its group to smooth the data. Ranked data was then used to 
calculate Pearson correlations between senescence signatures for each individual 
tumour within the group (Table 5.2), allowing investigation of whether the 
signatures are distinct signaling events or could be co-expressed in individual 
tumours. In all tumour types both DAS and mSS significantly correlated with All 
biomarkers (Table 5.2C). Furthermore, DAS and mSS never significantly correlated, 
suggesting that according to this senescence scoring method these two pathways 
are distinct signaling events at an individual tumour level. These observations  
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Figure 5.2 - Senescence scoring of mesenchymal tumours. Peritoneal mesothelioma, 
liposarcoma and MPNST samples were scored using (A) All markers from Table 5.1, (B) DAS 
markers, (C) mSS markers. Median senescence scores are shown with bars representative of 
the maximum and minimum values. 
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Table 5.2 - Correlation of senescence score rankings highlights signaling dynamics in 
individual tumours  
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confirmed that the results of the group analysis are pertinent at the level of 
individual tumours, implying that senescence phenotypes may be differentially 
activated during transformation. 
5.2.3.2 Supervised Hierarchical clustering using the mSS signature 
highlights heterogeneous subgroups within mesenchymal 
tumours and a prognostic signature in peritoneal mesotheliomas 
Given the essential nature of the establishment of a secreted inflammatory 
network of signaling in senescence induction (Kuilman et al. 2008) and the 
observations of differential expression patterns of secretory senescence in 
mesenchymal tumours and hMSCs, it seemed pertinent to utilise the mSS signature 
to further explore senescence signaling patterns in this pathway in mesenchymal 
tumours. After normalisation of gene expression array data, the expression 
patterns of only the mSS signature within each tumour type were examined using 
supervised hierarchical clustering (Figure 5.3A, and data not shown).  
Hierarchical clustering in peritoneal mesotheliomas split these tumours into two 
distinct groups, A and B (Figure 5.3A), corresponding to differential expression in 
two gene groups, 1 and 2 (Table 5.3). Specifically, group A tumours had higher 
expression of group 1 genes and lower expression of group 2 genes than group B 
tumours. The tumour groups, A and B, did not significantly correlate with any 
patients’ known histological characteristics, such as age or sex. Interestingly, 
tumours in group A were associated with improved survival compared to those in 
group B and this remained significant after adjusting for age and sex (Figure 5.3B). 
This suggested that even though senescence had been bypassed, the latent 
expression of different subsections of the secretory senescence pathway still 
affected patient outcome.  
To further explore the functions of the differentially expressed gene groups, 1 and 
2, enrichment for biological GO processes in each prognostic gene group was 
investigated. This analysis revealed that group 1 genes have functions in immune 
activation (p= 4.1E-10), chemotaxis (p= 1.6E-11), inflammation (p= 1.2E-8) and 
negative regulation of cell proliferation (p= 3E-16). This was concurrent with 
previous findings in other tumour types, that patients with high levels of local 
inflammation and immune invasion at the tumour site have improved survival  
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Figure 5.3 – Supervised hierarchical clustering using the mSS signature highlights gene 
groups correlating with survival in peritoneal mesotheliomas. Clustering of mesothelioma 
samples is shown in (A). Group A tumours had higher expression of group 1 genes and lower 
expression of group 2 genes, corresponding to a potential pro-inflammatory phenotype. Gene 
groups are given in Table 3. (B-D) Kaplan-Meier survival analyses of tumour groups from mSS 
supervised hierarchical clustering. (B) Peritoneal mesotheliomas, (C) MPNST and (D) 
Liposarcoma. Note: hierarchical clustering split the liposarcoma cohort into 3 major groups 
(denoted a, b and c) whereas all other tumours split into two groups (denoted a and b).  
 Only mesothelioma samples showed a significant association with survival improvement. P 
values shown in brackets are p-values after adjustment for age and sex. All survival analysis 
performed in SPSS (version 15). 
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Gene Group 1 
CAMP 
EEF1A1 
IGF2R 
IL1A 
IL6 
IL8 
CXCR2 
WNT2 
Gene Group 2 
EEF1A1 
IGF1 
IGF2 
IGFBP3 
IGFBP5 
IGFBP7 
CXCR2 
PAI1 
STMN1 
TGFB1 
 
Table 5.3 – Gene groups responsible for clustering in peritoneal mesotheliomas. Probes 
A_32_P47701, A_32_P44316 and A_32_P15320 for EEF1A1 appeared in group 1 while probe 
A_24_P763243 featured in group 2.  
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(Roxburgh et al. 2009). Furthermore, the genes in group 2 were involved with the 
regulation of cell growth (p= 3.4E-16), proliferation (p= 2E-13) and cell motion (p= 
1.3E-14). The increased expression of genes involved in cellular proliferation and 
cell motion may therefore be indicative of more aggressive tumours leading to 
decreased survival rate.  
The same analysis was also performed on the other two mesenchymal tumour 
types. Similar gene groups also split MPNST into 2 tumour groupings while 
liposarcomas were divided into three groups with high group 1 expression (A), low 
group 1 expression (B) and low expression of both groups (C) (data not shown). 
However, examination of survival revealed no significant difference between the 
groups in these tumours (Figures 5.3C & D). Nevertheless, these expression groups 
may reflect unknown biological factors and may warrant further investigation to 
improve understanding of the underlying biology and role of senescence in these 
subgroups. 
 
5.3 Discussion 
To improve the understanding of senescence signaling it is becoming increasingly 
necessary to look beyond the expression of individual genes and at the larger 
pathways they are involved in. The scoring approach presented here takes a 
percentage of the known senescence biomarker genes that are signaling in a pro-
senescent manner thereby reducing the information given by multiple biomarkers 
down to one quantifiable number. It is then possible to dissect the levels of 
particular senescence signaling pathways occurring in a sample at any one time and 
directly compare the levels of these pathways, giving us an insight into subsystems 
involved in senescence establishment and maintenance. First, the approach was 
validated using a number of publicly available datasets corresponding to scenarios 
where modulation of senescence signaling might be expected. Upon establishment 
of proof of concept an in-depth study into latent secretory senescence signaling 
using in-house generated mesenchymally derived tumour datasets was performed. 
The results of this analysis show that senescence signaling occurs in a context 
dependent manner. In certain situations, DAS and mSS programs coexist while in 
others they are distinct signaling events regulated in a time dependent fashion.  
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It must also be noted however that this exploration of latent senescence signaling 
using a scoring approach is the first of its kind and therefore future studies may 
choose to alter the exact combinations of genes in the signatures. Furthermore, 
additional dimensions to the scoring procedure, such as including an error 
calculation and/or weighting genes of particular interest, may also be added. 
However, for this pilot study such further complexities were omitted to allow 
initial assessment of the core approach. 
The induction of DNA damage by radiotherapy in cancer is commonplace in current 
treatment regimes (Ross 1999). Recent evidence suggests that senescence is 
frequently induced after radiation exposure (Jones et al. 2005; Quick et al. 2006; 
Gewirtz et al. 2008). To gain a further understanding of the individual roles of DAS 
and mSS signaling in this process the examination of colon tumours and normal 
tissues pre and post radiotherapy from publicly available data, was undertaken. As 
well as observing a general increase in senescence signaling post radiation exposure 
concurrent with the literature, this pilot studysuggested that secretory senescence 
signaling is not induced by radiotherapy in colon adenocarcinoma, while there was 
a trend in favor of an increase in DAS signaling in these samples. This distinction 
had not previously been made and may present important opportunities for 
immune activating adjuvant therapies through the activation of secretory 
senescence signaling in tumours of patients receiving radiotherapy. 
The scoring system was next applied to a gene expression dataset comprising 
doxorubicin or 5-FU treatments of the breast cancer cell lines ZR-75-1, ME16C, and 
MCF7 (Troester et al. 2004). Here again increased representation of all biomarkers, 
consistent with the emerging concept of drug-induced accelerated senescence, was 
observed. The scoring system therefore also reported increased senescence in a 
second therapeutic intervention scenario. In contrast with the radiotherapeutic 
context, both DAS and mSS subsystems were induced by drug treatments although 
induced DAS signaling still predominated. The distinction between the levels of 
mSS and DAS in response to the two treatment types had not previously been 
documented.  
To determine whether the scoring system identified increased senescence signaling 
in the normal “physiological” context of replicative senescence, a time-course 
dataset corresponding to gradual replicative senescence of hMSCs with increasing 
passage was explored (Wagner et al. 2008). Investigation of all biomarkers showed 
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a gradual increase with passage with a plateau between passages 6-8. By dissection 
of DAS and mSS elements the scoring system showed that this plateau corresponded 
to a point at which DAS signaling sharply increased. This was subsequently followed 
by an increase in secretory senescence signaling concurrent with a transient 
decrease in DAS signaling. Such a decrease in DAS signaling may highlight a specific 
time-point for the secretory senescence pathway to signal cellular distress to 
surrounding cells, as previously observed in the literature (Rodier et al. 2009) and 
further highlights the distinct nature of the two signaling pathways. This was the 
first time such a temporal switch in senescence signaling has been documented. 
Previous data on individual senescence genes in melanoma has suggested that 
senescence is a barrier to tumour progression (Bennett 2008). Application of the 
scoring approach to a melanoma progression dataset showed that not only did 
senescence signaling remain active after immortalization but that the levels of 
senescence signaling of all types in primary tumours were higher than that seen in 
benign nevi. This suggests that although the senescence program has been 
bypassed the signaling pathways continue to operate in melanoma. Nevi, however, 
remain the most established in vivo example of senescent cells and therefore this 
result was somewhat surprising. Given that this was a pilot study of the scoring 
method this presents two possible scenarios. Firstly, the scoring method may not 
accurately capture latent senescence levels in this cell type. Alternatively, this 
experimental approach may have uncovered a novel biological effect not previously 
seen with other techniques. In the case of this second scenario it is conceivable 
that as the nevi have progressed to a final senescent phenotype the requirement 
for repeated latent senescence signaling maybe reduced. However, melanomas and 
metastatic tumours continue to proliferate and therefore may continue to trigger 
the senescence signaling cascades leading to high levels of latent signaling despite 
bypass of the final program.  
 In addition to the general increase in senescence signaling over nevi,differential 
expression of secretory and DNA damage/chromatin senescence pathways in 
primary lesions and metastasis, with secretory elements of senescence showing a 
trend towards down regulation in metastases, were observed. Down regulation of 
secretory senescence pathways in metastatic tumours may facilitate immune 
evasion and disease progression. Despite the down-regulation of secretory 
senescence the DAS elements of senescence continue to signal. The latent signaling 
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of senescence in tumours and metastasis may present opportunities for therapies to 
reinstate the correct endpoint of these pathways and halt further disease 
progression. The data from this pilot study therefore suggests that therapies 
targeted to induce secretory senescence in metastatic melanoma may warrant 
further investigation and together, the results from all public datasets confirmed 
that this experimental scoring system is potentially able to detect the contribution 
of individual senescence signaling subsystems in a variety of contexts. 
Next, a more in-depth investigation of senescence signaling in individual 
mesenchymally derived tumours was performed. Initial examination of the 
correlations between the rankings of individual tumours from three main 
mesenchymal malignancies, liposarcoma, MPNST and mesothelioma, highlighted 
similar patterns of senescence signaling in individual tumours of all 3 types. Scores 
for All biomarkers significantly correlated with those for DAS and mSS in all cases. 
In contrast, DAS and mSS scores showed no correlation suggesting that these 
signaling processes are distinct events at an individual tumour level. This is 
consistent with analysis of the larger tumour groups, where increased mSS scores in 
mesothelioma and DAS scores in liposarcoma were observed in comparison to other 
tumour types. As distinct events, it is possible to hypothesise that these signaling 
processes may influence other clinical factors such as prognosis or response to 
treatment. 
Previous studies have examined individual senescence markers and their prognostic 
significance in these tumour types (Watanabe et al. 2001; Borczuk et al. 2005; Oda 
et al. 2005) but not the prognostic significance of entire senescence signaling 
pathways. Distinctions between the different senescence signaling dynamics in 
individual tumours gives improved understanding of the cellular context prior to 
treatment being applied and potentially helps to make the move towards patient 
tailored targeted therapeutics more realistic. Given the importance of the 
establishment of a secretory senescence network in the induction of senescence 
(Kuilman et al. 2008) this may be a pathway that could be perturbed by different 
mechanisms to effectively prevent senescence induction. To this end, a more in-
depth analysis of the patterns of expression of secretory senescence in the three 
mesenchymal tumour types was undertaken. 
Hierarchical clustering of peritoneal mesotheliomas split the tumours into two 
groups based on distinct expression patterns of subsets of secretory senescence 
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genes involved either in pro-inflammatory and immune activating processes or in 
pro-growth and proliferation processes. Interestingly, the groupings showed 
significant correlation with survival; in particular, those tumours displaying 
increased expression of pro-inflammatory genes had improved survival compared 
with the lower expressing group. The functions of these genes are therefore likely 
to be of importance in the underlying tumour biology of mesotheliomas. Although 
hierarchical clustering also divided the MPNST and liposarcoma samples into 2 and 
3 clusters, respectively, based on similar gene groups, no association with survival 
was observed. However, improved survival associated with tumours with increased 
immune infiltration has previously been documented (Roxburgh et al. 2009) and the 
activation of specific secretory senescence pathways may facilitate this. Given the 
secretory nature of these molecules, their measurement in patient serum will 
improve understanding of the role of senescence signaling in patient outcome for 
these and other tumour types. 
The application of senescence scoring is a useful tool for assessing senescence 
signaling in general, as well as individual senescence pathways, applicable to any 
gene expression microarray dataset. Application to other tumour types could 
significantly improve the understanding of senescence signaling in cancer and aid in 
the development of mechanistic studies of these pathways. This initial pilot study 
of latent senescence signaling in human tumours provides a first-glimpse of its 
potential importance in tumour biology.  
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6 Latent expression of senescence pathways in 
NCI60 cell lines highlights patterns of drug 
resistance or sensitivity different from that 
observed with apoptosis scoring 
6.1 Introduction 
During the development of an anti-cancer therapeutic drug much time is spent 
investigating the response of different cell types to drug exposure, with the ideal 
drug being non-toxic in normal cells and tissues and highly toxic in cancer cells. 
The efficacy of drugs in different cell types is a highly studied topic and many 
individual molecules, such as ATP-binding cassette transporters, have been 
attributed to drug resistance in cancer (Bachmeier et al. 2009). However, the role 
of larger cellular pathways on cells’ responses to drug exposure is still unclear.  
The majority of drugs aim to remove the tumour by specifically inducing apoptosis 
in the cancer cells. This is usually achieved by targeting molecules whose 
expression is unique and critical to the cellular survival of the tumour. For 
example, the activation of repressed tumour suppressors such as p53 (Wang et al. 
2008), repression of oncogenes' activity such as BRAF (Espinosa et al. 2007) and 
targeting therapies to genes uniquely expressed in immortalized cells such as 
hTERT (Shay et al. 2008; Bilsland et al. 2009). However, the induction of cancer 
cell apoptosis relies upon the ability of this pathway to be successfully activated 
and implemented. As tumours may have become resistant to pro-apoptotic 
signaling on their route to neoplasia there exists a subset of tumours that are 
inherently resistant to pro-apoptotic drugs. In this situation, the permanent 
removal from the cell cycle through the induction of cellular senescence therefore 
presents an attractive alternative therapeutic endpoint to apoptosis. (Braig et al. 
2006; Majumder et al. 2008; Prieur et al. 2008). Indeed recent published evidence, 
in combination with the data presented in the previous chapter, suggests that the 
more traditional cancer therapies of chemo and radiotherapy actually may induce 
high levels of cellular senescence as well as apoptosis (Jones et al. 2005; Quick et 
al. 2006; Gewirtz et al. 2008). Knowing when senescence induction will be 
successful and which drugs to utilize may improve patient outcome. To achieve this 
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however an improved understanding of the interaction between senescence 
signaling and drug resistance is needed. 
In the previous chapter, the latent expression level of individual senescence 
signaling pathways, utilizing an experimental scoring technique, was shown to vary 
between tumour types; during disease progression and in response to chemo- and 
radiotherapeutics. In the same chapter, the prognostic implications of expression 
of particular gene subsets of the secretory senescence pathway in peritoneal 
mesotheliomas were highlighted demonstrating that latent signaling pathways may 
have an influence on clinical parameters. The effect of latent expression of 
senescence signaling pathways on drug response in tumours is currently unknown.  
To this end, publicly available data was utilised to examine associations between 
expression levels of senescence signaling pathways and drug resistance in the NCI60 
cell line panel. Furthermore, through the contrast with apoptosis score associated 
drug associations; senescence specific drug associations were explored. 
6.2 Results 
6.2.1 Senescence scoring of NCI60 cell lines shows no significant 
correlation between expression of secretory senescence 
signals and DA senescence signals 
It was hypothesized that cellular response to individual drug types may be linked to 
the latent expression of different signaling pathways. However, before examination 
the relationships of different signaling pathway with response to drugs could occur, 
an understanding of the relationships between cell types and the signaling 
pathways themselves in the dataset was required. To this end, a combination of 
scatter plots, hierarchical clustering and Pearson correlations were generated.  
To explore the expression patterns of molecules within the secretory senescence 
(mSS), damage associated senescence (DAS) and apoptotic signaling pathways 
between cell types hierarchical clustering was performed. Figure 6.1 shows 
dendrograms for (A) apoptosis (B) secretory senescence and (C) damage associated 
senescence. Examination of the clustering of the NCI60 lines by apoptosis scores 
revealed a potential relationship between cell type and apoptosis score that was 
not as clearly seen in either of the two senescence scores. Apoptosis score split the 
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samples into 4 main cluster groups (Figure 6.1A). Enrichment for some of the cell 
types in the different clusters was observed, for example the first cluster was 
enriched for melanoma and leukemia cell lines whereas the fourth was enriched for 
CNS and renal cell lines. This suggested that cell types may have specific 
expression patterns of particular apoptosis signaling molecules, therefore 
indicating differing regulation mechanisms for apoptosis signaling between cell 
types. The dendrograms for secretory senescence (Figure 6.1B) and damage 
associated senescence (Figure 6.1C) showed less clear clustering by cell type where 
both are initially split into two large clusters followed by further divisions into 
smaller clusters. Although some cell type specific clusters were be observed, for 
example small melanoma clusters were seen in both Figure 6.1B and C, in general 
there was not a strong relationship between the clustering and cell type. This may 
suggest that underlying the senescence signaling for both of these pathways were 
expression patterns that are not cell type specific. Regulation mechanisms of 
secretory or DA senescence respectively may therefore transcend cell type, 
however further studies using larger cohorts would be required to conclusively 
prove these hypothesises.  
To fully understand the relationship of a larger signaling pathway with other 
factors, such as drug resistance, it is necessary to look beyond the individual genes 
and instead use quantitative values of overall pathway signaling. To this end, the 
latent expression of damage associated (DA) senescence, secretory and apoptotic 
signaling in the NCI60 cell lines of public data was scored as per chapter 5 of this 
study. Table 6.1 details apoptosis genes details used for apoptosis scoring. As 
discussed in the previous chapter this scoring method is relatively experimental 
and as such may require further alterations (such as the potential addition of 
methods of measuring error or weighting key genes) in future studies. However, as 
a first look pilot study into the potential relationship between drug response and 
latent senescence signaling the method serves as a useful starting point. 
Figure 6.2 shows the senescence scores for (A) mSS and (B) DAS and (C) apoptosis in 
each cell type as a scatter plot. Examination of each individual signaling type 
revealed that each cell type had an individual range of scores. Comparison of the 
baseline levels of each signaling pathway revealed similar ranges of both secretory 
and DA senescence signaling whereas apoptotic signaling was generally much higher 
in all cell types. This may be reflective of higher tolerance of apoptosis signals in 
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Figure 6.1 – Hierarchical clustering using secretory senescence, damage associated 
senescence and apoptosis pathways highlights cell type specific regulation of apoptosis. 
Hierarchical clustering using the genes of (A) the apoptosis pathway (see Table 6.1), (B) mSS 
and (C) DAS. Branches are labelled by cell type colour according to attached legend. Cell type 
abbreviations are as follows BR = breast, CNS = central nervous system, CO = colon, LC = 
lung, LE = leukaemia, ME = melanoma, OV = ovarian, PR = prostate, RE = Renal, UN = 
Unknown. 
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Gene Symbol Direction 
ABL1 Increase 
APAF1 Increase 
BAD Increase 
BARD1 Increase 
BAX Increase 
BMF Increase 
BRCA1 Increase 
CASP3 Increase 
CASP9 Increase 
CDC2 Increase 
CDKN2A Increase 
DRAM1 Increase 
E2F1 Increase 
GADD45A Increase 
GADD45B Increase 
JUN Increase 
MAP2K4 Increase 
MAP3K4 Increase 
MAPK10 Increase 
MAPK8 Increase 
MAPK9 Increase 
POU2F1 Increase 
PRKCD Increase 
RAD9A Increase 
RAD9B Increase 
TP53 Increase 
TP73 Increase 
YWHAQ Increase 
BCL2 Decrease 
BCL2L11 Decrease 
MDM2 Decrease 
SFN Decrease 
 
Table 6.1 – Genes and their direction of expression used in latent apoptosis scoring. 
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Figure 6.2 - Scatter plot of each signaling pathway highlights cell type specific expression 
patterns. Scatter plots of (A) mSS, (B) DAS and (C) apoptosis scores grouped by cell type. Cell 
type abbreviations are as follows BR = breast, CNS = central nervous system, CO = colon, LC = 
lung, LE = leukaemia, ME = melanoma, OV = ovarian, PR = prostate, RE = Renal, UN = 
Unknown. 
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comparison to either of the senescence signaling pathways. Further examination of 
the relationships between different signaling pathways in individual cell types 
allowed understanding of the interplay between them. For example, leukemia cell 
lines had a higher level of DAS signaling (median score 66.7 %) than secretory 
senescence (median score 53.1 %). Given that apoptosis is also a programmed 
response to DNA damage signaling, it may therefore be expected that these cells 
would also have a high level of apoptotic signaling. However, this cell type showed 
the lowest median levels of apoptosis signaling of 66.7 %. The data generated from 
this pilot study of latent senescence scoring may therefore suggest that to continue 
to proliferate, leukemia cells may not be able to tolerate both high levels of DA 
senescence and apoptosis signaling without triggering one of the two processes. 
The exact thresholds required to trigger apoptosis or senescence in this manner 
may vary from tumour to tumour do to different selection pressures induced by 
their cellular contexts and microenvironments. This may therefore account for the 
level of variability seen in these relationships.  
In addition, cross comparison of the different in individual tumour types using this 
experimental scoring system highlighted novel signaling patterns in cell types 
previously unexplored.. For example, observations of higher secretory senescence 
than DA senescence signaling in central nervous tumour cells (CNS) and the inverse 
for leukemic cells (LE) had not been previously documented. Such patterns may 
assist in the understanding of the interaction between cell microenvironment and 
latent senescence signaling. For example, increased secretion of pro-inflammatory 
and chemotactic molecules in blood born tumours, such as leukemia, may not be 
conducive to tumorigenesis due to the potential for fast removal by immune cells. 
Those cells with high secretory senescence signaling may therefore be selected 
against in favor of those with low secretory senescence signaling, thus leading to a 
tumour cell population with low secretory senescence signaling. In contrast, solid 
tumours of immune privileged sites, such as the central nervous system, may not 
be under such pressures and expression of secretory senescence molecules may 
instead assist in processes such angiogenesis.  
In this dataset, Melanomas (Me) had generally higher levels of DA senescence than 
secretory senescence, in contrast with what was observed in the melanoma dataset 
in chapter 5. However, this pattern of expression is the same as those observed in 
metastatic melanoma and may therefore suggest that these melanoma cell lines 
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are more biologically similar to metastic melanoma than primary melanoma 
tumours. Alternatively, this may also indicate that the scoring system requires 
further optomisation to accurately capture latent senescence levels in cell lines as 
opposed to primary biopsies. 
Finally, to gain an understanding of whether the latent expression of any of the 
combinations of signaling pathways were linked events in individual cell lines, 
correlations between the signatures were calculated (Table 6.2). As per the 
previous chapter, the senescence scores were ranked to allow directly comparable 
in a single cell line. Pearson correlations were then calculated for each 
combination of scores. No significant correlation between the secretory and DA 
senescence signaling pathways (p = 0.119) was observed, indicating that their 
expression was not a linked event, consistent with the findings of the previous 
chapter of this study. This may also suggest that the latent expression of these 
senescence signaling pathways are under independent selection pressures and/or 
are regulated differently. Significant correlations between the senescence scores 
and apoptosis pathways were however observed (mSS p = < 0.001, DAS p = 0.029). 
These observations suggest that the latent expression of either senescence 
pathway may potentially trigger an apoptosis response or vice versa. Alternatively, 
due to the low strength of the correlations (0.439 for mSS and 0.283 for DAS), this 
may more reflect the ability of a cell to tolerate both mSS/DAS and apoptotic 
latent signaling rather than a cause and effect relationship. 
The assessment of patterns of latent senescence score in cells grown in culture 
using this experimental scoring technique may be affected by small variances 
between experimental conditions when cells are cultured by different groups. To 
investigate the effect, if any, these variances had on the latent expression patterns 
of secretory senescence; DA senescence and apoptotic signaling, two of the NCI60 
cell lines were assayed in house (DU145 and HT29). The scoring of the gene 
expression data for GSE5846 showed that both of these cell lines had higher levels 
of secretory senescence (mSS) than DA senescence and the in house microarray 
data reflected this pattern (Figure 6.3). In both cases apoptosis signaling was found 
to be at lower relative levels than that observed in the public data however, these 
levels remained above those of secretory senescence. These differences may have 
been due potential experimental factors that differ between this analysis and that 
of the original dataset, such as age and confluence of cell cultures upon extraction  
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 mSS Apoptosis DAS 
mSS 1   
Apoptosis 0.439  
(p=< 0.001) 
1  
DAS 0.203 
(p = 0.119) 
0.283  
(p = 0.029 ) 
1 
Table 6.2 - Correlations between the three latent signaling pathway scores. Correlation is 
shown with p value beneath in brackets 
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Figure 6.3 - In-house gene expression microarrays and public data of (A) HT29 and (B) DU145 
cell lines and latent senescence scoring shows similar patterns of latent expression of 
senescence pathways. In-house arrays were performed in duplicate and the median value of 
the two scores is shown with the error bars depicted maximum and minimum values. As 
GSE5846 data was not performed in duplicate no error bars are available for this data. 
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or growth medium variations. This data may therefore suggest that to directly 
compare datasets from different experimental sets some normalization of the 
actual scores by method such as the ranking may be required. However, as the 
general patterns of latent senescence signaling remained the same between the 
two datasets, it was concluded that patterns of latent senescence signaling were 
not strongly affected by the cell culture variations between sites. 
Overall, the combination of the hierarchical clustering  and experimental 
senescence scoring analyses were potentially suggestive of a situation whereby 
apoptosis signaling was regulated in a cell type specific manner whereas 
senescence scoring, for either secretory or DA senescence, was reflective of 
common molecular changes that transcend cell type. Furthermore, the data from 
this initial study suggested that secretory and DA senescence may be distinct 
signaling events in the NCI60 cell line panel. However, a combination of a single 
latent senescence and apoptotic latent signaling may be tolerable by cells and 
neither is enough to induce full apoptosis nor senescence activation. The dynamic 
nature of the expression and interplay between these latent signaling pathways 
suggested that although not fully active these pathways were still regulated. These 
observations therefore suggested that latent signaling pathways may potentially 
have an impact on other biological/clinical parameters, such as cellular responses 
to drugs. 
6.2.2 Virtual compound screen identifies differing drug activity 
resistances linked to damage associated, secretory 
senescence and apoptosis pathways. 
It was therefore hypothesized that the latent signaling levels of secretory 
senescence, DA senescence and apoptosis pathways may have the ability to affect 
the efficacy of compounds to induce growth inhibition in tumour cells. Examination 
of a potential cause-and-effect relationship between secretory senescence, DA 
senescence, apoptosis scores and the concentration of compounds required to give 
a 50 % growth inhibition (GI50) through regression analysis was undertaken. 71, 250 
and 61 compounds with unique significant relationships (regression p < 0.05) 
between growth inhibition and DA senescence, secretory senescence and apoptosis 
respectively were identified. A further 3 compounds overlapped between all three  
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Figure 6.4 - Venn Diagram of compounds with significant regressions for each latent signaling 
pathway. Compounds with a regression p value of < 0.05 and latent signaling levels of 
apoptosis (blue), mSS (red) and DAS (green).  
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Figure 6.5 - Interval plot of slope of the lines for unique compound regressions. The mean 
slope of the line for the compounds with unique associations with each pathway is plotted with 
their 95% confidence intervals. The negative slope of the line for all three scores shows that 
with increasing score for each of these pathways cell lines become increasingly sensitive to 
the compounds.  
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 scores (Figure 6.4). To understand whether the different latent signaling pathways 
were generally causing resistance or sensitivity for different compounds the 
average direction of the slope of the line was explored (Figure 6.5). This analysis 
revealed that all three pathways generally identified unique drugs to which cell 
lines were sensitive shown by the negative values for the slope of the line. This 
therefore suggests that the latent expression levels of these pathways may 
potentially have a significant impact on the response to therapy by particular drugs 
in patients. This analysis is reliant on the experiment scoring procedure presented 
in chapter 5 and therefore is presented as a proof-of-concept demonstration that 
the scores of latent signaling pathway can be applied to experimental data to 
discover potential drugs to which patients may be sensitive. Further laboratory 
validation of these scores and their relationships with drug sensitivities is required 
before they could be applied in the clinic. However, as a first exploration of such 
relationships this virtual screen provides an interesting starting point. 
6.2.3 Investigation of predicted activities of significant compounds 
reveals drug class associations linked with each signaling 
pathway. 
Examination of the predicted molecular targets and activities of the significant 
compounds for each signaling pathway may improve current understanding of the 
key molecular types that each latent signaling pathway were targeting uniquely. 
After further validation, such knowledge may help to tailor the particular drug to 
use when a particular therapy (such as kinase inhibition) has been suggested. To 
this end, activity modeling of the original compounds used in the screen using 
graph-theory connectivity indices to build a decision tree model was performed. 
The model showed 7 predicted activities of the compounds within the screen GPCR 
agonist inhibition, GPCR antagonist inhibition, kinase inhibition, protease 
inhibition, PDE inhibition, ligand-gated ion channel inhibition, nuclear hormone 
receptor inhibition. The distribution of unique hits to each senescence signaling 
pathway, as well as those significant for apoptosis, were then graphed as a 
proportion of the total number of compounds in each list normalized to the total 
proportion of the original list that each drug class represented. This allowed an 
analysis of the differential effects of each scoring pathway without the  
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Figure 6.6 - Predicted Activities of compounds significantly associated with latent signaling 
pathways. Graph-theory connectivity indices were used to create a decision tree model by 
which compounds were mapped to predicted biological activities. The fold enrichments of  
predicted activities for the unique compounds for mSS (red), DAS (blue) and apoptosis (green) 
were normalised to the size of each list and the proportion of drug class present in the entire 
screen.  
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confounding of the information with unequal list sizes or proportions of predicted 
drug activities in the original drug screen for each drug class.  
In this plot (Figure 6.6) protease inhibitors were observed to be the only category 
to have the greatest proportion of significant regressions in DA senescence. Given 
that the caspase signaling cascade is associated with the activation of apoptosis 
rather than senescence it is interesting that the latent DA senescence score should 
identify more protease inhibition sensitivities than apoptosis scoring. 
This may be suggestive of a situation whereby cells with a high level of DNA 
damage signaling (as observed by the high DA senescence scores) have blocked 
apoptotic effector cascades. The direct inhibition of these pathways may be 
sufficient to alter the cellular response and trigger the induction of an alternative 
growth arrest mechanism, such as senescence. Given the experimental nature of 
the scoring system further validation of such concepts would be required before 
being able to apply these observations clinically. Further investigation into the 
exact targets and molecular mechanisms behind this trend are not possible from 
bioinformatic analysis of this data but may warrant future experimental 
investigation.  
This analysis also revealed that cells with high secretory senescence scoring had a 
particular enrichment for sensitivity to compounds with predicted activities as 
kinases and PDE inhibitors. The sensitivity of these cells to PDE inhibition may 
reflect the requirement for the inhibition of signaling processes mediated by cAMP 
or cGMP, which PDEs enzymatically degrade, to prevent the full activation of the 
senescence program. 
These relationships between senescence signaling pathways and drug activity in 
this pilot study therefore suggested that although senescence has been bypassed, 
expression of latent senescence signaling pathways may still have the potential to 
cause distinct biological effects.  
The cross comparison of senescence signaling and apoptosis signaling data resulted 
in the observation of a contrast in the predicted drug activity enrichments. For 
example, cells with high apoptosis score appeared to be particularly enriched for 
sensitivity to growth inhibition by compounds with predicted activities as ligand-
gated ion channel inhibitors, nuclear hormone receptor inhibitors and GPCR 
antagonist inhibitors, where both senescence signaling pathways show lower 
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relative levels of association. This suggested that cells showing high apoptosis 
scores were more sensitive to growth inhibition by these particular mechanisms 
than cells with high levels of either of the senescence pathways.  
6.3 Discussion 
Upon treatment with a drug different cell types respond with varying degrees of 
growth inhibition. The activities of individual molecule types have been previously 
attributed to drug resistance (Bachmeier et al. 2009) however the impact of larger 
signaling pathways on drug resistance has not been fully assessed. As the data in 
the previous chapter highlighted potential differential expression patterns of latent 
damage associated (DA) and secretory senescence signaling in human tumours, it 
was decided to examine whether latent senescence signaling could be a factor 
affecting response to drug treatment, utilizing the experimental latent senescence 
scoring procedure developed in chapter 5 of this study. Furthermore, the results of 
these two senescence signaling pathways were then compared with that of 
apoptosis to try and identify whether these latent signaling pathways could 
potentially affect response to treatment differently. 
Initially the expression levels of  secretory senescence, DA senescence and 
apoptotic signaling pathways themselves and their relationships between cell types 
were examined. Hierarchical clustering of apoptosis signaling molecules showed 
some grouping of the cell lines by cell type (Figure 6.1A). This suggested that these 
expression patterns may be a result of cell type specific regulatory mechanisms. 
Conversely, hierarchical clustering of both secretory and damage associated 
senescence signaling molecules showed little clustering by cell type. These 
observations therefore suggested that the regulatory mechanisms behind latent 
senescence signaling were potentially common between cell types and not cell 
type specific. Through the application of the tentative pathway scoring system 
introduced in chapter 5, the overall levels of latent signaling of each pathway were 
also examined in each of the 60 cell lines. By examining scatter-plots and 
correlations between the scores the relationships between the latent signaling 
pathways were further examined (Figure 6.2 and Table 6.2). Differential expression 
patterns of secretory and DA senescence utilizing the experimental scoring system 
in melanomas suggested that these melanoma cell cultures may be more similar in 
nature to metastatic melanoma than primary melanoma. In addition, further 
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differential expression patterns not previously observed were also highlighted in 
this dataset, such as higher levels of damage associated senescence signaling than 
secretory senescence in leukemia cells. These patterns of differential expression in 
these signaling pathways may be reflective of differential selection pressures in 
these cells during tumorigenesis. For example, blood born leukemia cells with high 
levels of secretory senescence may be selected against due to increased immune 
activation. A significant correlation between both senescence scores and apoptosis 
score were observed. As both DA senescence and apoptosis signaling contains an 
element of DNA damage response it is conceivable that the latent expression of the 
two pathways could be linked events. Induction of secretory senescence in 
response to damage associated senescence signaling has also previously been 
observed (Rodier et al. 2009) and this may account for the correlation of apoptosis 
and secretory senescence pathways. Alternatively, these observations may also 
reflect the ability of cells to tolerate different types of latent signaling pathways 
at the same time. High levels of both senescence pathways and apoptosis signaling 
may be sufficient to trigger a full apoptotic or senescence response. The additive 
effects of these pathways may therefore act as a selection mechanism for cells 
undergoing tumorigenesis. In support of this concept, the cells in which the highest 
levels of DA senescence were observed, leukemia cells, also had the lowest levels 
of latent apoptosis signaling. As this scoring technique is the first of its kind to 
attempt to quantify the latent expression of a pathway in human cells the 
conclusions drawn from this initial study remain  hypothetical and will require 
further validation.  
Next regression analysis was used explore drugs with a cause-and-effect 
relationship between score and the drug concentration required to induce a 50 % 
growth inhibition in each cell line. 71, 250 and 61 compounds with significant 
relationships (regression p < 0.05) between growth inhibition and DA senescence, 
secretory senescence and apoptosis respectively were identified (Figure 6.4). As 
these compounds showed significance to only one pathway, treatment of tumours 
could potentially be directed by knowledge of only one pathway score without the 
requirement for measurement of the other two. However, the fact that these drugs 
were significant for a particular latent signaling pathway alone would not be 
sufficient to direct treatment. A measure of drug resistance or sensitivity is 
required to determine whether a particular drug should be used or avoided. To 
assess this the slope of the line of regression in each case was examined, whereby 
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a negative slope would indicate that with increasing latent signaling score, less 
drug was required to induce 50% growth inhibition i.e. cell lines became 
increasingly sensitive with increasing latent signaling score. Upon plotting the 
mean and 95% confidence intervals of the slope of the line for each set of unique 
significant regressions it was observed that cells with a high score for any of the 
pathways were generally resistant to their significant compounds (Figure 6.5). 
These results were validated in part by the unique identification of sensitivity to 
compounds known to induce apoptosis through the use of apoptosis score, such as 
bruceantin (CID295929, slope of line = -2.24, p = 0.0288) (Cuendet et al. 2004). 
This pilot study therefore suggested that the virtual drug screening technique may 
indeed be capable of highlighting drug sensitivity linked with the activities of 
specific pathways. Such knowledge may aid in the ability to target drugs to induce 
specific cellular states, such as high latent apoptosis or cellular senescence 
signaling. 
Investigation of the relationship between latent signaling pathways and drug 
resistance may be of  use in targeted drug therapy; however, it does not improve in 
the understanding of the molecular mechanisms behind drug resistance. To this 
end, the predicted activities of the significantly associated compounds were 
explored. Through the use of graph-theory connectivity indices a decision tree 
model of predicted activities was built. By examining the predicted activities 
associated with each latent signaling type it was hoped that insights into the 
potential molecular mechanisms behind the associations could be gained (Figure 
6.6). This analysis revealed enrichment for resistance to growth inhibition by 
proteases in cell lines with high latent DA senescence scores. Given the central role 
of caspases in initiation of apoptosis (Riedl & Shi, 2004), it was somewhat surprising 
that it was DA senescence signaling rather than apoptosis signaling that was most 
enriched in this category. However, this may be indicative of a potential situation 
whereby direct inhibition of the apoptotic mechanisms under a background of high 
DNA damage signaling is sufficient to alter the cellular response and trigger 
senescence. This may therefore suggest that tumours with a high DA senescence 
score that are resistant to treatment by pro-apoptotic therapies may be better 
treated through inhibition of proteases directly. As these conclusions are drawn 
from an experimental and novel technique further laboratory investigation will be 
require which is unfortunately beyond the scope of this first look bioinformatic 
study.  
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Further potential molecular mechanisms were also highlighted through the 
enrichment of PDE inhibitors in compounds with significant regressions with 
secretory senescence. PDEs enzymatically degrade cAMP and cGMP (Bender and 
Beavo 2006). The observation of sensitivity to growth inhibition through the 
inhibition of PDE inhibitors in cells with high secretory senescence was suggestive 
of the requirement for deregulation of signaling through these molecules, to 
prevent the induction of the senescence program. This was consistent with 
previous reports in melanomas. Melanomas that acquire RAS mutations require 
deregulated cAMP metabolism, potentially by increased phosphodiesterase activity, 
for transformation (Dumaz et al. 2006). Furthermore, cAMP is well reported to play 
a central role in the regulation of the expression of pro-inflammatory and immune 
responses (Peters-Golden 2009) Given the known pro-inflammatory nature of 
secretory senescence signaling it is possible to hypothesise that latent secretory 
senescence signaling and cAMP metabolism disruption in melanoma may be 
connected. The inhibition of PDEs may therefore alter the regulation of cAMP in 
these pro-inflammatory pathways leading to reestablishment of the correct cAMP 
metabolism balance, senescence induction and growth inhibition.  
Further contrasting effects of latent signaling pathways were highlighted by the 
observation that drugs significantly correlated with apoptosis were particularly 
enriched for predicted activities not enriched in either of the senescence pathways 
(Figure 6.6 blue bars). For example, sensitivity to growth inhibition via the 
inhibition of GPCR antagonists was almost highly enriched in latent apoptotic 
signaling compared to the other latent scores. G-protein coupled receptors (GPCRs) 
act as central nodes in the transduction of many different extracellular signals and 
are a highly explored target in drug discovery (Vassilatis et al. 2003). GPCR 
antagonists therefore block the signal transduction of these extracellular signals. 
Sensitivity to growth inhibition by inhibition of these molecules may suggest that 
these cells are utilizing GPCR antagonists to block extracellular signals that may 
lead to full induction of the apoptotic program. Furthermore, significant 
correlations between latent apoptosis signaling and latent secretory senescence 
signaling were observed. These extracellular signals may therefore potentially be in 
the form of pro-inflammatory signals produced by the cell itself.  
In conclusion, this initial examination of relationship between latent senescence 
and apoptosis signaling to growth inhibition by 1401 different compounds 
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highlighted the potential impact of these latent signaling patterns on response to 
drug treatment. This tentative data suggests that cells’ route to senescence bypass 
and the resulting latent expression of senescence signaling pathways may confer 
sensitivity to induction of growth arrest through particular drug targeting 
mechanisms. For example, protease inhibition in tumours with high DA senescence 
scores or dependence on cAMP mediated signals in cells with high secretory 
senescence scores. Comparison of these findings with the results of the same 
process using apoptosis signaling showed distinct drug class sensitivities in each 
class. This therefore suggests that the measurement of latent signaling pathways in 
patient samples may facilitate improved selection of appropriate compounds to 
which the tumour would be more sensitive. Furthermore, the impact of latent 
senescence signaling can be seen to extend to response to specific drug types; thus 
further highlighting its importance in human cancer.  
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7 Summary and Conclusions 
Before senescence induction can be fully utilised as a realistic anti-cancer 
therapy there is a requirement for a better understanding of the pathways 
surrounding senescence signaling. The main aims of this study were to ascertain 
an improved understanding as to the layers of regulation that surround 
senescence signaling and bypass and their impact on in human tumours. The 
results presented here improve the current level of understanding and highlight 
the importance of senescence signaling and regulation during tumorigenesis. 
This study has highlighted transcriptional differences in senescence bypass 
mechanisms, the potential of miRNAs as regulators of senescence and the impact 
of latent senescence signaling upon patient outcome and response to therapy. 
7.1 Transcriptional regulation of senescence bypass 
Through the use of gene expression microarrays 1305 genes were found to have 
differential expression patterns between cells utilizing either ALT or telomerase 
for bypass of replicative senescence. This study was the first to attempt to 
characterise the expression differences between the two mechanisms in an 
attempt to gain a better understanding of the regulation behind choosing and 
maintaining a particular telomere maintenance mechanism. The observation of 
similar expression patterns of the 1305 gene signature in ALT cells and human 
mesenchymal stem cells may explain the preponderance of mesenchymal ALT 
tumours in vivo and points to a potential mesenchymal origin for ALT. This was 
the first and, to date, only study to have documented a direct link between gene 
expression patterns in ALT cells and mesenchymal stem cells. To test the 
applicability of the 1305 gene signature in vivo, hierarchical clustering of 
liposarcoma biopsy gene expression data was utilized and by combining 
overlapping gene expression profiles found within the 1305 gene signature, a 
refined 297 sub-signature was generated. Functional investigation of this 
signature revealed a complex hTERT regulatory network that extended our 
current knowledge of the strict regulatory mechanisms surrounding telomerase 
expression in ALT cells. Furthermore, the observation of significant differences 
in expression of a large number of downstream targets of the transcription 
factor c-Myc within the 297 gene signature led to further investigation of the 
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role of c-Myc in senescence bypass by different TMMs. As c-Myc is a well-known 
transcriptional activator of hTERT, upon direct experimental investigation the 
findings of lower c-Myc activity and reduced c-Myc binding at the hTERT 
promoter in ALT cell lines was unsurprising. However, upon further investigation 
as to the mechanism behind the decreased expression of c-Myc in ALT cells this 
project highlighted that c-Myc regulation difference in ALT were not primarily 
caused by differences in expression of c-Myc itself nor either of its DNA binding 
partners MAX and MAD. Instead, the competitive binding of the DNA E-boxes by 
the relatively understudied gene TCEAL7 was highlighted as one of the potential 
mechanisms by which ALT cells regulate c-Myc activity. Furthermore, probing of 
the kinome through siRNA screening revealed 106 hTERT regulatory kinases in 
ALT cells, of which the top transcriptional regulator was c-Myc.  
The data presented in Chapter 3 therefore extends current knowledge of the 
molecular differences between senescence bypass mechanisms. In addition, 
further functional investigations of these regulatory networks highlighted a 
central role for c-Myc in the regulation of both telomerase expression and the 
larger regulatory network surrounding telomerase regulation. It is unlikely that 
perturbation of a single molecule within this complex regulatory network would 
be sufficient to induce senescence. However, detailed knowledge of such 
regulatory networks may improve the ability to develop adjuvant therapeutics to 
further reinforce therapeutic approaches targeted at cells utilizing telomerase. 
7.2 miRNAs as regulators of senescence signaling 
Chapter 3 highlighted the complex gene expression and kinase regulatory 
networks surrounding the decision between telomere maintenance mechanisms. 
The establishment of such large complex networks during the bypass of 
senescence would require multiple levels of regulation and miRNAs represent a 
relatively simple mechanism by which this could be achieved.  Given the 
knowledge that each miRNA has many targets, each with on average 1000 target 
genes, it would be possible to establish such networks through the actions of a 
relatively small number of miRNAs. The role of miRNAs in the regulation of 
senescence signaling is currently poorly understood. Therefore, before their 
potential for perturbation during the process senescence bypass could be 
established their overall potential in senescence signaling regulation was 
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assessed. To this end, a literature search revealed 12 miRNAs with experimental 
evidence of involvement in senescence regulation. The potential of these 
senescence associated miRNAs (SA-miRNAs) to regulate the multiple pathway 
changes required to create the senescent cell phenotype was then assessed 
through functional enrichment analysis on their theoretical target genes. The 
analysis showed significant enrichment for pathways involving cytoskeletal 
remodeling, cell-cycle and proliferation, thus demonstrating the potential of the 
SA-miRNAs to not only regulate the cell-cycle arrest but also the morphological 
changes in cell size and shape required for the formation of the senescent 
phenotype. Furthermore, the SA-miRNAs were shown to be able to regulate 
significant pathways for senescence regardless of the senescence stimulus 
through regulation of apoptosis signaling, pro-inflammatory and cell cycle 
processes. The observation of potential apoptosis signaling and pro-inflammatory 
signaling regulation potential highlights the potential of miRNAs to operate at 
the pathway level, regulating both the damage associated and secretory 
senescence pathways regardless of the type of senescence stimulation received. 
Having demonstrated the potential for miRNAs to regulate senescence signaling 
pathways, miRNA microarrays on mesenchymal tumours were then utilised to 
examine their potential in regulating the decision between telomere 
maintenance mechanisms during senescence bypass. 25, 14 and 9 miRNAs which 
were significantly differentially expressed between telomere maintenance 
mechanisms in liposarcomas, peritoneal mesotheliomas and MPNST respectively. 
Furthermore, examination of miRNA expression in relation to patient outcome 
also revealed groups of miRNAs with prognostic significance in each tumour 
type. Overlaps between the prognostic and TMM associated miRNAs further 
highlighted the potential prognostic significance and implications of TMM in 
these tumour types consistent with the current literature (Costa et al. 2006; 
Cairney et al. 2008).  
When combined, the data presented in Chapter 4 therefore demonstrate the 
importance of miRNAs as potential regulators of senescence induction as well as 
their potential implications during tumorigenesis. Furthermore, as miRNA 
regulation is a post-transcriptional process, senescence pathways may remain 
latently expressed after transformation, thus removing the requirement to 
transcriptionally regulate every gene involved in the senescence individually 
during senescence bypass.  
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7.3 Scoring of Latent senescence signaling 
The data showing the potential regulation of senescence by miRNAs in the 
previous chapter presented the possibility of latent expression of genes involved 
in senescence signaling pathways after senescence bypass. Such expression has 
been observed in animal models, however, has not been previously explored in 
human tumours. Furthermore, the impact of such latent expression upon clinical 
factors, such as disease progression and patient outcome, has not previously 
been established.  
However, before this could be ascertained there was a requirement to develop a 
method by which the latent expression levels of these pathways could be 
measured quantitatively. To this end, an experimental scoring approach was 
developed which reduced the latent expression levels of the senescence 
signaling to a single percentage. Furthermore, the method also allowed the 
dissection of the latent expression levels of individual senescence pathways in 
any gene expression dataset. After development, the method was first applied 
to a number of publicly available datasets whereby senescence induction would 
be expected to occur. The scoring system confirmed increased senescence 
scoring in response to both chemo- and radiotherapeutics in human tumours. 
Furthermore, dissection of the secretory and damage associated pathways 
highlighted induction of both senescence signaling pathways to varying degrees 
after both treatments. The experimental scoring system also highlighted 
dynamic expression patterns of the two signaling pathways during disease 
progression in melanoma. High levels of damage associated senescence signaling 
appears to be more associated with metastatic tumours whereas increased 
secretory senescence signaling was observed in primary lesions. This suggests 
that although unable to induce the senescence program these pathways are still 
actively regulated and may potentially have an impact on tumour progression. 
Finally, the scoring system was applied to human mesenchymal stem cells 
undergoing replicative senescence through repeated passage. As well as a 
general increase in overall senescence score with increasing passage, a transient 
spike in damage associated senescence was observed at passage 6, immediately 
followed by a spike in secretory senescence signaling at passage 7. Such timed 
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differential expression patterns are consistent with concept that secretory 
senescence is induced upon prolonged damage associated signaling (Rodier et al. 
2009) and therefore potentiallydemonstrate the ability of the scoring method to 
correctly characterize signaling dynamics during senescence induction. It must 
be noted however that as this is an initial pilot study and the first method of its 
kind to quantify the latent activities of an entire pathway further validation of 
the results are required. The method itself is inherently flexible and future 
studies may choose to alter the gene content and direction of expression 
required for the signatures or introduce further statistical tests of error or 
weighting. 
Having validated the scoring approach in multiple cell types the method was 
utilised to explore latent senescence signaling in the mesenchymal tumour 
dataset. Dynamic latent expression patterns of the secretory and damage 
associated senescence pathways were observed in the mesenchymal tumours 
consistent with their potentially different routes to tumour progression. 
Examination of correlations between these scores in individual tumours however 
highlighted that the two pathways are potentially distinct events in all three 
tumour types. Further examination of the secretory senescence pathway in 
these tumours was undertaken using hierarchical clustering. The resulting 
dendrograms highlighted subgroups of peritoneal mesotheliomas with distinct 
patterns of latent expression of 2 gene groups of the secretory senescence 
pathway. Furthermore, these groups showed significant correlation with 
survival. Upon investigation as to the functional differences in the responsible 
gene groups it was discovered that tumours expressing the pro-inflammatory, 
chemotactic and anti-proliferative aspects of the secretory senescence pathway 
showed improved survival, consistent with similar observations in the literature 
(Roxburgh et al. 2009). 
The results presented in this chapter firstly highlight the potential of the 
developed senescence scoring method to explore latent signaling in any gene 
expression dataset. To date, this is the first method presented to quantitatively 
estimate latent senescence signaling in human tumours and as such, after 
further validation may facilitate further investigations in other tumour and 
tissue types. Application of the method highlighted the potential prognostic 
implications of latent senescence signaling and therefore suggests that further 
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investigation is warranted. The data presented in this chapter suggests that 
although the senescence program has been bypassed during the process of 
tumorigenesis the latent expression of its signaling pathways may still have the 
potential to influence cellular responses.   
 
7.4 The implications of latent senescence signaling in 
cellular drug response 
A first look at the potential biological effects of latent senescence signaling in 
human tumours had been explored in the previous chapter. Different cell types 
respond to drug treatments in different ways. Whether latent senescence 
signaling levels play a role in these differential responses had not been 
previously explored. Through the combined exploration of publicly available 
gene expression data and GI50 data for 1401 drugs in the NCI60 cell lines, a 
virtual drug screen was performed exploring the relationship between these 
experimental latent senescence score and response to particular drugs. 
Furthermore, application of the same novel scoring methodology using an 
apoptosis signature allowed exploration of the relationships between the latent 
expression of the two pathways as well as their common and distinct drug 
associations.  
Initial exploration of the relationships between the cell types and latent 
expression of the senescence and apoptosis signaling pathways using hierarchical 
clustering highlighted potentially tissue type specific mechanisms of latent 
apoptosis regulation not observed in latent senescence signaling. Furthermore, 
exploration of signaling dynamics of these pathways within cell types confirmed 
similar signaling dynamics in melanoma cell lines as those observed in the 
metastatic melanoma biopsies in the previous chapter. The significant 
correlation of the apoptosis score with both the senescence signaling pathways 
at the individual cell line level was also observed. This may reflect the linkage 
of the two latent signaling pathways to apoptosis signaling. However, given that 
the correlation was relatively weak it is more likely that this in fact represents 
an ability to tolerate both signal types simultaneously rather than direct linkage. 
However, the lack of significant correlations between the senescence pathways 
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in this dataset supports the observations of the previous chapter that these are 
unlinked distinct signaling events.  
To examine the relationships between latent expression of senescence pathways 
and apoptosis, linear regression was used to find drugs with significant cause-
and-effect relationships with individual drugs. 71, 250 and 61 compounds with 
unique significant relationships (regression p < 0.05) between growth inhibition 
and DA senescence, secretory senescence and apoptosis respectively were 
identified. Furthermore, examination of the direction of the regressions showed 
that associated scores generally identified drugs to which cell lines were 
sensitive rather than resistant. The identification of these individual drugs 
uniquely with their respective latent signaling scores further highlights the 
potential differing biological effects of the two senescence pathways, even after 
senescence bypass. Analysis of the predicted activities of the significant 
compounds also highlighted differences between the impacts of each latent 
signaling pathway. Cells with a high damage associated senescence score show 
particular sensitivity to protease inhibitors whereas cells with high secretory 
senescence are particularly sensitive to PDE inhibitors. The ability to distinguish 
particular drugs to which tumours are sensitive from a single experiment would 
be invaluable to the clinical community. As with the previous chapter the results 
and conclusions built on this experiemental scoring technique would require 
further validation before they could be applied clinically. However, the data 
presented in chapter 6 suggests that even after bypass, senescence signaling 
may remain an important factor in cancer cell biology. 
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Appendix I– Gene-lists resulting from this work 
Table 3 - 1305 genes Differentially Expressed between ALT and Telomerase Cell lines. 
Genename Genbank 
Fold Change in 
ALT 
TERT NM_198253 -46.32 
C10orf35 NM_145306 -29.45 
ST6GAL1 NM_173216 -28.83 
CHD7 NM_017780 -22.15 
EEF1A2 NM_001958 -21.87 
DUSP2 NM_004418 -21.86 
K03200 K03200 -21.74 
SLC39A4 NM_130849 -18.24 
FAM83H NM_198488 -17.30 
CHD7 NM_017780 -16.78 
PRKCZ NM_002744 -16.58 
B3GNT5 NM_032047 -14.16 
ARHGAP4 NM_001666 -13.92 
RAB11FIP4 NM_032932 -13.66 
LOC112703 NM_138411 -11.78 
ZDHHC23 NM_173570 -11.15 
BM802662 BM802662 -10.70 
ENST00000361080 AW136529 -10.50 
DIAPH2 NM_007309 -10.43 
AK123704 AK123704 -10.17 
PNPLA4 NM_004650 -10.00 
C9orf58 NM_001002260 -9.72 
MDFI NM_005586 -9.23 
SLC6A8 NM_005629 -8.78 
ADAM11 NM_002390 -8.75 
CEBPA NM_004364 -8.74 
LAMA5 NM_005560 -8.34 
ENST00000330947 BC035081 -8.18 
ZFP64 NM_199427 -8.17 
LOC649542 XM_938617 -8.07 
SLC6A10P NR_003083 -8.03 
HOMER2 NM_199330 -7.90 
FAM59A NM_022751 -7.55 
TP53TG3 NM_016212 -7.44 
CEBPA NM_004364 -6.93 
BOLA1 NM_016074 -6.92 
LOC254057 AK024653 -6.89 
BG741106 BG741106 -6.81 
RHOF NM_019034 -6.70 
RHOF NM_019034 -6.63 
LLGL2 NM_004524 -6.60 
AK025613 AK025613 -6.49 
Kyle Lafferty-Whyte, 2010  Appendix I, 189 
Genename Genbank 
Fold Change in 
ALT 
RAB11FIP1 NM_001002233 -6.40 
LRRC8B NM_015350 -6.34 
MAPK11 NM_002751 -6.28 
STAU2 AK002152 -6.20 
FOXO1A NM_002015 -6.00 
KIAA0485 AB007954 -5.93 
HCP1 AL832613 -5.86 
BTG2 NM_006763 -5.83 
ENST00000220507 CR618466 -5.75 
GP1BB NM_000407 -5.60 
ARID3B NM_006465 -5.50 
LPHN1 NM_001008701 -5.41 
GPRC5C NM_022036 -5.14 
AFG3L1 NM_001132 -5.05 
TCF15 NM_004609 -5.05 
THC2337923 THC2337923 -4.94 
BCAN BC005081 -4.93 
LRP4 NM_002334 -4.93 
SMAD9 NM_005905 -4.93 
LOC92312 XM_044166 -4.89 
AFG3L1 NM_001132 -4.83 
ORF1-FL49 NM_032412 -4.79 
ASB13 NM_024701 -4.76 
ELL3 NM_025165 -4.73 
A_32_P26721 A_32_P26721 -4.72 
AF086442 AF086442 -4.70 
THC2290002 THC2290002 -4.66 
ACOT11 NM_147161 -4.63 
LONRF1 NM_152271 -4.57 
RHOF NM_019034 -4.49 
PRKX NM_005044 -4.47 
ARHGAP27 NM_199282 -4.42 
P15RS NM_018170 -4.41 
AP1S3 BC021898 -4.40 
ELL3 NM_025165 -4.38 
CR607745 CR607745 -4.34 
DRG2 NM_001388 -4.32 
CDC42SE1 NM_020239 -4.29 
CR603803 CR603803 -4.28 
RNF44 NM_014901 -4.28 
CBS NM_000071 -4.22 
AP1S3 NM_001039569 -4.14 
FLJ35740 NM_147195 -4.14 
PIGZ NM_025163 -4.13 
SULT4A1 NM_014351 -4.11 
EPB41L4B NM_018424 -4.11 
C9orf16 NM_024112 -4.05 
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Genename Genbank 
Fold Change in 
ALT 
BAIAP2 NM_017451 -4.02 
C10orf77 NM_024789 -4.01 
LOC155060 NM_001004302 -4.01 
ACCN2 NM_020039 -4.00 
THC2350463 THC2350463 -3.98 
HES4 NM_021170 -3.97 
TMCC1 NM_001017395 -3.97 
ABHD14B NM_032750 -3.97 
KLHL24 NM_017644 -3.91 
RICS NM_014715 -3.90 
MSTP9 NR_002729 -3.88 
TMEM80 NM_174940 -3.85 
C20orf45 NM_016045 -3.85 
KIAA1984 AB075864 -3.85 
NSUN5 NM_148956 -3.84 
SLC6A8 NM_005629 -3.80 
AK094629 AK094629 -3.79 
TMCC1 NM_001017395 -3.78 
LONRF1 NM_152271 -3.78 
RICS NM_014715 -3.72 
TRIM72 NM_001008274 -3.68 
CBS NM_000071 -3.67 
LASS6 NM_203463 -3.65 
AA554330 AA554330 -3.64 
THC2455149 THC2455149 -3.63 
BQ072652 BQ072652 -3.60 
CENTA1 NM_006869 -3.59 
REEP6 NM_138393 -3.56 
ASB13 NM_024701 -3.54 
PIK3C2B NM_002646 -3.53 
KGFLP1 NM_174950 -3.52 
ANKRD13B NM_152345 -3.51 
GOLGA8E NM_001012423 -3.50 
ME2 NM_002396 -3.49 
RBM38 NM_017495 -3.49 
ENST00000372821 ENST00000372821 -3.49 
C10orf57 NM_025125 -3.48 
TADA3L NM_006354 -3.46 
PLS1 NM_002670 -3.46 
BC039151 BC039151 -3.45 
BC030211 BC030211 -3.41 
BC038512 BC038512 -3.40 
RP11-138L21.1 AK024257 -3.39 
TMEM80 NM_174940 -3.38 
LOC137886 AK126300 -3.37 
THC2411839 THC2411839 -3.35 
FLJ22795 NM_025084 -3.33 
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Genename Genbank 
Fold Change in 
ALT 
SLC16A9 NM_194298 -3.32 
DUSP22 NM_020185 -3.32 
THC2408033 THC2408033 -3.26 
AK123627 AK123627 -3.25 
C3orf17 NM_015412 -3.24 
ATP6V1E2 NM_080653 -3.24 
DPM3 NM_018973 -3.21 
STRBP NM_018387 -3.21 
DPM3 NM_018973 -3.21 
CRIPAK NM_175918 -3.20 
NUDT14 NM_177533 -3.19 
FLJ22795 AF316855 -3.18 
SLC44A1 NM_022109 -3.18 
GLI4 NM_138465 -3.18 
ZNF692 NM_017865 -3.18 
AK023328 AK023328 -3.15 
MLLT10 NM_004641 -3.13 
VWA1 NM_022834 -3.13 
POU5F1 NM_002701 -3.13 
PAPOLG AB209304 -3.12 
LASS6 NM_203463 -3.10 
LYPLA2 NM_007260 -3.09 
BC015977 BC015977 -3.09 
DECR2 NM_020664 -3.09 
RHBDD1 NM_032276 -3.09 
RABGAP1L AB007940 -3.08 
SR140 AB002330 -3.08 
AATK AK131529 -3.07 
COMTD1 NM_144589 -3.04 
AK026811 AK026811 -3.04 
P15RS NM_018170 -3.03 
SEPN1 NM_020451 -3.03 
RRM2B NM_015713 -3.03 
A_32_P163472 A_32_P163472 -3.03 
SLC22A18AS NM_007105 -3.02 
HNRPA3 NM_194247 -3.02 
C8orf73 AF289596 -3.00 
TTLL3 NM_015644 -2.99 
SNCB NM_001001502 -2.98 
ANKRD57 NM_023016 -2.97 
NSUN5B NM_145645 -2.96 
C9orf9 NM_018956 -2.96 
AP2A2 NM_012305 -2.94 
FLJ22795 AF316855 -2.93 
NHLRC2 AK126751 -2.91 
SSBP4 NM_032627 -2.90 
C16orf14 NM_138418 -2.90 
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ABCA2 NM_001606 -2.89 
TMTC4 NM_032813 -2.88 
C19orf25 NM_152482 -2.88 
TPM1 NM_001018008 -2.88 
OR5L2 NM_001004739 -2.88 
AK023412 AK023412 -2.86 
TNFRSF10B NM_003842 -2.85 
PER2 NM_022817 -2.83 
TMUB1 NM_031434 -2.82 
MARCKSL1 NM_023009 -2.81 
NFE2L2 AF323119 -2.79 
BC065260 BC065260 -2.78 
ENST00000357529 AB033064 -2.78 
C3orf64 NM_173654 -2.78 
NARS NM_004539 -2.78 
UBE2Q1 NM_017582 -2.77 
MMP15 NM_002428 -2.76 
NUDT12 NM_031438 -2.76 
FDXR NM_024417 -2.75 
THC2281304 THC2281304 -2.74 
TRABD NM_025204 -2.74 
RASA2 NM_006506 -2.72 
ENST00000377492 ENST00000377492 -2.71 
SEPW1 NM_003009 -2.71 
AK024035 AK024035 -2.70 
BM984383 BM984383 -2.70 
ENST00000368426 AK127884 -2.70 
LOC132241 AK096589 -2.69 
C18orf17 NM_153211 -2.69 
THC2303284 AA988138 -2.69 
USPL1 NM_005800 -2.69 
THC2371272 THC2371272 -2.69 
BQ017638 BQ017638 -2.68 
BIVM NM_017693 -2.67 
BC064492 BC064492 -2.66 
CR620599 CR620599 -2.66 
FUK NM_145059 -2.66 
MGC4172 NM_024308 -2.64 
ABCA1 NM_005502 -2.64 
BCORL1 NM_021946 -2.63 
NUDT14 NM_177533 -2.63 
PRKY NM_002760 -2.63 
BCL7A NM_020993 -2.62 
A_23_P20793 A_23_P20793 -2.62 
AK057710 AK057710 -2.59 
UGT2B17 NM_001077 -2.59 
MLSTD2 NM_032228 -2.59 
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LOC389634 BC037255 -2.59 
A_24_P410256 A_24_P410256 -2.59 
C1orf63 NM_020317 -2.59 
THC2428713 THC2428713 -2.58 
CXorf15 NM_018360 -2.57 
A_32_P98854 A_32_P98854 -2.57 
LOC90835 NM_001014979 -2.57 
FAM72A NM_207418 -2.56 
A_32_P225768 A_32_P225768 -2.56 
ENST00000251847 AB046810 -2.55 
FAM27E2 NM_001013404 -2.55 
TLOC1 NM_003262 -2.55 
ASAH1 NM_004315 -2.55 
LOC653801 XM_934188 -2.55 
THC2271717 THC2271717 -2.54 
ZNF508 NM_014913 -2.52 
SECISBP2 NM_024077 -2.52 
CR625561 CR625561 -2.52 
THC2280003 THC2280003 -2.51 
NSUN5C NM_148936 -2.50 
KIAA1893 NM_052899 -2.50 
C1orf63 AK027318 -2.50 
ZNF658 NM_033160 -2.50 
GALNT1 NM_020474 -2.50 
C6orf115 BC014953 -2.50 
CDC42SE1 NM_020239 -2.49 
FAM120C BC016138 -2.49 
PICK1 NM_012407 -2.48 
BC000228 BC000228 -2.48 
ENST00000377492 ENST00000377492 -2.48 
C9orf9 NM_018956 -2.48 
DCPS NM_014026 -2.48 
C21orf119 NM_032910 -2.47 
SERGEF AJ243950 -2.47 
ATP5D NM_001001975 -2.47 
TADA3L NM_006354 -2.46 
JAM3 NM_032801 -2.46 
THC2437177 THC2437177 -2.46 
THC2438117 THC2438117 -2.45 
STAU2 NM_014393 -2.45 
HDHD2 NM_032124 -2.45 
BX093417 BX093417 -2.45 
MRPS21 NM_031901 -2.45 
C13orf8 NM_032436 -2.45 
BM461836 BM461836 -2.45 
PTP4A3 NM_032611 -2.44 
A_24_P455100 A_24_P455100 -2.43 
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AK054852 AK054852 -2.42 
BC000845 BC000845 -2.41 
C21orf59 NM_021254 -2.41 
GSR NM_000637 -2.40 
PSME3 NM_176863 -2.40 
LOC90835 NM_001014979 -2.40 
DSCR3 NM_006052 -2.40 
ZNF444 NM_018337 -2.40 
LOC653639 XM_934787 -2.39 
LOC285813 AK094269 -2.39 
TP53INP1 NM_033285 -2.39 
C17orf58 NM_181655 -2.39 
Magmas NM_016069 -2.39 
DA234975 DA234975 -2.38 
ADAM11 NM_002390 -2.38 
AGPAT4 NM_020133 -2.37 
ENST00000377492 BC032035 -2.37 
ZMYM2 NM_003453 -2.36 
MRPL23 NM_021134 -2.36 
INTS10 NM_018142 -2.36 
ATPAF1 NM_022745 -2.35 
MRPS21 NM_031901 -2.35 
CR610205 CR610205 -2.34 
A_24_P204334 A_24_P204334 -2.34 
ENST00000295628 BC013757 -2.33 
YOD1 NM_018566 -2.33 
INTS3 NM_023015 -2.33 
ZDHHC13 NM_019028 -2.32 
LYPLA1 NM_006330 -2.32 
AK131288 AK131288 -2.31 
AK057071 AK057071 -2.31 
LOC440295 NM_198181 -2.31 
RABL2A NM_013412 -2.30 
RNASET2 NM_003730 -2.30 
ZCCHC14 NM_015144 -2.30 
THC2373624 THC2373624 -2.30 
ZNF195 NM_007152 -2.29 
THC2435127 THC2435127 -2.29 
AK022936 AK022936 -2.28 
ENST00000358583 AK090778 -2.28 
A_24_P651129 A_24_P651129 -2.28 
CR600908 CR600908 -2.28 
EHMT1 NM_024757 -2.27 
PIK3C2A NM_002645 -2.27 
TMEM67 NM_153704 -2.27 
SERGEF NM_012139 -2.26 
PRKCBP1 AL137703 -2.26 
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ENST00000361227 AY423734 -2.25 
MBD5 BC014534 -2.25 
PRKCBP1 NM_012408 -2.25 
THC2363557 THC2363557 -2.24 
GUK1 NM_000858 -2.24 
CMTM7 NM_138410 -2.24 
C1orf121 BC020640 -2.24 
SNAPC4 NM_003086 -2.24 
THC2263651 THC2263651 -2.24 
ZNF658 NM_033160 -2.24 
SELI NM_033505 -2.22 
WDR42A NM_015726 -2.22 
QSER1 NM_024774 -2.22 
SESN2 NM_031459 -2.22 
WDR4 NM_033661 -2.22 
LRDD NM_018494 -2.22 
BE388027 BE388027 -2.22 
PDIA5 NM_006810 -2.22 
SLC4A2 NM_003040 -2.21 
IVNS1ABP NM_016389 -2.21 
ENST00000366847 ENST00000366847 -2.21 
TM6SF1 AK055438 -2.21 
DNMT3A NM_175630 -2.20 
PCGF1 NM_032673 -2.20 
BG259069 BG259069 -2.20 
HEATR2 NM_017802 -2.20 
THC2373625 THC2373625 -2.20 
HNRPA3 NM_194247 -2.19 
TAF5L NM_001025247 -2.19 
THC2312785 THC2312785 -2.19 
SBF2 NM_030962 -2.19 
C6orf70 NM_018341 -2.19 
ENST00000361453 AK026903 -2.19 
LENG8 NM_052925 -2.18 
SCYL3 NM_020423 -2.18 
BTBD3 NM_014962 -2.18 
AF085351 AF085351 -2.18 
FLYWCH1 NM_020912 -2.18 
PVRL1 NM_203286 -2.17 
DAB2IP NM_032552 -2.17 
RHPN1 BC025767 -2.17 
CR590163 CR590163 -2.17 
SETDB1 NM_012432 -2.17 
CLK2 NM_001291 -2.16 
LOC643837 CR601056 -2.16 
tcag7.1017 NM_001004351 -2.16 
UBE2D1 NM_003338 -2.16 
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A_24_P169903 A_24_P169903 -2.15 
A_24_P384239 A_24_P384239 -2.15 
ENST00000382957 AK124953 -2.15 
ENST00000380985 ENST00000380985 -2.14 
ULK3 AL117482 -2.14 
ZNF33B NM_006955 -2.14 
PRKAR1B NM_002735 -2.14 
AF038199 AF038199 -2.14 
A_24_P101601 A_24_P101601 -2.14 
G6PC3 NM_138387 -2.13 
GPIAP1 NM_005898 -2.13 
KIAA1545 AB046765 -2.13 
CREM NM_001881 -2.13 
IGF2R NM_000876 -2.13 
BE612504 BE612504 -2.13 
ENST00000369239 AL080186 -2.13 
C17orf85 BC011733 -2.13 
CSK NM_004383 -2.13 
THC2450500 THC2450500 -2.12 
CR601496 CR601496 -2.12 
HSD17B1 BC033110 -2.11 
RHBDD1 BC062636 -2.11 
POU2F1 NM_002697 -2.11 
AV645774 AV645774 -2.11 
WDR8 NM_017818 -2.11 
DDB2 NM_000107 -2.11 
FAM3C NM_014888 -2.10 
APOA1BP NM_144772 -2.10 
USP21 NM_012475 -2.10 
CLK2 NM_003993 -2.10 
AGTPBP1 NM_015239 -2.10 
A_32_P73580 A_32_P73580 -2.10 
CREG1 NM_003851 -2.10 
PLEKHA8 NM_032639 -2.09 
KIAA1008 NM_014953 -2.09 
RGS14 NM_006480 -2.09 
CRYZL1 AK057604 -2.09 
ZDHHC13 NM_019028 -2.09 
SLC37A3 NM_032295 -2.09 
TXNL4A NM_006701 -2.08 
CAMSAP1 AL834528 -2.08 
ENST00000339986 AF242519 -2.08 
LYPLA1 NM_006330 -2.08 
AK097322 AK097322 -2.08 
COX17 NM_005694 -2.07 
B4GALT3 NM_003779 -2.07 
ATP5D NM_001001975 -2.07 
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TMCO3 NM_017905 -2.07 
BX393727 BX393727 -2.06 
TTC13 NM_024525 -2.06 
ZBTB39 NM_014830 -2.06 
PYCR2 NM_013328 -2.06 
EHMT1 NM_024757 -2.06 
MAN1B1 NM_016219 -2.06 
ENST00000299756 XM_939387 -2.05 
APOM NM_019101 -2.05 
GMCL1 NM_178439 -2.05 
BC092421 BC092421 -2.05 
ALDH5A1 NM_170740 -2.05 
ZFP64 NM_018197 -2.04 
TFB2M NM_022366 -2.04 
ZNF124 NM_003431 -2.04 
KLHL11 NM_018143 -2.04 
IARS NM_013417 -2.03 
POLG2 NM_007215 -2.03 
A_32_P32923 A_32_P32923 -2.03 
SETDB1 NM_012432 -2.03 
POGK NM_017542 -2.02 
MBOAT1 AK131269 -2.02 
KRTAP4-7 BX648343 -2.02 
BC002811 BC002811 -2.02 
BX107836 BX107836 -2.01 
C9orf86 NM_024718 -2.01 
ENST00000367590 AK023131 -2.01 
BC065520 BC065520 -2.01 
THC2338854 THC2338854 -2.01 
DUSP22 AK000383 -2.01 
TMEM68 NM_152417 -2.01 
ISG20L2 NM_030980 -2.01 
A_24_P681563 A_24_P681563 -2.01 
ELMO3 NM_024712 -2.01 
A_24_P552987 A_24_P552987 -2.00 
SFRS7 NM_001031684 -2.00 
AF143879 AF143879 -2.00 
USPL1 NM_005800 -2.00 
SATB1 NM_002971 -2.00 
DMTF1 NM_021145 -2.00 
ZNF337 NM_015655 -2.00 
BX648950 BX648950 -2.00 
TFB1M NM_016020 -1.99 
MAPBPIP NM_014017 -1.99 
RFX5 NM_000449 -1.98 
THC2374442 THC2374442 -1.98 
LOC168850 NM_176814 -1.98 
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WHSC1 NM_133334 -1.98 
PLEKHG2 NM_022835 -1.98 
ENST00000378954 CR617774 -1.98 
YY1AP1 NM_139118 -1.98 
CR608275 CR608275 -1.98 
THC2320516 THC2320516 -1.98 
BF576096 BF576096 -1.97 
PLEKHJ1 NM_018049 -1.97 
THC2309459 THC2309459 -1.97 
THC2437122 THC2437122 -1.97 
NENF NM_013349 -1.97 
PERLD1 NM_033419 -1.97 
SIRT5 NM_012241 -1.97 
CNDP2 NM_018235 -1.97 
C16orf35 NM_001039476 -1.97 
LRSAM1 NM_138361 -1.97 
A_24_P920664 A_24_P920664 -1.96 
TXNDC4 NM_015051 -1.96 
ATP6V1F NM_004231 -1.96 
PCGF3 NM_006315 -1.96 
BC019667 BC019667 -1.96 
FAS NM_000043 -1.96 
ENST00000361789 M28016 -1.96 
RP11-125A7.3 NM_015058 -1.96 
ITIH5 NM_030569 -1.96 
ENST00000361227 AB017116 -1.96 
PYGO2 NM_138300 -1.96 
LOC653056 XM_930744 -1.95 
THC2300907 THC2300907 -1.95 
PEX7 NM_000288 -1.95 
CUGBP1 AB210019 -1.94 
CR611122 CR611122 -1.94 
HSD17B1 BC033110 -1.94 
RALGDS NM_006266 -1.94 
DBR1 NM_016216 -1.94 
CR608907 CR608907 -1.94 
GTF3C3 NM_012086 -1.94 
REPIN1 NM_014374 -1.93 
ACAD11 NM_032169 -1.93 
KIAA0907 NM_014949 -1.93 
TCF12 NM_207038 -1.93 
MDS032 AK074683 -1.93 
THC2336404 THC2336404 -1.93 
TMTC4 NM_032813 -1.92 
ECT2 NM_018098 -1.92 
GCN5L2 NM_021078 -1.92 
C1orf26 NM_017673 -1.92 
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PPCDC NM_021823 -1.92 
AA714039 AA714039 -1.91 
HAX1 NM_006118 -1.91 
TOMM20 NM_014765 -1.91 
C9orf37 NM_032937 -1.91 
A_23_P2032 A_23_P2032 -1.91 
ZNF499 NM_032792 -1.91 
AARS NM_001605 -1.90 
CTAGE3 AF338231 -1.89 
ANKS6 NM_173551 -1.89 
ENST00000270201 AF231919 -1.89 
GMCL1 NM_178439 -1.89 
C14orf124 NM_020195 -1.89 
AI090937 AI090937 -1.89 
NT5C NM_014595 -1.89 
MAPBPIP NM_014017 -1.89 
C7orf28A NM_015622 -1.88 
KIAA0368 BC021127 -1.88 
UEVLD NM_018314 -1.88 
THC2309459 THC2309459 -1.88 
PIK3R4 NM_014602 -1.88 
AF144054 AF144054 -1.88 
TUBGCP3 NM_006322 -1.88 
NFE2L2 NM_006164 -1.87 
THUMPD3 NM_015453 -1.87 
TBC1D16 AK091923 -1.87 
CREB3L4 NM_130898 -1.87 
GYLTL1B NM_152312 -1.87 
ZBTB41 NM_194314 -1.87 
ARRDC2 NM_015683 -1.87 
NFX1 NM_002504 -1.87 
ZCSL3 NM_181706 -1.87 
CCBL1 NM_004059 -1.87 
ARL6IP2 NM_022374 -1.86 
MRPS26 NM_030811 -1.86 
BX537520 BX537520 -1.86 
RYK NM_001005861 -1.86 
A_24_P912871 A_24_P912871 -1.86 
IRF2BP1 NM_015649 -1.86 
HGS AK097197 -1.85 
SNRPA NM_004596 -1.85 
ENST00000301042 AL713659 -1.85 
A_24_P290134 A_24_P290134 -1.85 
A_32_P85880 A_32_P85880 -1.84 
PFAAP5 NM_014887 -1.84 
NIT1 NM_005600 -1.84 
PCGF3 NM_006315 -1.84 
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PIGV NM_017837 -1.84 
TOR2A NM_130459 -1.84 
THRAP6 NM_080651 -1.83 
THC2409451 THC2409451 -1.83 
ENST00000367620 ENST00000367620 -1.83 
GNA13 NM_006572 -1.83 
RAP2B NM_002886 -1.82 
C15orf39 BC011905 -1.82 
RAI16 NM_022749 -1.82 
ZNF385 NM_015481 -1.82 
SENP8 NM_145204 -1.82 
NSUN5C NM_032158 -1.82 
MAN1B1 NM_016219 -1.82 
GPR125 NM_145290 -1.82 
CLK2 NM_001291 -1.82 
CYFIP1 NM_014608 -1.81 
ATP2A2 NM_001681 -1.81 
A_24_P834646 A_24_P834646 -1.81 
SPTY2D1 NM_194285 -1.81 
ATP9B NM_198531 -1.81 
CCDC24 NM_152499 -1.81 
THC2371517 THC2371517 -1.81 
STX6 NM_005819 -1.81 
GNPTAB NM_024312 -1.80 
WDR68 NM_005828 -1.80 
PDDC1 NM_182612 -1.80 
CD518214 CD518214 -1.79 
NCKAP1 NM_205842 -1.78 
KIAA1468 NM_020854 -1.78 
ENST00000361204 CR614040 -1.78 
ZNF687 NM_020832 -1.78 
STARD3 NM_006804 -1.77 
ENST00000252509 ENST00000252509 -1.77 
A_24_P341731 A_24_P341731 -1.77 
TTC17 BC041893 -1.76 
A_24_P213284 A_24_P213284 -1.76 
A_24_P608790 A_24_P608790 -1.76 
DDX46 NM_014829 -1.76 
THC2304728 THC2304728 -1.76 
DYNC2H1 AF288405 -1.76 
CACNB1 NM_000723 -1.76 
ACSL3 NM_004457 -1.76 
BC033528 BC033528 -1.75 
DKFZp667M2411 AL713754 -1.75 
SARS2 NM_017827 -1.75 
AGPAT4 NM_001012733 -1.75 
CCNL1 NM_020307 -1.75 
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BX116163 BX116163 -1.75 
THC2365025 AA385540 -1.75 
ENST00000222396 AB017004 -1.74 
ZNF524 NM_153219 -1.74 
PLEKHJ1 NM_018049 -1.74 
RBAK NM_021163 -1.74 
TFDP2 NM_006286 -1.74 
C11orf17 NM_020642 -1.74 
COQ7 NM_016138 -1.74 
ENST00000319822 BC111692 -1.73 
NDUFA1 NM_004541 -1.73 
METT5D1 NM_152636 -1.73 
FRAT2 NM_012083 -1.73 
LOC653319 NM_001040715 -1.73 
GIPC1 NM_005716 -1.73 
TOP1MT NM_052963 -1.73 
C9orf142 NM_183241 -1.72 
SNX4 NM_003794 -1.72 
ENST00000366862 AB007952 -1.72 
BX648855 BX648855 -1.71 
MAG NM_080600 -1.71 
AK058000 AK058000 -1.71 
NOM1 NM_138400 -1.71 
THC2437430 THC2437430 -1.71 
BTBD12 NM_032444 -1.71 
PMS2L1 BC044214 -1.70 
A_24_P212764 A_24_P212764 -1.70 
RABL2A BC111008 -1.70 
WDR85 NM_138778 -1.70 
THC2355570 THC2355570 -1.70 
AK026497 AK026497 -1.69 
FLJ12700 NM_024910 -1.69 
AF289615 AF289615 -1.69 
FAM108A1 NM_031213 -1.68 
AA807805 AA807805 -1.68 
CRTC2 NM_181715 -1.68 
ENST00000373816 CA438977 -1.68 
MCL1 NM_021960 -1.67 
BM054818 BM054818 -1.67 
CBLL1 NM_024814 -1.67 
RAB14 NM_016322 -1.67 
SETD4 NM_001007260 -1.67 
LPGAT1 NM_014873 -1.67 
MRPS2 NM_016034 -1.67 
AK129652 AK129652 -1.66 
TADA1L NM_053053 -1.66 
CUTL1 NM_181552 -1.66 
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PRSS15 NM_004793 -1.66 
ZBED5 NM_021211 -1.66 
ARMC4 NM_018076 -1.65 
PRKD3 NM_005813 -1.65 
LOC653256 XM_926634 -1.65 
GNB1 NM_002074 -1.65 
LOC389607 NM_001013651 -1.64 
SUZ12 NM_015355 -1.64 
IFT122 NM_018262 -1.64 
THC2407545 THC2407545 -1.64 
ZNF7 NM_003416 -1.64 
SYMPK NM_004819 -1.64 
HMG20B NM_006339 -1.64 
PMS2L5 NM_174930 -1.62 
USP48 NM_032236 -1.62 
BC031316 BC031316 -1.62 
THC2274016 THC2274016 -1.61 
C7orf28B NM_198097 -1.61 
SMEK2 NM_020463 -1.61 
AGGF1 NM_018046 -1.60 
ATXN2L NM_145714 -1.60 
THC2312955 THC2312955 -1.59 
RFWD2 NM_022457 -1.59 
ARRDC2 NM_015683 -1.59 
ADH5 NM_000671 -1.59 
CRTC2 NM_181715 -1.59 
ENST00000275546 ENST00000275546 -1.59 
THC2406595 THC2406595 -1.59 
FAM108A1 NM_031213 -1.58 
HDAC5 NM_001015053 -1.58 
THC2388093 THC2388093 -1.58 
76P NM_014444 -1.57 
RP4-691N24.1 NM_025176 -1.57 
KIAA1370 NM_019600 -1.57 
MAPK6 NM_002748 -1.57 
CRY2 NM_021117 -1.57 
HDAC1 NM_004964 -1.56 
YOD1 NM_018566 -1.56 
ENST00000321795 AK096609 -1.56 
GCS1 NM_006302 -1.56 
BANP NM_017869 -1.56 
A_24_P67268 A_24_P67268 -1.54 
THC2366654 THC2366654 -1.54 
CDK5RAP2 NM_018249 -1.53 
GTF3C2 NM_001521 -1.53 
KIAA1333 NM_017769 -1.53 
ITPA NM_033453 -1.53 
Kyle Lafferty-Whyte, 2010  Appendix I, 203 
Genename Genbank 
Fold Change in 
ALT 
DHX8 NM_004941 -1.53 
DBF4B NM_145663 -1.52 
ENST00000244249 XM_497963 -1.52 
ANKHD1 NM_017747 -1.52 
LOC285749 AK026691 -1.52 
A_24_P761386 A_24_P761386 -1.51 
THC2267302 THC2267302 -1.51 
A_24_P913961 A_24_P913961 -1.51 
CN431194 CN431194 -1.50 
DKFZP434A0131 NM_018991 -1.50 
ZFAND5 NM_006007 -1.49 
ING1 NM_198219 -1.48 
APRIN NM_015032 -1.48 
IGF2BP3 NM_006547 -1.48 
CDK10 NM_052987 -1.48 
TASP1 NM_017714 -1.46 
C17orf37 NM_032339 -1.46 
SLC25A36 AL049246 -1.46 
A_24_P50666 A_24_P50666 -1.45 
MYOHD1 NM_025109 -1.45 
KIAA1542 NM_020901 -1.44 
SMG5 NM_015327 -1.44 
ATXN7L3 BC037418 -1.43 
CDC42SE2 NM_020240 -1.42 
VBP1 NM_003372 -1.42 
ENST00000374865 BC015133 -1.40 
GRB2 NM_002086 -1.40 
RFWD2 NM_022457 -1.40 
C7orf38 NM_145111 -1.40 
COG2 AL832190 -1.39 
NEK8 NM_178170 -1.37 
A_32_P80587 A_32_P80587 -1.37 
CDC2L1 NM_033489 -1.36 
UBADC1 NM_016172 -1.36 
SNAPC4 NM_003086 -1.31 
ENST00000295907 CR593252 -1.26 
C21orf96 AK024509 -1.25 
TMEM41B NM_015012 -1.23 
A_32_P112531 A_32_P112531 -1.18 
A_24_P477102 A_24_P477102 -1.18 
THC2280383 THC2280383 -1.14 
ZNF638 NM_014497 -1.13 
APOBEC3C NM_014508 -1.01 
MUTYH NM_012222 1.03 
AF086548 AF086548 1.03 
ENST00000217537 BC108287 1.05 
FAM3C NM_014888 1.05 
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ENST00000375816 BM458572 1.06 
CDC2L1 BC062579 1.07 
ZNF414 AK074191 1.16 
ENST00000375664 ENST00000375664 1.27 
COX5A NM_004255 1.30 
THC2280867 THC2280867 1.32 
EEF1D NM_032378 1.37 
EIF2C3 NM_024852 1.38 
AF086335 AF086335 1.41 
HERC5 NM_016323 1.42 
ENST00000266712 CR749309 1.44 
FRYL BC021803 1.46 
DA292134 DA292134 1.47 
GSG1 NM_031289 1.47 
MMP19 NM_002429 1.48 
CCIN NM_005893 1.49 
LOC51035 NM_015853 1.49 
SPCS2 NM_014752 1.50 
C11orf2 NM_013265 1.50 
ENST00000298129 AK056666 1.51 
BTBD11 NM_152322 1.52 
TM9SF4 NM_014742 1.54 
TSR2 NM_058163 1.55 
A_32_P48066 A_32_P48066 1.56 
LOC51035 NM_015853 1.57 
PTP4A2 NM_080392 1.57 
POLD3 NM_006591 1.57 
USP33 NM_201626 1.57 
KLHDC2 NM_014315 1.58 
PCBD2 NM_032151 1.59 
KRTAP2-4 NM_033184 1.59 
ATP5S NM_001003803 1.59 
C14orf166 NM_016039 1.60 
LEMD2 NM_181336 1.60 
HTRA2 NM_145074 1.60 
SNX8 NM_013321 1.60 
FN3KRP NM_024619 1.62 
XRCC1 NM_006297 1.62 
ECOP NM_030796 1.62 
TJP1 NM_003257 1.63 
KITLG NM_000899 1.63 
GOSR2 NM_054022 1.63 
CRSP8 NM_004269 1.63 
IL13RA1 NM_001560 1.64 
IL1RAP NM_002182 1.65 
CYB5R1 NM_016243 1.65 
TIMP3 NM_000362 1.65 
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DRAP1 NM_006442 1.66 
ROCK2 NM_004850 1.66 
THC2275767 THC2275767 1.66 
A_24_P75408 A_24_P75408 1.66 
TMTC3 NM_181783 1.66 
A_32_P174385 A_32_P174385 1.67 
AK098307 AK098307 1.68 
MGAT1 NM_002406 1.69 
CR611332 CR611332 1.69 
ZFP91 NM_053023 1.70 
A_24_P943429 A_24_P943429 1.70 
MRPL30 NM_145212 1.71 
PPM1A NM_177951 1.71 
HIPK1 NM_152696 1.71 
TK1 NM_003258 1.71 
TEX261 NM_144582 1.71 
TPX2 NM_012112 1.72 
TGOLN2 NM_006464 1.72 
ACTR10 NM_018477 1.72 
EDARADD NM_080738 1.73 
C2orf18 NM_017877 1.73 
ARHGAP10 NM_024605 1.74 
C20orf172 NM_024918 1.74 
CR594732 CR594732 1.74 
ZNF197 NM_006991 1.75 
ZNF136 NM_003437 1.75 
PGK1 NM_000291 1.75 
TYW1 NM_018264 1.75 
C15orf24 NM_020154 1.75 
AK2 NM_001625 1.76 
C20orf24 NM_018840 1.76 
SAP30L NM_024632 1.76 
ENO1 NM_001428 1.76 
M6PRBP1 NM_005817 1.77 
THRA NM_003250 1.77 
TANC2 AJ278120 1.77 
RAP1A NM_001010935 1.77 
PRKRIP1 NM_024653 1.78 
TBC1D19 NM_018317 1.78 
GPATC1 NM_018025 1.78 
RABAC1 NM_006423 1.78 
THC2406192 THC2406192 1.78 
NAGK NM_017567 1.79 
RBL1 NM_002895 1.79 
TMEM97 NM_014573 1.80 
ZFYVE26 NM_015346 1.81 
SRD5A1 NM_001047 1.81 
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MTCH1 NM_014341 1.81 
ERBB2IP NM_018695 1.82 
C14orf100 NM_016475 1.82 
FBXO33 NM_203301 1.82 
FADS1 NM_013402 1.84 
CDADC1 NM_030911 1.85 
SNAI2 U97060 1.86 
MAX NM_145113 1.86 
CUL4B BX647096 1.87 
MYO18A NM_078471 1.87 
ENST00000238571 L40403 1.87 
ENST00000297145 AF274937 1.88 
LOC51255 NM_016494 1.88 
FAM50A NM_004699 1.90 
FLJ10099 NM_017994 1.90 
C14orf106 NM_018353 1.90 
RBPSUH NM_203284 1.90 
MTHFD1 NM_005956 1.91 
NRM NM_007243 1.91 
CREB3 NM_006368 1.91 
BRMS1 NM_015399 1.91 
ACOT8 NM_005469 1.92 
TIMM9 NM_012460 1.92 
THC2275804 CB133932 1.92 
MSH2 NM_000251 1.93 
GGCX NM_000821 1.94 
ATP6V0E NM_003945 1.94 
AK022110 AK022110 1.94 
STX5 NM_003164 1.94 
PTTG2 NM_006607 1.94 
THC2346166 THC2346166 1.94 
KIAA1458 BC031691 1.95 
ENST00000332935 BC053534 1.95 
TRAPPC6B BC030604 1.95 
BX101252 BX101252 1.95 
ZNF43 NM_003423 1.96 
U69195 U69195 1.96 
COMMD9 NM_014186 1.96 
C14orf10 NM_017917 1.97 
ACTR10 NM_018477 1.97 
AIP NM_003977 1.97 
COMMD1 NM_152516 1.97 
ENST00000355691 L06133 1.97 
TMEM127 NM_017849 1.98 
FAM14B NM_206949 1.98 
PTRF NM_012232 1.98 
MGC10433 NM_024321 1.98 
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AIP NM_003977 1.98 
FANCM NM_020937 1.98 
FZD1 NM_003505 1.99 
WDHD1 NM_007086 1.99 
AK092888 AK092888 1.99 
ETNK1 NM_018638 2.01 
VTI1B NM_006370 2.02 
PTTG3 NR_002734 2.02 
SBDS NM_016038 2.03 
GOLT1B NM_016072 2.04 
AI933337 AI933337 2.04 
COTL1 NM_021149 2.04 
C14orf112 NM_016468 2.05 
SLC4A7 NM_003615 2.05 
CGRRF1 NM_006568 2.06 
TEGT NM_003217 2.07 
NLN NM_020726 2.07 
SBDS NM_016038 2.08 
SNX15 NM_013306 2.08 
TMEM127 NM_017849 2.08 
ACTR1A NM_005736 2.08 
ERGIC2 NM_016570 2.09 
AHCYL1 NM_006621 2.09 
A_23_P136857 A_23_P136857 2.10 
ANLN NM_018685 2.10 
BG284526 BG284526 2.10 
SPATA7 NM_018418 2.11 
ZNF138 NM_006524 2.11 
NAT12 NM_001011713 2.11 
RCP9 NM_014478 2.12 
VEGFB NM_003377 2.12 
BI771091 BI771091 2.12 
ZDHHC7 NM_017740 2.13 
DYNC1H1 NM_001376 2.13 
CALU NM_001219 2.13 
CTTN NM_005231 2.14 
CEP57 BC039711 2.14 
CR601835 CR601835 2.15 
AK3L1 NM_001005353 2.15 
MYL6 NM_079423 2.15 
SSH1 NM_018984 2.16 
MLH1 NM_000249 2.17 
A_32_P4608 A_32_P4608 2.17 
ZC3H14 NM_207660 2.17 
AK092468 AK092468 2.17 
A_24_P340886 A_24_P340886 2.17 
CR602702 CR602702 2.18 
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BC090057 BC090057 2.18 
ENST00000310218 ENST00000310218 2.18 
FOXM1 NM_202002 2.19 
WDR22 NM_003861 2.19 
ZFP41 AK024438 2.19 
MAP4K5 NM_198794 2.19 
ARF4 NM_001660 2.19 
CD63 NM_001780 2.19 
KIAA1641 NM_020970 2.20 
RELA BC014095 2.20 
A_32_P64894 A_32_P64894 2.20 
C14orf159 NM_024952 2.20 
STAT2 NM_005419 2.20 
VTI1B NM_006370 2.21 
STK38 NM_007271 2.22 
SCYL1 NM_020680 2.22 
FGFR1OP2 NM_015633 2.22 
C6orf106 NM_024294 2.22 
FBXW8 NM_153348 2.22 
BC024198 BC024198 2.22 
TP53INP2 NM_021202 2.22 
GALNTL4 NM_198516 2.22 
DRAP1 NM_006442 2.24 
KDELR2 NM_006854 2.25 
A_24_P835388 A_24_P835388 2.25 
POLA2 NM_002689 2.26 
C12orf43 NM_022895 2.26 
UBL3 NM_007106 2.26 
AK022059 AK022059 2.26 
THC2406182 THC2406182 2.27 
DA422275 DA422275 2.27 
A_24_P341058 A_24_P341058 2.28 
POP4 NM_006627 2.29 
SMPD3 NM_018667 2.29 
VEGFB NM_003377 2.30 
THC2334619 THC2334619 2.30 
MXRA7 NM_001008528 2.30 
SAR1B NM_016103 2.30 
SEC61G NM_014302 2.30 
ENST00000252134 AB020626 2.31 
A_24_P144556 A_24_P144556 2.31 
THC2268341 AA701118 2.31 
KDELR2 NM_006854 2.31 
WDR20 NM_181302 2.33 
PTPRG NM_002841 2.33 
MTCH1 NM_014341 2.33 
C14orf151 NM_032714 2.34 
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DB328061 DB328061 2.34 
A_24_P101493 A_24_P101493 2.34 
THC2308298 THC2308298 2.34 
DDEF1 NM_018482 2.34 
ZC3H14 NM_024824 2.35 
CD63 NM_001780 2.35 
MGAT2 NM_002408 2.36 
SLC6A6 NM_003043 2.36 
KIAA1666 BC035246 2.38 
SEC24D NM_014822 2.39 
AK124956 AK124956 2.40 
C12orf23 NM_152261 2.41 
LRRFIP2 NM_006309 2.41 
LASP1 NM_006148 2.41 
AYP1 NM_032193 2.42 
ZNF313 NM_018683 2.42 
THC2364429 THC2364429 2.43 
AHCYL1 NM_006621 2.44 
AF118081 AF118081 2.44 
C6orf148 NM_030568 2.44 
GNG12 NM_018841 2.45 
A_24_P32735 A_24_P32735 2.45 
A_32_P63886 A_32_P63886 2.45 
MGC24039 BC020855 2.46 
RBPSUH NM_203284 2.46 
RCP9 NM_014478 2.46 
DNAJB4 NM_007034 2.46 
LMAN2L NM_030805 2.47 
ZHX3 NM_015035 2.47 
C6orf148 NM_030568 2.48 
MMP19 NM_002429 2.48 
KDELR3 NM_016657 2.49 
SLC44A2 NM_020428 2.49 
ALG14 NM_144988 2.50 
THC2431726 THC2431726 2.50 
CYP2U1 NM_183075 2.51 
MPP5 NM_022474 2.51 
MPP5 NM_022474 2.53 
CA420826 CA420826 2.54 
CXorf43 NM_144657 2.54 
STK38 NM_007271 2.54 
C20orf111 NM_016470 2.54 
MGC14376 NM_032895 2.54 
GRPR U57365 2.55 
KIAA0831 NM_014924 2.55 
ATP6V1D NM_015994 2.55 
DNAJB4 NM_007034 2.56 
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FIBCD1 NM_032843 2.57 
PARVA NM_018222 2.57 
ABHD4 NM_022060 2.58 
REXO2 NM_015523 2.58 
LOC253981 AK025431 2.59 
ENST00000381942 AK126071 2.59 
AP4S1 NM_007077 2.60 
WDR25 NM_024515 2.60 
PTPN21 NM_007039 2.60 
ARHGEF17 NM_014786 2.60 
PCDHB13 NM_018933 2.62 
SEC14L1 NM_003003 2.64 
SLC39A7 NM_006979 2.64 
C12orf4 NM_020374 2.64 
E2F1 NM_005225 2.65 
THC2267829 CN429806 2.66 
NDST1 BC012888 2.67 
MEIS3P1 NR_002211 2.67 
OXSR1 NM_005109 2.68 
LPP NM_005578 2.68 
COMMD10 NM_016144 2.71 
B2M NM_004048 2.71 
SGCB NM_000232 2.72 
FLJ40330 BC031698 2.72 
DOPEY2 NM_005128 2.73 
ENST00000334564 ENST00000334564 2.75 
CXXC5 NM_016463 2.76 
AK098360 AK098360 2.76 
PUS7L NM_031292 2.77 
NUBPL NM_025152 2.77 
C9orf39 NM_017738 2.78 
KIAA1666 BC035246 2.78 
MICB NM_005931 2.79 
CDKN3 NM_005192 2.81 
PML NM_002675 2.84 
UCP3 NM_003356 2.85 
PXK AK131385 2.85 
STOM NM_198194 2.85 
WDR21A NM_181340 2.85 
ATP10D NM_020453 2.86 
DKFZP564J0863 NM_015459 2.86 
CCDC6 S72869 2.86 
PTEN NM_000314 2.87 
BMP2K NM_017593 2.88 
LOC286016 NR_002187 2.88 
MYL6 NM_079423 2.88 
ERCC2 NM_000400 2.89 
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CXXC5 NM_016463 2.90 
SOCS5 NM_144949 2.93 
LOC221362 AK095359 2.93 
ITPR2 NM_002223 2.93 
CENPQ NM_018132 2.95 
CFL2 NM_021914 2.95 
FLJ40330 BX648045 2.96 
KLHDC1 NM_172193 2.97 
C14orf28 NM_001017923 2.99 
A_24_P753760 A_24_P753760 2.99 
BG009439 BG009439 3.00 
ICK NM_016513 3.02 
ENST00000375180 AK125664 3.03 
AVEN NM_020371 3.04 
WDR21A NM_181340 3.04 
BF217859 BF217859 3.05 
FTL NM_000146 3.07 
PARVA NM_018222 3.08 
CDH24 AK057922 3.08 
A_24_P101352 A_24_P101352 3.09 
IL6ST NM_002184 3.11 
C11orf60 NM_020153 3.15 
SLC30A7 NM_133496 3.16 
FLJ31715 AK056277 3.17 
BE825944 BE825944 3.17 
ANKRD13A NM_033121 3.18 
ANXA5 NM_001154 3.19 
SELPLG NM_003006 3.20 
TSPAN9 NM_006675 3.20 
TRAM2 NM_012288 3.20 
MET NM_000245 3.26 
CHST7 NM_019886 3.26 
GULP1 NM_016315 3.26 
DNAJB5 NM_012266 3.31 
COL18A1 NM_030582 3.34 
BX101288 BX101288 3.34 
LOC387882 NM_207376 3.39 
STOM NM_198194 3.42 
ENST00000367545 AK023675 3.42 
FZD2 NM_001466 3.43 
CREB3L1 NM_052854 3.44 
TACC1 NM_006283 3.51 
AK3L2 NM_001002921 3.54 
TRIM62 NM_018207 3.55 
GPRASP2 NM_001004051 3.57 
CSDE1 NM_001007553 3.57 
GALNT10 NM_198321 3.58 
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C14orf132 NM_020215 3.60 
RBPSUH D14041 3.63 
C6orf128 NM_145316 3.68 
PIGK NM_005482 3.68 
MYH9 NM_002473 3.72 
ENST00000308604 BC070200 3.74 
A_32_P93792 A_32_P93792 3.75 
DKFZp667G2110 NM_153605 3.77 
CHES1 NM_005197 3.82 
STK17B NM_004226 3.84 
TRIM16 NM_006470 3.85 
MGC4677 NM_052871 3.88 
MET NM_000245 3.88 
CD109 NM_133493 3.88 
SLC16A2 NM_006517 3.88 
ENST00000372072 AK000180 3.92 
BHLHB9 NM_030639 3.93 
PCDHB7 NM_018940 3.93 
HPSE NM_006665 3.93 
TMEM25 NM_032780 3.95 
CD40 NM_001250 3.96 
ARID5B NM_032199 3.99 
TACC1 NM_006283 3.99 
EHD1 NM_006795 4.01 
LMCD1 NM_014583 4.02 
C14orf46 BC009539 4.03 
A_24_P917668 A_24_P917668 4.03 
ABHD9 NM_024794 4.05 
APLN NM_017413 4.11 
LONRF3 NM_024778 4.11 
LOC92689 NM_138389 4.24 
FZD7 NM_003507 4.24 
SEL1L NM_005065 4.27 
STC2 NM_003714 4.29 
FTL NM_000146 4.33 
LAMP2 NM_002294 4.38 
BIN1 NM_139346 4.38 
ENO2 NM_001975 4.40 
ADC NM_052998 4.40 
AF075027 AF075027 4.41 
PRKCA NM_002737 4.43 
UPP1 NM_181597 4.44 
RAB8B NM_016530 4.48 
THC2267053 THC2267053 4.51 
CUZD1 NM_022034 4.54 
BE816002 BE816002 4.61 
SOCS1 NM_003745 4.64 
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C14orf139 BC008299 4.66 
SCD5 NM_001037582 4.67 
APOLD1 NM_030817 4.71 
TEAD3 NM_003214 4.74 
HLA-E NM_005516 4.76 
APLN NM_017413 4.77 
A_24_P938006 A_24_P938006 4.82 
BU684362 BU684362 4.83 
TPM1 NM_001018004 4.83 
CAMK2D NM_172127 4.84 
BE795374 BE795374 4.85 
FTL NM_000146 4.86 
TCHP NM_032300 4.91 
BIN1 NM_139346 4.94 
A_24_P281683 A_24_P281683 4.95 
PXK NM_017771 4.96 
ACTN1 NM_001102 4.97 
HLA-C BC002463 5.00 
AK127258 AK127258 5.02 
HLA-E NM_005516 5.03 
CHES1 NM_005197 5.03 
CACNA1C NM_000719 5.14 
HLA-A NM_002116 5.17 
SCGB3A2 NM_054023 5.22 
PRKCA NM_002737 5.26 
CAMK2D NM_001221 5.29 
THC2346243 THC2346243 5.35 
NRN1 NM_016588 5.54 
N48043 N48043 5.57 
C10orf25 NM_001039380 5.57 
TMEM45A NM_018004 5.64 
GLYATL2 NM_145016 5.70 
HLA-G NM_002127 5.71 
A_24_P32715 A_24_P32715 5.71 
SH3BP4 NM_014521 5.72 
AHNAK NM_001620 5.73 
ZNF501 NM_145044 5.75 
TRAM2 NM_012288 5.78 
ENST00000376802 AF287958 5.79 
BF217859 BF217859 5.95 
EHD1 AF099011 5.98 
ALDH6A1 NM_005589 5.98 
EPS8 NM_004447 6.03 
C6orf65 NM_152731 6.21 
ADAMTSL1 NM_139238 6.21 
ACTN1 NM_001102 6.22 
BNC2 NM_017637 6.35 
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RSNL2 NM_024692 6.42 
RP1-32F7.2 NM_173698 6.49 
SAMD4A AB028976 6.52 
TPM1 NM_000366 6.53 
HLA-C CR598918 6.60 
ENST00000380195 BC001304 6.90 
C16orf45 NM_033201 6.92 
TPM1 NM_001018004 6.97 
HLA-H NR_001434 7.45 
TPM1 NM_001018004 7.47 
PRKCDBP NM_145040 7.48 
FAM46B NM_052943 7.62 
HLA-E NM_005516 7.63 
PRKD1 NM_002742 7.63 
AK094175 AK094175 7.65 
FLNC NM_001458 7.71 
A_24_P237896 A_24_P237896 7.76 
CR608347 CR608347 7.79 
EDG2 NM_057159 7.84 
C1orf118 NM_001039463 8.18 
STC2 NM_003714 8.22 
ENST00000383518 M64259 8.31 
MATN2 NM_030583 8.33 
S100A4 NM_002961 8.36 
A_24_P101771 A_24_P101771 8.47 
HLA-F NM_018950 8.54 
HLA-C BC008457 8.64 
MGC16121 BC007360 8.71 
FGF2 NM_002006 8.75 
TFPI NM_001032281 8.92 
RGNEF AK025816 8.98 
DKFZP686A01247 NM_014988 9.05 
PAPSS2 NM_001015880 9.14 
ENST00000376793 ENST00000376793 9.24 
ENST00000373886 AK130049 9.28 
HLA-B NM_005514 9.33 
MN1 NM_002430 9.45 
FLJ45422 NM_001004349 9.60 
RBMS3 NM_014483 9.94 
PCDHB9 NM_019119 10.08 
FBLN5 NM_006329 10.15 
A_23_P125109 A_23_P125109 10.54 
HLA-C NM_002117 10.88 
NEXN NM_144573 11.08 
HLA-F NM_018950 11.10 
AHNAK NM_024060 11.11 
PPP1R3C NM_005398 11.38 
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Genename Genbank 
Fold Change in 
ALT 
COL6A1 NM_001848 11.55 
BC035647 BC035647 11.61 
NEXN NM_144573 11.76 
SLC8A1 NM_021097 11.97 
SYNC1 NM_030786 12.83 
PPAP2B NM_003713 12.97 
AK092921 AK092921 13.22 
BC089454 BC089454 13.23 
PAX8 NM_003466 13.38 
GPR39 AK122643 13.64 
EMR1 NM_001974 13.72 
DKFZP686A01247 NM_014988 13.86 
ADAMTS5 NM_007038 14.00 
GYPC NM_002101 14.76 
HLA-B NM_005514 14.95 
OXTR NM_000916 15.22 
C1R NM_001733 16.11 
KCNIP3 NM_013434 16.72 
ITGA1 NM_181501 16.73 
TFPI NM_006287 17.31 
FGF13 NM_004114 18.82 
AHRR AB033060 20.14 
DOC1 NM_182909 20.94 
FLJ36748 NM_152406 22.36 
SLC8A1 BX648299 22.73 
SYTL2 NM_206927 22.78 
CTSC NM_148170 23.35 
JAM2 NM_021219 25.15 
WNT5B NM_030775 26.41 
WNT5A NM_003392 28.99 
DPF3 NM_012074 29.49 
FBLN5 NM_006329 30.74 
PDGFRB NM_002609 30.77 
SFRP1 NM_003012 37.96 
MYEOV NM_138768 38.48 
COL16A1 NM_001856 47.62 
LOC51334 NM_016644 49.61 
SFRP1 NM_003012 50.92 
PTN NM_002825 54.79 
PTN NM_002825 66.78 
COL1A2 NM_000089 84.24 
PRKCDBP NM_145040 107.13 
COL1A1 Z74615 298.49 
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Table 4 : 297 Genes differentially expressed between ALT and telomerase positive cells in 
both liposarcomas and cell lines. 
Gene Name Genbank 
Fold Change in 
ALT 
Liposarcomas 
Fold Change in 
ALT Cell Lines 
TERT NM_198253 -10.33 -46.32 
SLC6A10P NR_003083 -9.98 -8.03 
MDFI NM_005586 -5.35 -9.23 
LOC92312 XM_044166 -5.31 -4.89 
TP53TG3 NM_016212 -5.08 -7.44 
LOC649542 XM_938617 -4.30 -8.07 
ITIH5 NM_030569 -4.28 -1.96 
LOC112703 NM_138411 -4.08 -11.78 
ALDH5A1 NM_170740 -3.31 -2.05 
SLC6A8 NM_005629 -3.27 -8.78 
KIAA1370 NM_019600 -3.13 -1.57 
PER2 NM_022817 -3.05 -2.83 
CEBPA NM_004364 -2.96 -8.74 
MSTP9 NR_002729 -2.93 -3.88 
CR625561 CR625561 -2.89 -2.52 
CEBPA NM_004364 -2.89 -6.93 
MARCKSL1 NM_023009 -2.88 -2.81 
SLC6A8 NM_005629 -2.85 -3.80 
C10orf35 NM_145306 -2.85 -29.45 
ENST00000361453 AK026903 -2.82 -2.19 
LRRC8B NM_015350 -2.81 -6.34 
FLJ22795 AF316855 -2.77 -3.18 
ENST00000330947 BC035081 -2.73 -8.18 
AK097322 AK097322 -2.64 -2.08 
MMP15 NM_002428 -2.50 -2.76 
ENST00000361227 AY423734 -2.49 -2.25 
FLJ22795 NM_025084 -2.48 -3.33 
BF576096 BF576096 -2.47 -1.97 
BC065260 BC065260 -2.42 -2.78 
TP53INP1 NM_033285 -2.40 -2.39 
KLHL24 NM_017644 -2.38 -3.91 
LYPLA1 NM_006330 -2.35 -2.32 
ENST00000301042 AL713659 -2.34 -1.85 
ENST00000361227 AB017116 -2.27 -1.96 
ST6GAL1 NM_173216 -2.25 -28.83 
GPRC5C NM_022036 -2.22 -5.14 
DUSP22 AK000383 -2.22 -2.01 
AK057071 AK057071 -2.22 -2.31 
BC019667 BC019667 -2.20 -1.96 
ASB13 NM_024701 -2.19 -3.54 
LYPLA1 NM_006330 -2.17 -2.08 
CR601496 CR601496 -2.16 -2.12 
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Gene Name Genbank 
Fold Change in 
ALT 
Liposarcomas 
Fold Change in 
ALT Cell Lines 
RNF44 NM_014901 -2.16 -4.28 
SLC39A4 NM_130849 -2.16 -18.24 
RP11-138L21.1 AK024257 -2.11 -3.39 
FLJ35740 NM_147195 -2.11 -4.14 
A_24_P204334 A_24_P204334 -2.08 -2.34 
AK131288 AK131288 -2.07 -2.31 
ORF1-FL49 NM_032412 -2.06 -4.79 
ZNF195 NM_007152 -2.05 -2.29 
PLEKHG2 NM_022835 -2.04 -1.98 
A_24_P384239 A_24_P384239 -2.04 -2.15 
RP11-125A7.3 NM_015058 -2.04 -1.96 
PIK3C2B NM_002646 -2.02 -3.53 
TFDP2 NM_006286 -2.01 -1.74 
AK023328 AK023328 -2.01 -3.15 
BX093417 BX093417 -2.01 -2.45 
DUSP22 NM_020185 -2.00 -3.32 
SULT4A1 NM_014351 -1.98 -4.11 
ENST00000252509 ENST00000252509 -1.97 -1.77 
CHD7 NM_017780 -1.96 -22.15 
THC2428713 THC2428713 -1.95 -2.58 
LPHN1 NM_001008701 -1.93 -5.41 
GCN5L2 NM_021078 -1.93 -1.92 
ENST00000372821 ENST00000372821 -1.90 -3.49 
CHD7 NM_017780 -1.90 -16.78 
ADAM11 NM_002390 -1.89 -8.75 
TBC1D16 AK091923 -1.89 -1.87 
CRY2 NM_021117 -1.89 -1.57 
TOP1MT NM_052963 -1.88 -1.73 
ZNF692 NM_017865 -1.85 -3.18 
KIAA1545 AB046765 -1.84 -2.13 
ANKRD13B NM_152345 -1.83 -3.51 
FLJ22795 AF316855 -1.82 -2.93 
TTC17 BC041893 -1.82 -1.76 
76P NM_014444 -1.82 -1.57 
CCNL1 NM_020307 -1.79 -1.75 
A_24_P608790 A_24_P608790 -1.79 -1.76 
ENST00000220507 CR618466 -1.78 -5.75 
THC2437122 THC2437122 -1.78 -1.97 
ENST00000369239 AL080186 -1.77 -2.13 
LOC653801 XM_934188 -1.77 -2.55 
KIAA0485 AB007954 -1.76 -5.93 
BCL7A NM_020993 -1.75 -2.62 
PCGF3 NM_006315 -1.73 -1.84 
MGC4172 NM_024308 -1.73 -2.64 
PMS2L1 BC044214 -1.73 -1.70 
ENST00000275546 ENST00000275546 -1.70 -1.59 
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Gene Name Genbank 
Fold Change in 
ALT 
Liposarcomas 
Fold Change in 
ALT Cell Lines 
AA554330 AA554330 -1.69 -3.64 
DECR2 NM_020664 -1.69 -3.09 
LOC440295 NM_198181 -1.69 -2.31 
GOLGA8E NM_001012423 -1.69 -3.50 
A_32_P80587 A_32_P80587 -1.67 -1.37 
THC2411839 THC2411839 -1.67 -3.35 
ASB13 NM_024701 -1.66 -4.76 
TOMM20 NM_014765 -1.63 -1.91 
tcag7.1017 NM_001004351 -1.63 -2.16 
P15RS NM_018170 -1.63 -3.03 
NUDT14 NM_177533 -1.61 -3.19 
FAM59A NM_022751 -1.60 -7.55 
LOC653639 XM_934787 -1.59 -2.39 
ASAH1 NM_004315 -1.59 -2.55 
B3GNT5 NM_032047 -1.59 -14.16 
REPIN1 NM_014374 -1.57 -1.93 
SLC16A9 NM_194298 -1.56 -3.32 
ENST00000270201 AF231919 -1.55 -1.89 
GLI4 NM_138465 -1.55 -3.18 
ADH5 NM_000671 -1.54 -1.59 
LONRF1 NM_152271 -1.54 -4.57 
ENST00000319822 BC111692 -1.53 -1.73 
HNRPA3 NM_194247 -1.53 -2.19 
BIVM NM_017693 -1.52 -2.67 
PMS2L5 NM_174930 -1.52 -1.62 
STAU2 AK002152 -1.51 -6.20 
LOC389607 NM_001013651 -1.51 -1.64 
A_24_P341731 A_24_P341731 -1.51 -1.77 
GP1BB NM_000407 -1.49 -5.60 
HNRPA3 NM_194247 -1.48 -3.02 
GPR125 NM_145290 -1.47 -1.82 
SIRT5 NM_012241 -1.47 -1.97 
CLK2 NM_003993 -1.47 -2.10 
APOM NM_019101 -1.46 -2.05 
AFG3L1 NM_001132 -1.46 -5.05 
TMEM80 NM_174940 -1.42 -3.38 
BX537520 BX537520 -1.41 -1.86 
ZMYM2 NM_003453 -1.37 -2.36 
ZFP64 NM_018197 -1.36 -2.04 
BC064492 BC064492 -1.34 -2.66 
PEX7 NM_000288 -1.33 -1.95 
DRG2 NM_001388 -1.32 -4.32 
ZFAND5 NM_006007 -1.32 -1.49 
PERLD1 NM_033419 -1.31 -1.97 
NSUN5B NM_145645 -1.29 -2.96 
GMCL1 NM_178439 -1.29 -1.89 
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Gene Name Genbank 
Fold Change in 
ALT 
Liposarcomas 
Fold Change in 
ALT Cell Lines 
HDAC5 NM_001015053 -1.29 -1.58 
TFB2M NM_022366 -1.29 -2.04 
NSUN5C NM_148936 -1.27 -2.50 
MAPK11 NM_002751 -1.26 -6.28 
NSUN5C NM_032158 -1.24 -1.82 
THC2455149 THC2455149 -1.23 -3.63 
ENST00000378954 CR617774 -1.22 -1.98 
NIT1 NM_005600 -1.20 -1.84 
AF086442 AF086442 -1.18 -4.70 
ATP5D NM_001001975 -1.15 -2.07 
HEATR2 NM_017802 -1.10 -2.20 
TM9SF4 NM_014742 1.10 1.54 
ZFP91 NM_053023 1.13 1.70 
A_32_P64894 A_32_P64894 1.14 2.20 
SBDS NM_016038 1.15 2.08 
CCIN NM_005893 1.15 1.49 
MGC24039 BC020855 1.16 2.46 
AIP NM_003977 1.18 1.97 
AIP NM_003977 1.21 1.98 
CR602702 CR602702 1.24 2.18 
SPCS2 NM_014752 1.24 1.50 
MYL6 NM_079423 1.29 2.15 
LEMD2 NM_181336 1.29 1.60 
FBXO33 NM_203301 1.31 1.82 
STX5 NM_003164 1.32 1.94 
TMEM127 NM_017849 1.34 1.98 
APOLD1 NM_030817 1.36 4.71 
ATP6V1D NM_015994 1.36 2.55 
C20orf24 NM_018840 1.37 1.76 
DYNC1H1 NM_001376 1.37 2.13 
WDHD1 NM_007086 1.38 1.99 
PTP4A2 NM_080392 1.39 1.57 
KIAA1458 BC031691 1.39 1.95 
UBL3 NM_007106 1.39 2.26 
NAT12 NM_001011713 1.40 2.11 
MGC10433 NM_024321 1.41 1.98 
POLA2 NM_002689 1.41 2.26 
ATP10D NM_020453 1.42 2.86 
MGAT1 NM_002406 1.43 1.69 
C12orf23 NM_152261 1.44 2.41 
U69195 U69195 1.44 1.96 
MTCH1 NM_014341 1.45 1.81 
BC024198 BC024198 1.45 2.22 
SYNC1 NM_030786 1.47 12.83 
C2orf18 NM_017877 1.49 1.73 
MGC16121 BC007360 1.49 8.71 
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Gene Name Genbank 
Fold Change in 
ALT 
Liposarcomas 
Fold Change in 
ALT Cell Lines 
TEAD3 NM_003214 1.50 4.74 
A_32_P93792 A_32_P93792 1.52 3.75 
FZD2 NM_001466 1.53 3.43 
APLN NM_017413 1.54 4.77 
AF086335 AF086335 1.55 1.41 
BRMS1 NM_015399 1.55 1.91 
ACOT8 NM_005469 1.55 1.92 
ZNF414 AK074191 1.55 1.16 
RBPSUH NM_203284 1.56 1.90 
POLD3 NM_006591 1.57 1.57 
SEC61G NM_014302 1.57 2.30 
ENST00000266712 CR749309 1.58 1.44 
LOC51255 NM_016494 1.61 1.88 
TPX2 NM_012112 1.62 1.72 
FAM50A NM_004699 1.63 1.90 
PTPN21 NM_007039 1.64 2.60 
ARF4 NM_001660 1.64 2.19 
THC2406182 THC2406182 1.65 2.27 
STK38 NM_007271 1.66 2.54 
CR601835 CR601835 1.66 2.15 
IL1RAP NM_002182 1.66 1.65 
C9orf39 NM_017738 1.67 2.78 
C15orf24 NM_020154 1.68 1.75 
CREB3 NM_006368 1.70 1.91 
PDGFRB NM_002609 1.70 30.77 
SLC4A7 NM_003615 1.71 2.05 
MICB NM_005931 1.72 2.79 
SAP30L NM_024632 1.72 1.76 
ECOP NM_030796 1.73 1.62 
PTPRG NM_002841 1.73 2.33 
ACTN1 NM_001102 1.73 4.97 
ACTN1 NM_001102 1.76 6.22 
AHNAK NM_024060 1.77 11.11 
AK022110 AK022110 1.78 1.94 
RAB8B NM_016530 1.78 4.48 
LASP1 NM_006148 1.79 2.41 
A_24_P835388 A_24_P835388 1.84 2.25 
ATP6V0E NM_003945 1.84 1.94 
ANXA5 NM_001154 1.85 3.19 
TGOLN2 NM_006464 1.88 1.72 
KDELR2 NM_006854 1.88 2.31 
FAM14B NM_206949 1.89 1.98 
SYTL2 NM_206927 1.89 22.78 
C20orf172 NM_024918 1.91 1.74 
ENST00000381942 AK126071 1.91 2.59 
FGF2 NM_002006 1.92 8.75 
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Gene Name Genbank 
Fold Change in 
ALT 
Liposarcomas 
Fold Change in 
ALT Cell Lines 
STK17B NM_004226 1.92 3.84 
PXK AK131385 1.93 2.85 
AK098360 AK098360 1.94 2.76 
CXXC5 NM_016463 1.94 2.76 
CYP2U1 NM_183075 1.95 2.51 
GNG12 NM_018841 1.99 2.45 
COTL1 NM_021149 2.00 2.04 
FLJ45422 NM_001004349 2.05 9.60 
NRM NM_007243 2.05 1.91 
RABAC1 NM_006423 2.07 1.78 
ITPR2 NM_002223 2.08 2.93 
A_24_P281683 A_24_P281683 2.09 4.95 
SNX8 NM_013321 2.13 1.60 
EHD1 NM_006795 2.14 4.01 
FTL NM_000146 2.14 3.07 
MXRA7 NM_001008528 2.14 2.30 
FTL NM_000146 2.16 4.86 
TPM1 NM_001018004 2.17 4.83 
E2F1 NM_005225 2.18 2.65 
FTL NM_000146 2.19 4.33 
LAMP2 NM_002294 2.19 4.38 
A_24_P32715 A_24_P32715 2.20 5.71 
SLC8A1 BX648299 2.25 22.73 
TK1 NM_003258 2.25 1.71 
KDELR3 NM_016657 2.27 2.49 
FOXM1 NM_202002 2.28 2.19 
TPM1 NM_001018004 2.30 6.97 
NEXN NM_144573 2.30 11.08 
TPM1 NM_001018004 2.31 7.47 
ZHX3 NM_015035 2.32 2.47 
ENST00000376802 AF287958 2.32 5.79 
DKFZP564J0863 NM_015459 2.33 2.86 
SELPLG NM_003006 2.34 3.20 
SOCS1 NM_003745 2.37 4.64 
SLC8A1 NM_021097 2.42 11.97 
HLA-F NM_018950 2.44 11.10 
PXK NM_017771 2.54 4.96 
LOC253981 AK025431 2.56 2.59 
FADS1 NM_013402 2.63 1.84 
AK022059 AK022059 2.67 2.26 
NEXN NM_144573 2.68 11.76 
PRKD1 NM_002742 2.69 7.63 
LOC92689 NM_138389 2.70 4.24 
CALU NM_001219 2.73 2.13 
SEC24D NM_014822 2.80 2.39 
PTTG2 NM_006607 2.86 1.94 
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Gene Name Genbank 
Fold Change in 
ALT 
Liposarcomas 
Fold Change in 
ALT Cell Lines 
AK094175 AK094175 2.86 7.65 
ENST00000308604 BC070200 3.02 3.74 
CTSC NM_148170 3.05 23.35 
TACC1 NM_006283 3.07 3.99 
CDKN3 NM_005192 3.10 2.81 
MGC4677 NM_052871 3.13 3.88 
SAMD4A AB028976 3.17 6.52 
ADAMTS5 NM_007038 3.26 14.00 
ABHD4 NM_022060 3.30 2.58 
KCNIP3 NM_013434 3.33 16.72 
TACC1 NM_006283 3.35 3.51 
HERC5 NM_016323 3.40 1.42 
PRKCDBP NM_145040 3.41 107.13 
KIAA1666 BC035246 3.68 2.38 
A_24_P753760 A_24_P753760 3.74 2.99 
TRAM2 NM_012288 3.78 5.78 
COL16A1 NM_001856 4.31 47.62 
ANLN NM_018685 4.64 2.10 
S100A4 NM_002961 4.89 8.36 
BNC2 NM_017637 5.38 6.35 
OXTR NM_000916 5.52 15.22 
ENO2 NM_001975 5.54 4.40 
PRKCA NM_002737 5.84 5.26 
TMEM45A NM_018004 6.09 5.64 
C1R NM_001733 6.26 16.11 
FZD1 NM_003505 6.35 1.99 
COL1A1 Z74615 10.18 298.49 
COL1A2 NM_000089 14.53 84.24 
 
Table 5: 106 hTERT regulatory kinases 
Gene Name 
Average Fold 
Change of Hits SE 
Q19PIK3CD −7.63 4.80 
SYK −5.1 1.08 
ERK8 −4.97 2.68 
STK17A −4.58 0.35 
EIF2AK3 −4.23 2.14 
TESK1 −4.15 0.51 
NME1 −4.11 1.56 
STK3 −3.98 0.01 
SGK2 −3.95 0.06 
NEK2 −3.93 0.79 
TEK −3.88 1.68 
STK38L −3.88 0.88 
T3JAM −3.87 1.22 
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Gene Name 
Average Fold 
Change of Hits SE 
TESK2 −3.87 0.59 
GALK1 −3.85 0.20 
STK22D −3.85 1.04 
TRIB1 −3.81 0.35 
TPK1 −3.63 0.40 
STK10 −3.61 0.70 
EEF2K −3.58 0.70 
PRKWNK1 −3.57 1.15 
PTK7 −3.56 0.92 
STK32C −3.54 0.33 
SGK −3.47 0.47 
STK17B −3.46 0.17 
MAPK3 −3.44 0.71 
STK35 −3.43 0.06 
TXNDC3 −3.37 0.42 
SNRK −3.37 0.89 
LOC390975 −3.37 0.12 
TYK2 −3.34 0.36 
STK11 −3.34 1.30 
TTBK1 −3.33 0.58 
STK22C −3.30 0.25 
STK32A −3.19 0.71 
SCGB2A1 −3.19 0.51 
MKNK1 −3.16 0.19 
STK24 −3.14 0.83 
TAO1 −3.1 0.20 
STK19 −3.05 0.01 
DKFZp434B1231 −3.00 0.09 
MAPK9 −2.98 0.69 
SBK1 −2.97 0.65 
PKMYT1 −2.97 0.58 
SH3BP4 −2.89 0.37 
MAPK8 −2.89 0.75 
STK4 −2.87 0.17 
COASY −2.84 0.48 
SSTK −2.81 0.60 
SIK2 −2.80 0.20 
NEK9 −2.76 0.46 
NEK8 −2.72 0.02 
CDK6 −2.72 0.47 
NEK7 −2.71 0.48 
SPHK2 −2.67 0.05 
PIP5K2C −2.66 0.58 
CRIM1 −2.66 0.60 
PGK2 −2.66 0.29 
DGUOK −2.65 0.35 
PRPSAP1 −2.63 0.45 
Kyle Lafferty-Whyte, 2010  Appendix I, 224 
Gene Name 
Average Fold 
Change of Hits SE 
CAMK1 −2.62 0.06 
PRKCN −2.61 0.08 
TXNDC6 −2.60 0.35 
STK6 −2.59 0.58 
PRKWNK2 −2.50 0.30 
STK16 −2.45 0.17 
KIAA1361 −2.42 0.28 
PTK9L −2.41 0.19 
SMG1 −2.40 0.41 
HRI −2.36 0.16 
PIK3CB −2.35 0.13 
TEX14 −2.34 0.10 
YES1 −2.32 0.08 
EPHB4 −2.31 0.03 
MAP3K5 −2.31 0.21 
PRKCH −2.31 0.11 
CARKL −2.29 0.09 
IHPK2 −2.28 0.10 
MAP4K5 −2.27 0.21 
MAP2K1 −2.27 0.11 
LOC390877 −2.24 0.05 
NEK3 −2.23 0.04 
PSKH2 −2.20 0.06 
MAP3K6 −2.17 0.15 
RPS6KA2 −2.17 0.08 
MAP3K14 −2.16 0.06 
RIPK5 −2.15 0.05 
TRIB2 −2.12 0.07 
PCTK2 −2.10 0.02 
CCRK 2.12 0.08 
MAP2K6 2.15 0.14 
NME4 2.17 0.16 
PRKCE 2.31 0.16 
CHKB 2.54 0.31 
IKBKE 2.64 0.59 
LOC91807 2.64 0.31 
AKAP2 2.86 0.82 
HIPK4 2.89 0.72 
BUB1 2.93 0.49 
ALK 2.99 0.77 
FLJ22955 3.03 0.32 
KIAA1811 3.06 0.98 
ARAF1 3.08 0.63 
IKBKG 3.20 0.56 
ACK1 4.09 1.39 
MAPKAPK5 4.76 0.09 
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Table 6: 87 Unique miRNAs able to distinguish between mesenchymal tumour types. 
miRNA 
hsa-let-7a* 
hsa-let-7e 
hsa-miR-100 
hsa-miR-103 
hsa-miR-125a-5p 
hsa-miR-127-3p 
hsa-miR-128 
hsa-miR-1299 
hsa-miR-130b 
hsa-miR-135b 
hsa-miR-142-3p 
hsa-miR-142-5p 
hsa-miR-144 
hsa-miR-146a 
hsa-miR-146b-5p 
hsa-miR-148a 
hsa-miR-150 
hsa-miR-152 
hsa-miR-1539 
hsa-miR-15a 
hsa-miR-15b 
hsa-miR-16 
hsa-miR-181a 
hsa-miR-181b 
hsa-miR-192 
hsa-miR-193a-5p 
hsa-miR-195* 
hsa-miR-196a 
hsa-miR-196b 
hsa-miR-21 
hsa-miR-21* 
hsa-miR-210 
hsa-miR-214 
hsa-miR-215 
hsa-miR-218 
hsa-miR-22 
hsa-miR-22* 
hsa-miR-223 
hsa-miR-24-1* 
hsa-miR-27a 
hsa-miR-27b 
hsa-miR-28-3p 
hsa-miR-28-5p 
hsa-miR-29a 
hsa-miR-29a* 
hsa-miR-29b 
hsa-miR-29b-1* 
hsa-miR-29c 
hsa-miR-29c* 
hsa-miR-301a 
hsa-miR-30a* 
hsa-miR-30e 
hsa-miR-30e* 
hsa-miR-32 
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miRNA 
hsa-miR-320c 
hsa-miR-320d 
hsa-miR-331-3p 
hsa-miR-337-5p 
hsa-miR-337-5p 
hsa-miR-338-3p 
hsa-miR-34a 
hsa-miR-34b* 
hsa-miR-361-3p 
hsa-miR-377 
hsa-miR-379 
hsa-miR-381 
hsa-miR-409-5p 
hsa-miR-410 
hsa-miR-454 
hsa-miR-455-3p 
hsa-miR-455-5p 
hsa-miR-487b 
hsa-miR-493 
hsa-miR-493* 
hsa-miR-500 
hsa-miR-500* 
hsa-miR-501-3p 
hsa-miR-513b 
hsa-miR-513c 
hsa-miR-532-5p 
hsa-miR-551b 
hsa-miR-566 
hsa-miR-574-5p 
hsa-miR-590-5p 
hsa-miR-660 
hsa-miR-874 
hsa-miR-95 
hsa-miR-99b 
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Appendix II– Tumour Histology and information. 
The following Table details all known Histological, telomere maintenance and 
survival information on record for tumour samples used in this study. The follow 
abbreviations are used in the table: Tel = Telomerase positive, ALT = Alternative 
Legnthening of Telomeres, F = Female, M = Male, M.R.C = myxoid round cell, 
Retroperit. = Retroperitoneum. N/A indicates points where data was 
unavailable.
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ID Tumour Type TMM Grade Histology Location 
Survival 
Status 
Survival 
(month) Age Sex 
S1038R  Liposarcoma TEL 2 M.R.C. N/A 0 57 48 F 
S1111 Liposarcoma TEL 2 M.R.C. (20-30%) Lower Extremity N/A N/A 43 M 
S1138R  Liposarcoma ALT 2 WD, Lipoma-Like N/A 0 50 N/A N/A 
S1364  Liposarcoma TEL 3 Dedifferentiated N/A 1 45 53 F 
S1423  Liposarcoma ALT 2 M.R.C. N/A 0 158 N/A N/A 
S272 Liposarcoma ALT 1 Myxoid Retroperit. N/A N/A 76 M 
S281 
Liposarcoma 
ALT 3 Pleomorphic, Myxoid 
Areas 
Upper Extremity 
N/A N/A 84 M 
S344  Liposarcoma ALT 1 Dedifferentiated Retroperit. 1 182 66 M 
S384 Liposarcoma ALT 2 M.R.C. (50%) Lower Extremity N/A N/A 54 F 
S498R Liposarcoma TEL N/A M.R.C. (70%) Lower Extremity N/A N/A 64 F 
S498R  Liposarcoma TEL N/A M.R.C. N/A 1 240 64 F 
S670R Liposarcoma TEL 2 M.R.C. Lower Extremity N/A N/A 48 F 
S694R  Liposarcoma ALT 2 M.R.C. N/A 1 53 71 M 
S711R Liposarcoma TEL 1 Myxoid Lower Extremity N/A N/A 55 F 
S717R1 Liposarcoma ALT 3 Pleomorphic Thorax N/A N/A 51 F 
S750R Liposarcoma TEL 2 M.R.C. (>25%) Lower Extremity N/A N/A 56 M 
S787  Liposarcoma TEL 2 M.R.C. (>25%) Lower Extremity 0 65 47 M 
S850  Liposarcoma ALT 2 Dedifferentiated Retroperit. 1 25 74 M 
S860  Liposarcoma TEL 2 M.R.C. Lower Extremity 1 204 73 F 
S861R Liposarcoma TEL 2 M.R.C. (>25%) Retroperit. N/A N/A 42 F 
S861R  Liposarcoma TEL 2 M.R.C. N/A 1 30 42 F 
S867R  Liposarcoma ALT 2 Pleomorphic Lower Extremity 0 34 66 F 
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ID Tumour Type TMM Grade Histology Location 
Survival 
Status 
Survival 
(month) Age Sex 
S904R Liposarcoma ALT 2 Pleomorphic Lower Extremity N/A N/A N/A  F 
S909  Liposarcoma ALT 1 Dedifferentiated Trunk 0 105 54 M 
3 Mesothelioma TEL 3 Biphasic N/A 1 33 63 M 
4 Mesothelioma TEL 2 Epithelial Solid N/A 0 30 29 M 
10 Mesothelioma TEL 3 Epithelial Solid N/A 0 26 66 F 
14 Mesothelioma ALT 2 Epithelial Solid N/A 0 25 37 F 
18 Mesothelioma TEL 3 Epithelial Solid N/A 1 40 66 M 
19 Mesothelioma TEL 3 Epithelial Solid N/A 1 6 42 F 
20 Mesothelioma TEL 3 Epithelial Solid N/A 1 36 55 M 
22 Mesothelioma TEL 3 Epithelial Solid N/A 1 27 73 F 
25 Mesothelioma TEL N/A Epithelial N/A N/A N/A 62 M 
28 Mesothelioma TEL N/A Biphasic N/A 1 10 65 F 
29 Mesothelioma ALT N/A Epithelial N/A 0 34 62 F 
31 Mesothelioma ALT N/A Epithelial N/A 0 32 22 M 
32 Mesothelioma ALT N/A Epithelial  N/A N/A N/A 54 M 
33 Mesothelioma ALT N/A Epithelial N/A 0 31 58 M 
43 Mesothelioma TEL 3 
Epithelial 
Tubulopapillary N/A 0 90 47 M 
7A  Mesothelioma TEL 3 
Epithelial 
Tubulopapillary N/A 0 34 52 F 
8B  Mesothelioma TEL 2 
Epithelial 
Tubulopapillary N/A 1 27 54 F 
S1223  MPNST ALT 2 Malignant (MPNST) N/A 0 59 64 F 
S1313  MPNST TEL 3 Malignant (MPNST) N/A 1 7 26 F 
S1451  MPNST ALT 3 Malignant (MPNST) N/A 1 8 51 M 
S1856  MPNST ALT 2 Malignant (MPNST) N/A 0 45 54 F 
S37  MPNST ALT 3 Malignant (MPNST) N/A 1 9 20 M 
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ID Tumour Type TMM Grade Histology Location 
Survival 
Status 
Survival 
(month) Age Sex 
S579M  MPNST ALT 2 Malignant (MPNST)  N/A 1 5 28 M 
S737  MPNST ALT 3 Malignant (MPNST)  N/A 1 52 59 M 
S738M MPNST TEL N/A Malignant (MPNST) N/A 1 30 59 F 
S758  MPNST TEL 3 Malignant (MPNST)  N/A 1 10 33 F 
S767M  MPNST TEL 3 Malignant (MPNST)  N/A 1 19 42 M 
S802R  MPNST TEL 3 Malignant (MPNST)  N/A 0 82 24 F 
S900R  MPNST TEL 2 Malignant (MPNST) N/A 1 31 28 F 
S966R  MPNST ALT N/A Malignant (MPNST)  N/A 1 31 28 F 
S327R  Synovial Sarcoma TEL 2 
Monophasic, Spindle 
Cells, G2 N/A 1 60 53 F 
S554M  Synovial Sarcoma TEL N/A N/A N/A N/A N/A N/A N/A 
S678M  Synovial Sarcoma TEL N/A Lung Metastasis N/A 1 98 49 M 
S695 Synovial Sarcoma TEL 3 Biphasic G3 N/A 1 41 27 F 
S865M  Synovial Sarcoma TEL N/A Metastasis (Lung) N/A 1 60 56 F 
S989  Synovial Sarcoma ALT 3 G3 PNET-Like N/A 1 16 38 F 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
